US20180193471A1 - ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE - Google Patents

Abstract

The present invention provides a nucleic acid conjugate comprising: a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs; and a ligand part, wherein an oligonucleotide with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to a target β2GPI mRNA sequence, and the 3′ end or 5′ end of the sense strand has a ligand part represented by following formula (I), formula (II), formula (III), formula (IV) or formula (V).

Description

TECHNICAL FIELD
• The present invention relates to a nucleic acid conjugate that suppresses β2GPI gene expression, a composition containing the conjugate, a medicine containing the composition and the like.
BACKGROUND ART
• β2-Glycoprotein 1 (β2GPI, also called apolipoprotein H (apoH)) is a soluble glycoprotein composed of 326 amino acid residues, which is principally produced in the liver (International Journal of Clinical and Laboratory Research, 1992, Vol. 21, pp. 256-263). β2GPI is thought to have various physiological actions, and is reportedly associated with platelet aggregation reactions, coagulation and fibrinolysis reactions, and uptake of oxidized LDL by macrophages (Non-Patent Document 1).
• In terms of an association with diseases, β2GPI is known as a principal antigen corresponding to antiphospholipid antibodies, which occur in autoimmune disorders such as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) (Non-Patent Document 2). Anti-β2GPI antibodies are also deeply involved in disease pathogenesis: it has been shown from clinical research and studies using animal models that complexes formed from β2GPI and anti-β2GPI antibodies generate activation signals on membrane receptors of various cells such as vascular endothelial cells, monocytes, platelets and trophoblasts, leading to pathologies characteristic of APS, such as thrombosis and abnormal pregnancy (Non-Patent Document 3). It is expected that such diseases can be prevented or treated by specifically inhibiting the formation of immune complexes consisting of β2GPI and anti-β2GPI antibodies. However, since β2GPI is present in blood at a relatively high concentration of 50 to 500 μg/mL, it is difficult to continuously inhibit all of β2GPI with, for example, an ordinary antibody medicine (Non-Patent Document 4).
• On the other hand, methods using RNA interference (hereinafter referred to as “RNAi”) are known as methods for suppressing expression of target genes. Specifically, it has been reported that expression of a target gene has been specifically inhibited by introducing a double-stranded RNA having a sequence identical to the target gene in nematodes (Nature, 1998, Vol. 391, No. 6669, pp. 806-811). It has also been discovered that expression of a target gene can be suppressed inDrosophilaby introducing a double-stranded RNA having a length of 21 to 23 bases instead of a longer double-stranded RNA. This is called short interfering RNA (siRNA) (WO 01/75164).
• RNAi has also been verified in many in vivo tests, and it has been reported that siRNA having a length of 50 base pairs or less provides effects in fetal animals (see the specification of US Patent Publication No. 2002/132788) and effects in adult mice (WO 03/10180) by. It has also been confirmed that intravenous administration of siRNA to fetal mice suppresses the expression of specific genes in the kidney, spleen, lungs, pancreas and liver (Nature Genetics, 2002, Vol. 32, No. 1, pp. 107-108). Furthermore, it has also been reported that direct administration of siRNA to brain cells suppresses the expression of a specific gene (Nature Biotechnology, 2002, Vol. 20, No. 10, pp. 1006-1010).
• One method that has been reported to be effective for delivering medicines (especially nucleic acids) in vivo is use of a nucleic acid complex (conjugate) having a targeting compound and a nucleic acid (especially siRNA). The targeting compound may be a ligand capable of binding to an expressed extracellular receptor. In particular, there have been many reports of nucleic acid conjugates using ligands such as N-acetyl-D-galactosamine (GalNAc), which can bind to the asialoglycoprotein receptor (ASGPR), which is highly expressed in liver cells. Recently, it was reported that nucleic acid conjugates having siRNA bound to such ligands can be effectively delivered to liver cells (Non-Patent Document 5).
• Complexes of targeting compounds and siRNA are described for example in Patent Documents 1 to 4.
• For example, Patent Documents 1 and 2 disclose the following nucleic acid conjugate.
• (In this formula and below, Ac represents acetyl group).
• Patent Document 3 discloses the following nucleic acid conjugate for example.
• Patent Document 4 also discloses similar nucleic acid conjugates.
• Although Patent Documents 5 and 6 disclose a part of a siRNA sequence targeting the human β2GPI gene, they do not disclose that this siRNA sequence suppresses expression of the human β2GPI gene.
CITATION LISTPatent Documents
• Patent Document 1: WO 2009/073809
• Patent Document 2: WO 2013/075035
• Patent Document 3: WO 2013/166121
• Patent Document 4: WO 2011/104169
• Patent Document 5: WO 2005/116204
• Patent Document 6: WO 2008/043561
Non-Patent Documents
• Non-Patent Document 1: Annals of the New York Academy of Sciences, 2013, Vol. 1285, pp. 44-58
• Non-Patent Document 2: Nature Review Rheumatology, 2011, Vol. 7, No. 6, pp. 330-339
• Non-Patent Document 3: The New England Journal of Medicine, 2013, Vol. 368, No. 11, pp. 1033-1044
• Non-Patent Document 4: Journal of Thrombosis and Haemostasis, 2011, Vol. 9, No. 7, pp. 1275-1284
• Non-Patent Document 5: Journal of American Chemical Society, 2014, Vol. 136, pp. 16958-16961
SUMMARY OF INVENTIONProblem to be Solved be the Invention
• An object of the present invention is to provide a nucleic acid conjugate that suppresses β2GPI gene expression, as well as a composition containing the conjugate, a medicine containing the composition and the like.
Means for Solving the Problem
• The present invention relates to (1) to (30) below.
• (1) A nucleic acid conjugate comprising: a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs; and a ligand part,
• wherein an oligonucleotide strand with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to a target 62GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16, and
• the 3′ end or 5′ end of the sense strand has the ligand part represented by formula (I), formula (II), formula (III), formula (IV) or formula (V):
• 
• (wherein,
• X is oligonucleotide-P(Z1)(Z2)-, where the oligonucleotide is the sense strand,
• Q is absent or -T4-[Q4-P4]q4-,
• R is the following structure
• 
• Z1 and Z2 are, independently of each other, O or S;
• q1, q2, q3 and q4 are, independently of each other, an integer from 0 to 20;
• P1, P2, P3 and P4 and T1, T2, T3 and T4 are, independently of each other, absent or —CO—, —NH—, —O—, —S—, —O—CO—, —NH—CO—, —CO—O— or CO—NH—, respectively, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of P1, P2, P3 and P4 may be the same or different,
• Q1, Q2, Q3 and Q4 are, independently of each other, absent or a substituted or unsubstituted C_1-14alkylene, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of Q1, Q2, Q3 and Q4 may be the same or different,
• L1, L2 and L3 are, independently of each other, a sugar ligand.)
• (2) The nucleic acid conjugate according to (1) above, wherein one or more of L1, L2 and L3 are a sugar ligand represented by the following structure
• 
• (wherein, Ac represents acetyl group).
• (3) The nucleic acid conjugate according to (1) or (2) above, wherein L1, L2 and L3 are identical.
• (4) The nucleic acid conjugate according to any of (1) to (3) above, wherein T1, T2 and T3 are identical, q1, q2 and q3 are identical, Q1, Q2 and Q3 are identical, and P1, P2 and P3 are identical.
• (5) The nucleic acid conjugate according to any of (1) to (4) above, wherein R is
• 
• (wherein, Ac represents acetyl group).
• (6) The nucleic acid conjugate according to any of (1) to (5) above, wherein R— Q- is
• 
• (wherein, Ac represents acetyl group, and Q4′ is a substituted or unsubstituted C_1-14alkylene).
• (7) The nucleic acid conjugate according to any of (1) to (6) above, comprising a ligand part represented by any of formulae (I) to (V) at the 3′ end of the sense strand of the double-stranded nucleic acid.
• (8) The nucleic acid conjugate according to any of (1) to (6) above, comprising a ligand part represented by any of formulae (I) to (V) at the 5′ end of the sense strand of the double-stranded nucleic acid.
• (9) The nucleic acid conjugate according to any of (1) to (8) above, wherein the duplex region comprises 11 to 27 base pairs, and
• the second nucleotide from the 5′ end of the antisense strand, which is complementary to the target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16, is complementary to the second ribonucleotide from the 3′ end of the target β2GPI mRNA sequence.
• (10) The nucleic acid conjugate according to any of (1) to (9) above, wherein the sense strand has a strand length of 21 to 25 nucleotides, and the antisense strand has a strand length of 21 to 25 nucleotides.
• (11) The nucleic acid conjugate according to any of (1) to (10) above, wherein the double-stranded nucleic acid in which the sense strand has a strand length of 21 to 25 nucleotides and the antisense strand has a strand length of 21 to 25 nucleotides comprises a duplex region of 19 to 21 base pairs.
• (12) The nucleic acid conjugate according to any of (1) to (9) above, wherein the 3′ end of the sense strand and the 5′ end of the antisense strand form a blunt end.
• (13) The nucleic acid conjugate according to any of (1) to (12) above, wherein the double-stranded nucleic acid comprises a 2′-modified nucleotide.
• (14) The nucleic acid conjugate according to (13) above, wherein 50% to 100% of the nucleotides in the duplex region is the 2′-modified nucleotide.
• (15) The nucleic acid conjugate according to (13) or (14) above, wherein the 2′-modified nucleotide is 2′-O-methyl modified nucleotide, 2′-F modified nucleotide or 2′-H modified nucleotide.
• (16) The nucleic acid conjugate according to any of (1) to (15) above, wherein the antisense strand comprises a sequence selected from the group of antisense strands described in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16.
• (17) The nucleic acid conjugate according to any of (1) to (15) above, wherein the sense strand comprises a sequence selected from the group of sense strands described in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16.
• (18) The nucleic acid conjugate according to any of (1) to (8) above, comprising sequences of a pair of sense/antisense strands selected from the group of sense/antisense strands described in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16.
• (19) A nucleic acid conjugate-comprising composition, comprising the nucleic acid conjugate according to any of (1) to (18) above.
• (20) A method for suppressing expression of a β2GPI gene, comprising introducing a double-stranded nucleic acid into cells by using the composition according to (19) above.
• (21) The method according to (20) above, wherein the cells are cells in the liver of a mammal.
• (22) The method according to (20) or (21) above, wherein the method of introduction into cells is a method of introduction into cells by intravenous administration or subcutaneous administration.
• (23) A method for treating a β2GPI-associated disease, comprising administrating a composition according to (19) above to a mammal.
• (24) The method according to (23) above, wherein the Iβ2GPI-associated disease is an autoimmune disease or thrombosis.
• (25) The method according to (23) or (24) above, wherein the method of administration is intravenous administration or subcutaneous administration.
• (26) A medicine for use in the treatment of a β2GPI-associated disease, comprising the composition according to (19) above.
• (27) The medicine according to (26) above, wherein the β2GPI-associated disease is an autoimmune disease or thrombosis.
• (28) The medicine according to (26) or (27) above, for intravenous administration or subcutaneous administration.
• (29) An agent for treating an autoimmune disease or thrombosis, comprising the composition according to (19) above.
• (30) The agent for treating an autoimmune disease or thrombosis according to (29) above, for intravenous administration or subcutaneous administration.
Advantageous Effects of Invention
• For example, an administration of a composition containing the nucleic acid conjugate of the present invention to a mammal can suppress β2GPI gene expression, thereby treating a β2GPI-associated disease in vivo.
DESCRIPTION OF EMBODIMENTS
• An example of a β2GPI gene (gene encoding β2GPI) targeted by the nucleic acid of the invention includes a gene corresponding to β2GPI cDNA (SEQ ID NO: 3541) recorded under Genbank Accession No. NM_000042, which produces full-length β2GPI mRNA.
• The present invention provides, as a medicine, a nucleic acid conjugate comprising a double-stranded nucleic acid capable of reducing or stopping β2GPI gene expression, and a ligand part.
• It also provides a method for treating a β2GPI-associated disease in vivo through suppression of β2GPI gene expression, by administering a nucleic acid conjugate-containing composition containing the conjugate to a mammal.
• Moreover, the present invention also provides a method for treating or preventing disorders mediated by anti-β2GPI antibodies.
• The nucleic acid conjugate of the present invention is a nucleic acid conjugate having a ligand part represented by formula (I), formula (II), formula (III), formula (IV) or formula (V) at the 3′ end or 5′ end of a sense strand constituting the double-stranded nucleic acid.
• 
• (wherein,
• X is oligonucleotide-P(Z1)(Z2)-, wherein the oligonucleotide is the sense strand,
• Q is absent or -T4-[Q4-P4]q4-,
• R is the following structure
• 
• Z1 and Z2 are, independently of each other, O or S;
• q1, q2, q3 and q4 are, independently of each other, an integer from 0 to 20;
• P1, P2, P3 and P4 and T1, T2, T3 and T4 are, independently of each other, absent or —CO—, —NH—, —O—, —S—, —O—CO—, —NH—CO—, —CO—O— or CO—NH—, respectively, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of P1, P2, P3 and P4 may be the same or different,
• Q1, Q2, Q3 and Q4 are, independently of each other, absent or a substituted or unsubstituted C_1-14alkylene, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of Q1, Q2, Q3 and Q4 may be the same or different,
• L1, L2 and L3 are, independently of each other, a sugar ligand.)
• In formulae (I) to (V) above, X is oligonucleotide-P(Z1)(Z2)-, in which the oligonucleotide is the sense strand of the double-stranded nucleic acid in the nucleic acid conjugate of the present invention.
• Z1 and Z2 above are, independently of each other, O or S, preferably Z1 is O and Z2 is S or O, and more preferably both Z1 and Z2 are O.
• The sense strand constituting the oligonucleotide includes those described below, and preferred sense strands are also described below.
• Q in formulae (I) to (V) above is either absent or -T4-[Q4-P4]q4-, preferably -T4-Q4-P4-, and more preferably —NH—CO-Q4—CO— (Q4 is defined as above).
• T4 is either absent, or —CO—, —NH—, —O—, —S—, —O—CO—, —NH—CO—, —CO—O— or —CO—NH—, preferably —NH, —NH—CO— or —CO—NH—, and more preferably —NH—CO—.
• Q4 above is either absent, or a substituted or unsubstituted C_1-14alkylene, preferably a C_4-14alkylene, more preferably a C_6-12alkylene, and still more preferably a C_8-10alkylene. When there are 2 or more Q4s (when q4 in the above formula is an integer from 2 to 20), Q4s may be the same or different.
• Q4′ above is a substituted or unsubstituted C_1-14alkylene, preferably a C_4-14alkylene, more preferably a C_6-12alkylene, and still more preferably a C_8-10alkylene.
• P4 above is either absent, or —CO—, —NH—, —O—, —S—, —O—CO—, —NH—CO—, —CO—O—or —CO—NH—, preferably —CO—, —O—, —O—CO—, —NH—CO—, —CO—O— or —CO—NH—, and more preferably —CO—, —O—, —NH—CO-or —CO—NH—. When there are 2 or more P4s (when q4 in the above formula is an integer from 2 to 20), P4s may be the same or different. When there is one P4 (when q4 in the formula is 1), P4 is preferably —CO—.
• q4 above is an integer from 0 to 20, preferably 0 to 4, more preferably 1 to 3, and still more preferably 1 to 2. When q4 in the above formula is an integer from 2 to 20, Q4s and P4s may be the same or different.
• R in formulae (I) to (V) above is a structure represented by formula (VI) above.
• q1, q2 and q3 in the formula (VI) are, independently of each other, an integer from 0 to 20, preferably q1, q2 and q3 are 2 to 4 and may be the same or different, more preferably are 2 to 4 and are all the same, and still more preferably are all 3.
• Q1, Q2 and Q3 in the formula (VI) are, independently of each other, absent or a substituted or unsubstituted C_1-14alkylene, preferably each is independently a C_1-5alkylene, and more preferably a C_2-4alkylene. When q1, q2 and q3 in the formula (VI) are integers from 2 to 20, Q1, Q2 and Q3 may be the same or different.
• The alkylene part of the substituted or unsubstituted C_1-14alkylenes of Q1, Q2, Q3 and Q4 in the formulae (I) to (VI) may be any C_1-14alkylenes. Examples of such C_1-14alkylenes include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene and tetradecylene.
• In the definitions of Q1, Q2, Q3 and Q4 above, examples of the substituents of the substituted or unsubstituted C_1-14alkylenes include alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl groups, hydroxyl group, C_1-4linear or branched alkoxy groups such as methoxy, ethoxy, propoxy and butoxy groups, cyano group, and halogen groups such as fluoro, chloro and bromo groups and the like.
• L1, L2 and L3 in formula (VI) above are, independently of each other, a sugar ligand.
• In the present invention, a sugar ligand is a group that derives from a saccharide (monosaccharide, disaccharide, trisaccharide, polysaccharide or the like) and that is capable of binding to a receptor expressed in a target cell. In the present invention, when a sugar ligand is bound by a glycoside bond for example, the sugar ligand as a group derived from a saccharide is considered to be a part excluding a hydroxyl group involved in binding of the saccharides constituting the sugar ligand. Moreover, when bound by a glycoside bond for example, the sugar ligand as a group derived from a saccharide is considered to be a part excluding a hydrogen atom of a hydroxyl group involved in binding of the saccharides constituting the sugar ligand.
• In the present invention, the sugar ligands may be selected according to the target cell of the double-stranded nucleic acid.
• Examples of monosaccharides include allose, altose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, fucosamine, fucose, fuculose, galactosamine, D-galactosaminitol, N-acetyl-galactosamine, galactose, glucosamine, N-acetyl-glucosamine, glucosaminitol, glucose, glucose-6-phosphate, gulose, glyceraldehyde, L-glycero-D-mannoheptose, glycerol, glycerone, gulose, idose, lyxose, mannosamine, mannose, mannose-6-phosphate, psicose, quinovose, quinovosamine, rhamnitol, rhamnosamine, rhamnose, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose and xylulose.
• Examples of disaccharides, trisaccharides and polysaccharides include abequose, acarbose, amicetose, amylopectin, amylose, apiose, arcanose, ascarylose, ascorbic acid, boivinose, cellobiose, cellotriose, cellulose, chacotriose, chalcose, chitin, colitose, cyclodextrin, cymarose, dextrin, 2-deoxyribose, 2-deoxyglucose, diginose, digitalose, digitoxose, evalose, evemitrose, fructo-oligosaccharide, galto-oligosaccharide, gentianose, gentiobiose, glucan, glucogen, glycogen, hamamelose, heparin, inulin, isolevoglucosenone, isomaltose, isomaltotriose, isopanose, kojibiose, lactose, lactosamine, lactosediamine, laminarabiose, levoglucosan, levoglucosenone, β-maltose, maltriose, mannan-oligosaccharide, manninotriose, melezitose, melibiose, muramic acid, mycarose, mycinose, neuraminic acid, nigerose, nojirimycin, noviose, oleandrose, panose, paratose, planteose, primeverose, raffinose, rhodinose, rutinose, sarmentose, sedoheptulose, sedoheptulosan, solatriose, sophorose, stachyose, streptose, sucrose, α,α-trehalose, trehalosamine, turanose, tyvelose, xylobiose and umbelliferose.
• Each monosaccharide in the saccharides may be in D-form or L-form, and may also be a mixture of D- and L-forms in any proportions.
• The saccharide may also include a deoxysaccharide (one in which an alcoholic hydroxyl group has been replaced by a hydrogen atom), an aminosaccharide (one in which an alcoholic hydroxyl group has been replaced by an amino group), a thiosaccharide (one in which an alcoholic hydroxyl group has been replaced by a thiol group, or C═O has been replaced by C═S, or a ring oxygen has been replaced by sulfur), a selenosaccharide, a tellurosaccharide, an azasaccharide (one in which a ring carbon has been replaced by nitrogen), an iminosaccharide (one in which a ring oxygen has been replaced by nitrogen), a phosphanosaccharide (one in which a ring oxygen has been replaced by phosphorus), a phosphasaccharide (one in which a ring carbon has been replaced by phosphorus), a C-substituted monosaccharide (one in which a hydrogen at a non-terminal carbon atom is replaced by a carbon atom), an unsaturated monosaccharide, an alditol (one in which a carbonyl group is replaced by a CHOH group), an aldonic acid (one in which an aldehyde group is replaced by a carboxyl group), a ketoaldonic acid, a uronic acid or an aldaric acid.
• Regarding aminosaccharides, examples of amino monosaccharides in the saccharide include galactosamine, glucosamine, mannosamine, fucosamine, quinovosamine, neuraminic acid, muramic acid, lactose diamine, acosamine, bacillosamine, daunosamine, desosamine, forosamine, gallosamine, kanosamine, kansosamine, mycaminose, mycosamine, perosamine, pneumosamine, purpurosamine and rhodosamine. An amino group of the aminosaccharide may also be replaced with an acetyl group or the like.
• Examples of sialic acid-containing sugar chains include sugar chains containing NeuAc at the non-reducing end of the sugar chain, such as sugar chains containing NeuAc-Gal-GlcNAc, and Neu5Acα(2-6)Galβ(1-3)GlcNAc.
• Each monosaccharide in the saccharide may be substituted with a substituent as long as it can bind to a receptor expressed on a target cell. For example, a hydroxyl group may be substituted, and one or more hydrogen atoms in each monosaccharide may be substituted with azide and/or an optionally substituted aryl group.
• Regarding the sugar ligand of the nucleic acid conjugate of the present invention, a sugar ligand that binds to a receptor expressed on the surface of a target cell is preferably selected to target each organ. When the targeted cell is a liver cell for example, a sugar ligand targeting a receptor expressed on the surface of liver cells is preferred, and a sugar ligand targeting asialoglycoprotein receptor (ASGPR) is more preferred.
• Mannose or N-acetylgalactosamine is preferred as the sugar ligand targeting ASGPR, and N-acetylgalactosamine is more preferred.
• The sugar derivatives described in Bioorganic Medicinal Chemistry, Vol. 7, pp. 7254-7264, 2009 and Journal of the American Chemical Society, Vol. 134, pp. 1978-1981, 2012 are known as sugar ligands with high affinity for ASGPR, and these may be used.
• The nucleic acid conjugate of the present invention may also form a salt with a pharmaceutically acceptable anion when a hydrogen ion is coordinated to a lone electron pair on any nitrogen atom.
• In the present invention, examples of pharmaceutically acceptable anions include inorganic ions such as chloride ion, bromide ion, nitrate ion, sulfate ion and phosphate ion, and organic acid ions such as acetate ion, oxalate ion, maleate ion, fumarate ion, citrate ion, benzoate ion and methanesulfonate ion.
• The method for producing the nucleic acid conjugate of the invention is explained here. In the production method given below, when a defined group changes under the conditions of the production method or is unsuited to implementing the production method, the target compound can be produced by applying methods ordinarily used in organic synthetic chemistry to introduce and remove protective groups, such as the methods described in Protective Groups in Organic Synthesis, Third Edition, T. W. Greene Ed., John Wiley & Sons Inc. (1999). Moreover, the order of reaction steps such as substituent introduction may also be changed as necessary.
• Production Method 1
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (I), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 3′ end of the oligonucleotide is represented by formula (I′)) can be produced by the following method. The phrase “the functional group at the right end of Q is —CO—” means that when Q in formula (I) is -T4-[Q4-P4]q4-, q4 is 0 and T4 is —CO—, or q4 is 1 or more and P4 in the -Q4-P— part of Q that binds directly to the nitrogen atom in formula (I) is —CO—.
• 
• (wherein, P1 is a protective group that can be deprotected with a base such as Fmoc, DMTr is p,p′-dimethoxytrityl group, R′ is R group in which each hydroxyl group is protected by a protective group such as acetyl group that can be deprotected with a base, Polymer is a solid-phase carrier, and Q′ is Q in which the functional group at the right end is —CO—.)
• Step 1
• Compound (I-B) can be produced by reacting compound (I-A) and p,p′-dimethoxytrityl chloride for 5 minutes to 100 hours at a temperature between 0° C. and 100° C. in a solvent such as pyridine in the presence of a co-solvent as necessary.
• Examples of the co-solvents include methanol, ethanol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N′-dimethylformamide (DMF), N,N-dimethylacetamide, N-methylpyrrolidone, pyridine and water, and these may be used alone or as a mixture.
• Step 2
• Compound (I-C) can be produced by reacting compound (I-B) for 5 minutes to 100 hours at a temperature between room temperature and 200° C. with or without a solvent in the presence of 1 to 1,000 equivalents of a secondary amine.
• Examples of the solvent include methanol, ethanol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N′-dimethylformamide (DMF), N,N-dimethylacetamide, N-methylpyrrolidone, pyridine and water, and these may be used alone or as a mixture.
• Examples of the secondary amine include diethylamine and piperidine.
• Step 3
• Compound (1-E) can be produced by reacting compounds (I-C) and (I-D) for 5 minutes to 100 hours at a temperature between room temperature and 200° C. with or without a solvent in the presence of 1 to 30 equivalents of a base, a condensing agent, and 0.01 to 30 equivalents of an additive as necessary.
• Examples of the solvent include those given as examples in step 2.
• Examples of the base include cesium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU) and N,N-dimethyl-4-aminopyridine (DMAP).
• Examples of the condensing agent include 1,3-dicyclohexane carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-hydrochloride (EDC), carbonyldiimidazole, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) and 2-chloro-1-methylpyridinium iodide.
• Examples of the additive include 1-hydroxybenzotriazole (HOBt) and 4-dimethylaminopyridine (DMAP).
• Compound (I-D) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, 16958-16961, 2014) or similar methods.
• Step 4
• Compound (I-F) can be produced by reacting compound (I-E) with succinic anhydride for 5 minutes to 100 hours at a temperature between room temperature and 200° C. in a solvent in the presence of 1 to 30 equivalents of a base.
• Examples of the solvent include those listed in step 2.
• Examples of the base include those listed in step 3.
• Step 5
• Compound (I-G) can be produced by reacting compound (I-F) with a terminally aminated solid-phase carrier for 5 minutes to 100 hours at a temperature between room temperature and 200° C. with or without a solvent in the presence of 1 to 30 equivalents of a base, a condensing agent, and 0.01 to 30 equivalents of an additive as necessary, and then further reacting with an acetic anhydride/pyridine solution for 5 minutes to 100 hours at a temperature between room temperature and 200° C.
• Examples of the solvent include those listed in step 2.
• Examples of the base, the condensing agent and the additive include those listed in step 3.
• The aminated solid-phase carrier may be a long-chain alkylamine-controlled pore glass (LCAA-CPG) or the like, and may be obtained as a commercial product.
• Step 6
• A nucleic acid conjugate in which the 3′ end of the sense strand constituting the double-stranded nucleic acid has a ligand part represented by formula (I) can be produced by elongating a corresponding nucleotide strand by known oligonucleotide chemical synthesis methods, using compound (I-G), and then performing desorption from the solid phase, deprotection of the protecting group and purification.
• Examples of known oligonucleotide chemical synthesis methods include phosphoramidite method, phosphorothioate method, phosphotriester method and CEM method (Nucleic Acids Research, Vol. 35, page 3287, 2007), and synthesis may be performed using an ABI3900 high throughput nucleic acid synthesizer (Applied Biosystems, Inc.).
• Desorption from the solid phase and deprotection can be performed following the oligonucleotide chemical synthesis by treating the product for 10 seconds to 72 hours with a base at a temperature of −80° C. to 200° C. with or without a solvent.
• Examples of the base include ammonia, methylamine, dimethylamine, ethylamine, diethylamine, isopropylamine, diisopropylamine, piperidine, triethylamine, ethylenediamine, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU) and potassium carbonate.
• Examples of the solvent include water, methanol, ethanol and THF.
• The oligonucleotide may be purified by a C18 reverse-phase column or anion exchange column, or preferably by a combination of these two methods. The purity of the nucleic acid conjugate after purification is preferably 90% or more, and more preferably 95% or more.
• In step 3 above, as necessary, compound (I-D) may be divided into two units and condensed with the compound (I-C) in two stages. Specifically, when Q′ is —NH—CO-Q4′-CO— for example (Q4′ is a substituted or unsubstituted C_1-14alkylene), in step 3, the compound (I-C) can be condensed with CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) by the same methods as in step 3, and the resulting ethyl ester compound can be hydrolyzed with a base such as lithium hydroxide in a solvent such as ethanol or water, and then condensed with R′—NH₂(R′ is defined as above) to obtain the target compound. CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) and R′—NH₂(R′ is defined as above) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) or similar methods. In Q4′, the substituent and alkylene part of the substituted or unsubstituted C_1-14alkylene are the same as above.
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (I), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q. The phrase “sense strand in which the functional group at the right end of Q is not —CO—” refers to sense strands of the nucleic acid conjugates having a ligand part represented by formula (I) other than the sense strands in which the functional group at the right end of Q is —CO—.
• Production Method 2
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (II), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 3′ end of the oligonucleotide is represented by formula (II′)) can be produced by the following method.
• 

  
• (wherein, DMTr, R, R′, X, Q′ and Polymer are defined as above. TBDMS represents t-butyldimethylsilyl group, and Fmoc represents 9-fluorenylmethyloxycarbonyl group.)
• Step 7
• Compound (II-A) can be produced by reacting compound (I-A), t-butyldimethylsilyl chloride and dimethylaminopyridine in a solvent such as N,N-dimethylformamide (DMF) for 5 minutes to 100 hours at a temperature between 0° C. and 100° C., preferably in the presence of 2 equivalents of a base.
• Examples of the base include those listed in step 3 of Production method 1.
• Step 8
• Compound (II-B) can be produced using compound (II-A) under conditions similar to those of step 1 of Production method 1.
• Step 9
• Compound (II-C) can be produced by reacting compound (II-B) and tetrabutylammonium fluoride (TBAF) for 5 minutes to 100 hours at a temperature between room temperature and 200° C. in a solvent.
• Examples of the solvent include those listed in step 2.
• Step 10
• Compound (II-D) can be produced using compound (II-C) under conditions similar to those of step 2 of Production method 1.
• Step 11
• Compound (II-E) can be produced using compound (II-D) and compound (I-D) under conditions similar to those of step 3 of Production method 1.
• Steps 12 to 14
• Compound (II′) can be produced using compound (II-E) under conditions similar to those of steps 4 to 6 of Production method 1.
• In step 11 above, as necessary, compound (I-D) may be divided into two units and condensed with compound (II-C) in two stages. Specifically, when Q′ is —NH—CO-Q4′-CO— for example (Q4′ is a substituted or unsubstituted C_1-14alkylene), in step 11, compound (II-C) can be condensed with CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) by the same methods as in step 11, and the resulting ethyl ester compound can be hydrolyzed with a base such as lithium hydroxide in a solvent such as ethanol or water, and then condensed with R′—NH₂(R′ is defined as above) to obtain the target compound. CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) and R′—NH₂(R′ is defined as above) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) or similar methods. In Q4′, the substituent and alkylene part in the substituted or unsubstituted C_1-14alkylene are the same as above.
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (II), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 3
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (III), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 3′ end of the oligonucleotide is represented by formula (III′)) can be produced by the following method.
• 
• (wherein, DMTr, Fmoc, R, R′, Q′, X and Polymer are defined as above.)
• Compound (III′) can be produced using compound (III-A) under conditions similar to those of steps 1 to 6 of Production method 1. Compound (III-A) can be obtained as a commercial product.
• Step 15
• Compound (III-B) can be produced using compound (III-A) under conditions similar to those of step 1 of Production method 1.
• Compound (III-A) can be purchased as a commercial product.
• Step 16
• Compound (III-C) can be produced using compound (III-B) under conditions similar to those of step 2 of Production method 1.
• Step 17
• Compound (III-E) can be produced using compound (III-C) under conditions similar to those of step 3 of Production method 1.
• Steps 18 to 20
• Compound (III′) can be produced using compound (III-E) under conditions similar to those of steps 4 to 6 of Production method 1.
• In step 17 above, as necessary, compound (I-D) may be divided into two units and condensed with compound (III-C) in two stages. Specifically, when Q′ is —NH—CO-Q4′-CO— for example (Q4′ is a substituted or unsubstituted C_1-14alkylene), in step 17, compound (III-C) can be condensed with CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) by the same methods as in step 17, and the resulting ethyl ester compound can be hydrolyzed with a base such as lithium hydroxide in a solvent such as ethanol or water, and then condensed with R′—NH₂(R′ is defined as above) to obtain the target compound. CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) and R′—NH₂(R′ is defined as above) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) or similar methods. In Q4′, the substituent and alkylene part of the substituted or unsubstituted C_1-14alkylene are the same as above.
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (III), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 4
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (IV), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 3′ end of the oligonucleotide is represented by formula (IV′)) can be produced by the following method.
• 
• (wherein, DMTr, Fmoc, R′, Q′, X and Polymer are defined as above.)
• Compound (IV′) can be produced using compound (IV-A) under conditions similar to those of steps 1 to 6 of Production method 1. Compound (IV-A) may be obtained as a commercial product.
• In step 23 above, as necessary, compound (I-D) may be divided into two units and condensed with compound (IV-C) in two stages. Specifically, when Q′ is —NH—CO-Q4′-CO— for example (Q4′ is a substituted or unsubstituted C_1-14alkylene), in step 23, compound (IV-C) can be condensed with CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) by the same methods as in step 23, and the resulting ethyl ester compound can be hydrolyzed with a base such as lithium hydroxide in a solvent such as ethanol or water, and then condensed with R′—NH₂(R′ is defined as above) to obtain the target compound. CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) and R′—NH₂(R′ is defined as above) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) or similar methods. In Q4′, the substituent and alkylene part of the substituted or unsubstituted C_1-14alkylene are the same as above.
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (IV), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 5
• Of the sense strands in which the 3′ end of the oligonucleotide is represented by formula (V), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 3′ end of the oligonucleotide is represented by formula (V′)) can be produced by the following Production method 5.
• 
• (wherein, DMTr, R′, X, Q′, TBDMS, Fmoc and Polymer are defined as above.)
• Compound (V′) can be produced using compound (IV-A) under conditions similar to those of steps 1 to 7 in Production method 2. Compound (IV-A) can be obtained as a commercial product.
• In step 31 above, as necessary, compound (I-D) may be divided into two units and condensed with compound (V-D) in two stages. Specifically, when Q′ is —NH—CO-Q4′-CO— for example (Q4′ is a substituted or unsubstituted C_1-14alkylene), in step 31, compound (V-D) can be condensed with CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) by the same methods as in step 31, and the resulting ethyl ester compound can be hydrolyzed with a base such as lithium hydroxide in a solvent such as ethanol or water, and then condensed with R′—NH₂(R′ is defined as above) to obtain the target compound. CH₃CH₂—O—CO-Q4′-CO—OH (Q4′ is defined as above) and R′—NH₂(R′ is defined as above) can be obtained by known methods (see for example Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) or similar methods. In Q4′, the substituent and alkylene part of the substituted or unsubstituted C_1-14alkylene are the same as above.
• Of the nucleic acid conjugates in which the 3′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (V), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 6
• Of the sense strands in which the 5′ end of the oligonucleotide is represented by formula (I), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 5′ end of the oligonucleotide is represented by formula (I″)) can be produced by following Production method 6.
• 
• (wherein, R, R′, Q′, DMTr and X are defined as above.)
• Step 35
• Compound (I-H) can be produced by reacting compound (II-E) with 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphodiamidite for 5 minutes to 100 hours at a temperature between room temperature and 200° C. with or without a solvent in the presence of a base and a reaction accelerator.
• Examples of the solvent include those listed in step 2 of Production method 1.
• Examples of the base include those listed in step 3 of Production method 1.
• The reaction accelerator may be 1H-tetrazole, 4,5-dicyanoimidazole, 5-ethylthiotetrazole or 5-benzylthiotetrazole for example, and may be purchased as a commercial product.
• Step 36
• A sense strand in which the 5′ end of the oligonucleotide is represented by formula (I) can be produced by elongating a oligonucleotide strand, using compound (I-H) and then finally performing desorption from the solid phase, deprotection of the protecting group and purification. Desorption from the solid phase, deprotection of the protecting group and purification may each be performed as in step 6 of Production method 1.
• Furthermore, as in Production method 1, of the nucleic acid conjugates in which the 5′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (I), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 7
• Of the sense strands in which the 5′ end of the oligonucleotide is represented by formula (II), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 5′ end of the oligonucleotide is represented by formula (II″)) can be produced under conditions similar to those of steps 35 and 36 of Production method 6.
• 
• (wherein, R, R′, Q′, DMTr and X are as defined above.)
• Moreover, as in Production method 2, of the nucleic acid conjugates in which the 5′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (II), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 8
• Of the sense strands in which the 5′ end of the oligonucleotide is represented by formula (III), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 5′ end of the oligonucleotide is represented by formula (III′)) can be produced under conditions similar to those of steps 35 and 36 of Production method 6.
• 
• (wherein, R, R′, Q′, DMTr and X are as defined above.)
• As in Production method 3, of the nucleic acid conjugates in which the 5′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (III), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under the reaction conditions optimized according to the structure of Q.
• Production Method 9
• Of the sense strands in which the 5′ end of the oligonucleotide is represented by formula (IV), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 5′ end of the oligonucleotide is represented by formula (IV′)) can be produced under conditions similar to those of steps 35 and 36 of Production method 6.
• 
• (wherein, R, R′, Q′, DMTr and X are as defined above.)
• As in Production method 4, of the nucleic acid conjugates in which the 5′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (IV), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 10
• Of the sense strands in which the 5′ end of the oligonucleotide is represented by formula (V), a sense strand in which the functional group at the right end of Q is —CO— (a sense strand in which the 5′ end of the oligonucleotide is represented by formula (V′)) can be produced under conditions similar to those of steps 35 and 36 of Production method 6.
• 
• (wherein, R, R′, Q′, DMTr and X are as defined above.)
• As in Production method 5, of the nucleic acid conjugates in which the 5′ end of the sense strand of the double-stranded nucleic acid has a ligand part represented by formula (V), a sense strand in which the functional group at the right end of Q is not —CO— can be prepared by methods similar to those described above, known methods or a combination thereof under reaction conditions optimized according to the structure of Q.
• Production Method 11
• The sense strand of a double-stranded nucleic acid in which the 3′ end or 5′ end of the sense strand has a ligand part represented by formula (I) to (V) and the antisense strand of the double-stranded nucleic acid can be dissolved in water or a suitable buffer, and mixed to obtain a nucleic acid conjugate in which the 3′ or 5′ end of the sense strand of the double-stranded nucleic acid is represented by formula (I).
• Examples of the buffer include acetic acid buffer, tris buffer, citric acid buffer, phosphoric acid buffer and water, and these may be used alone or in a mixture.
• The mixing ratio of the sense strand and the antisense strand is preferably 0.5 to 2 equivalents, more preferably 0.9 to 1.1 equivalents, or still more preferably 0.95 to 1.05 equivalents of the antisense strand per 1 equivalent of the sense strand.
• After the sense strand and the antisense strand are mixed, suitable annealing may be performed. Annealing is performed by first heating the mixture of the sense strand and the antisense strand to a temperature of preferably 50° C. to 100° C., more preferably 60° C. to 100° C., or still more preferably 80° C. to 100° C., and then gradually cooling to room temperature.
• The antisense strand can be obtained by the known oligonucleotide synthesis methods described above.
• The nucleic acid conjugate described herein can be obtained in the form of a salt such as an acid addition salt, metal salt, ammonium salt, organic amine addition salt, amino acid addition salt or the like.
• The acid addition salt may be an inorganic acid salt such as hydrochloride salt, sulfate salt or phosphate salt, or an organic acid salt such as acetate salt, maleate salt, fumarate salt, citrate salt or methanesulfonate salt. The metal salt may be an alkali metal salt such as sodium salt or potassium salt, an alkali earth metal salt such as magnesium salt or calcium salt, or an aluminum salt, zinc salt or the like. The ammonium salt may be a salt of ammonium, tetramethylammonium or the like. The organic amine addition salt may be an addition salt of morpholine, piperidine or the like. The amino acid addition salt may be an addition salt of lysine, glycine, phenylalanine or the like.
• If a salt of the nucleic acid conjugate described herein is desired, when the conjugate is obtained in the form of a desired salt, it may be purified as it is, while when it is obtained in a free form, the conjugate may be dissolved or suspended in a suitable solvent, to which a corresponding acid or base is added, and the conjugate is then isolated and purified. In order to substitute the counter-ion forming the conjugate salt with another counter-ion, the conjugate salt may be dissolved or suspended in a suitable solvent, to which an acid, base and/or salt (for example, inorganic salts such as sodium chloride and ammonium chloride) is added in an amount of several equivalents to a large excess, and the conjugate is then isolated and purified.
• Stereoisomers such as geometric isomers and optical isomers, tautomers and the like may be present in the nucleic acid conjugate described herein. All possible isomers and mixtures thereof are encompassed in the present invention.
• The nucleic acid conjugate described herein may also exist in the form of an adduct with water or various solvents. These adducts are also encompassed in the present invention.
• Moreover, the nucleic acid conjugate of the present invention also encompasses those in which a part or all of the atoms in the molecule have been replaced with atoms with a different mass number (isotopes) (such as deuterium).
• Specific examples of the nucleic acid conjugate of the present invention are described in Table 1. However, the nucleic acid conjugate of the present invention is not limited to these.
• In Table 1, the oligonucleotide part in nucleic acid conjugates I to V represents the sense strand of the double-stranded nucleic acid, examples of which include the sense strands represented by the sense strand sequence in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16 below.
• In the present invention, a nucleic acid containing a base sequence complementary to β2GPI mRNA is called an antisense strand nucleic acid, and a nucleic acid containing a base sequence complementary to the base sequence of the antisense strand nucleic acid is also a sense strand nucleic acid.
• The double-stranded nucleic acid constituting the nucleic acid conjugate in the present invention is a double-stranded nucleic acid having the ability to reduce or stop expression of the β2GPI gene when introduced into mammalian cells, and is a double-stranded nucleic acid having a sense strand and an antisense strand. The sense strand and the antisense strand comprise at least 11 base pairs, and at least 17 and not more than 30 nucleotides in the antisense strand (in other words, an oligonucleotide strand with a strand length of 17 to 30 nucleotides) are complementary to a target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16.
• The double-stranded nucleic acid constituting the nucleic acid conjugate of the present invention may be any molecule that is a polymer of nucleotides or molecules having a function equivalent to that of the nucleotide. Examples thereof include RNA (a polymer of ribonucleotides), DNA (a polymer of deoxyribonucleotides), chimera nucleic acids consisting of RNA and DNA, and nucleotide polymers in which at least one nucleotide in these nucleic acids has been replaced with a molecule having a function equivalent to that of the nucleotide. Derivatives containing at least one molecule having a function equivalent to that of the nucleotide in these nucleic acids are also encompassed in the double-stranded nucleic acid of the present invention, which is used as a medicine. Moreover, uracil (U) may be unambiguously replaced with thymine (T).
• Examples of the molecules having a function equivalent to a nucleotide include nucleotide derivatives. The nucleotide derivative may be any molecule obtained by modifying a nucleotide, and is preferably a molecule obtained by modifying a ribonucleotide or deoxyribonucleotide in order to increase or stabilize nuclease resistance, increase affinity for a complement strand nucleic acid, increase cell permeability or achieve visibility, in comparison with RNA or DNA.
• Examples of the molecules obtained by modifying nucleotides include sugar-modified nucleotides, phosphate diester bond-modified nucleotides, base-modified nucleotides, and nucleotides in which at least one of the sugar part, phosphate diester bond and base has been modified.
• The sugar-modified nucleotide may be a nucleotide in which all or part of the chemical structure of the sugar in the nucleotide has been modified or replaced with any substituent, or replaced with any atom, and is preferably a 2′-modified nucleotide.
• The 2′-modified nucleotide may be a nucleotide in which the 2′-OH group of ribose for example has been replaced with a substituent selected from the group consisting of H, OR, R, R′OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (where, R is alkyl or aryl, preferably C_1-6alkyl, and R′ is alkylene, preferably C_1-6alkylene), preferably a nucleotide in which the 2′-OH group has been replaced with H, F or methoxy group, more preferably a nucleotide in which the 2′-OH group has been replaced with F or methoxy group. It may also be a nucleotide in which the 2′-OH group has been replaced with a substituent selected from the group consisting of 2-(methoxy)ethoxy, 3-aminopropoxy, 2-[(N,N-dimethylamino)oxy]ethoxy, 3-(N,N-dimethylamino)propoxy, 2-[2-(N,N-dimethylamino)ethoxy]ethoxy, 2-(methylamino)-2-oxoethoxy, 2-(N-methylcarbamoyl)etoxy and 2-cyanoetoxy.
• The 2′-modified nucleotides constitute preferably 50% to 100%, more preferably 70% to 100%, or still more preferably 90% to 100% of the nucleotides in the double-stranded nucleic acid region. Moreover, the 2′-modified nucleotides constitute preferably 20% to 40%, more preferably 40% to 60%, or still more preferably 60% to 100% of the nucleotides of the sense strand. Furthermore, the 2′-O-methyl-modified nucleotides constitute preferably 0% to 40%, more preferably 10% to 20%, or still more preferably 20% to 40% of the nucleotides of the antisense strand.
• The phosphate diester bond-modified nucleotide may be a nucleotide in which all or part of the chemical structure of the phosphate diester bond of the nucleotide has been modified or replaced with any substituent, or replaced with any atom. Examples thereof include nucleotides in which the phosphate diester bond has been replaced with a phosphorothioate bond, nucleotides in which the phosphate diester bond has been replaced with a phosphorodithioate bond, nucleotides in which the phosphate diester bond has been replaced with an alkylphosphonate bond, and nucleotides in which the phosphate diester bond has been replaced with a phosphoramidate bond
• The base-modified nucleotide may be a nucleotide in which all or part of the chemical structure of the base of the nucleotide has been modified or replaced with any substituent, or replaced with any atom. Examples thereof include those in which an oxygen atom in the base has been replaced with a sulfur atom, those in which a hydrogen atom has been replaced with a C_1-6alkyl group, halogen or the like, those in which a methyl group has been replaced with hydrogen, hydroxymethyl or C_2-6alkyl group or the like, and those in which an amino group has been replaced with a C_1-6alkyl group, C_1-6alkanoyl group, oxo group, hydroxy group or the like.
• Examples of the nucleotide derivatives also include those obtained by adding another chemical substance such as a peptide, a protein, a sugar, a lipid, a phospholipid, phenazine, folate, phenanthrizine, anthraquinone, acridine, fluorescein, rhodamine, coumarin and a dye, either directly or via a linker, to a nucleotide or a nucleotide in which at least one of the sugar part, phosphate diester bond and base is modified. Specific examples include 5′-polyamine addition nucleotide derivatives, cholesterol addition nucleotide derivatives, steroid addition nucleotide derivatives, bile acid addition nucleotide derivatives, vitamin addition nucleotide derivatives, Cy5 addition nucleotide derivatives, Cy3 addition nucleotide derivatives, 6-FAM addition nucleotide derivatives and biotin addition nucleotide derivatives.
• The nucleotide derivative may also form, together with another nucleotide or nucleotide derivative in the nucleic acid, a crosslinked structure such as an alkylene structure, peptide structure, nucleotide structure, ether structure, ester structure and a combination of at least one of these structures.
• The term “complementation” described herein means a relationship in which a base pair can be formed between two bases, such as relationships between adenine and thymine or uracil and between guanine and cytosine, which form mild hydrogen bonds to make the whole duplex region double-helical.
• The term “complementary” described herein means not only the case in which two nucleotide sequences are completely complementary to each other, but also the case in which two nucleotide sequences have 0% to 30%, 0% to 20% or 0% to 10% mismatched nucleotides. For example, this means that an antisense strand complementary to β2GPI mRNA may have one or more substituted nucleotides in a base sequence completely complementary to the partial base sequence of that mRNA. Specifically, the antisense strand may have 1 to 8, preferably 1 to 6, 1 to 4, 1 to 3, or especially 2 or 1 mismatched nucleotide in relation to the target sequence of the target gene. If the antisense strand is 21 nucleotides in length for example, it may have 6, 5, 4, 3, 2, or 1 mismatched nucleotide in relation to the target sequence of the target gene. The mismatches may be located at the 5′ end or the 3′ end of the either sequence.
• The term “complementary” also encompasses the case in which one nucleotide sequence which is completely complementary to another nucleotide sequence has one or more added and/or deleted nucleotides. For example, β2GPI mRNA and the antisense strand nucleic acid of the present invention may have one or two bulge bases in the antisense strand and/or the target β2GPI mRNA region due to addition and/or deletion of a base in the antisense strand.
• The double-stranded nucleic acid of the present invention used as a medicine may be composed of any nucleotides or derivatives thereof as long as it is a nucleic acid containing a base sequence complementary to a partial base sequence of β2GPI mRNA, and/or a nucleic acid containing a base sequence complementary to the base sequence of said nucleic acid. In the double-stranded nucleic acid of the present invention, the nucleic acid containing a base sequence complementary to the target β2GPI mRNA sequence and the nucleic acid containing a base sequence complementary to the nucleotide sequence of said nucleic acid may be of any length as long as they can form a duplex strand of at least 11 base pairs. The length of the sequence capable of forming the duplex strand is normally 11 to 35 bases, preferably 15 to 30 bases, more preferably 17 to 25 bases, still more preferably 17 to 23 bases, and yet more preferably 19 to 23 bases.
• A nucleic acid containing a base sequence complementary to the target β2GPI mRNA sequence may be used as the antisense strand in the nucleic acid conjugate of the present invention. It is also possible to use a nucleic acid obtained by deleting, substituting or adding 1 to 3, preferably 1 to 2, and more preferably 1 base in said nucleic acid
• Either a single-stranded nucleic acid that contains a base sequence complementary to the target β2GPI mRNA sequence and that suppresses β2GPI expression, or a double-stranded nucleic acid that has a nucleic acid containing a base sequence complementary to the target β2GPI mRNA sequence and a nucleic acid containing a base sequence complementary to the base sequence of said nucleic acid and that suppresses β2GPI expression, may be used favorably as the nucleic acid that suppresses β2GPI expression.
• The double-stranded nucleic acid of the present invention is a nucleic acid having two nucleotide strands which are paired and having a duplex region of at least 11 base pairs. The duplex region is a region in which nucleotides or derivatives thereof constituting the double-stranded nucleic acid form base pairs, leading to a double strand. The duplex region consists of normally 11 to 27 base pairs, preferably 15 to 25 base pairs, more preferably 15 to 23 base pairs, and still more preferably 17 to 21 base pairs.
• The single-stranded nucleic acid constituting the double-stranded nucleic consists of normally 11 to 30 bases, preferably 15 to 29 bases, more preferably 15 to 27 bases, still more preferably 15 to 25 bases, and yet more preferably 17 to 23 bases.
• When the double-stranded nucleic acid of the present invention used as a medicine has an additional nucleotide or nucleotide derivative not forming a double strand at the 3′ side or the 5′ side following the duplex region, this is called an overhang. When there is an overhang, the nucleotide constituting the overhang may be a ribonucleotide, a deoxyribonucleotide or a derivatives thereof.
• A double-stranded nucleic acid having an overhang may be one having an overhang consisting of 1 to 6 bases, normally 1 to 3 bases, or preferably 2 bases at the 3′ end or the 5′ end of at least one strand. Examples thereof include those having an overhang consisting of dTdT (where, dT represents deoxythymidine) or UU (where, U represents uridine). The antisense strand alone, the sense strand alone or both of the antisense strand and the sense strand may have an overhang. In the present invention, a double-stranded nucleic acid having an overhang in the antisense strand is preferred. An oligonucleotide strand consisting of 17 to 30 nucleotides including a duplex region and a subsequent overhang in the antisense strand is sufficiently complementary to a target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16. A nucleic acid molecule that produces a double-stranded nucleic acid by an action of a ribonuclease such as Dicer (WO 2005/089287), a double-stranded nucleic acid forming a blunt end with no overhang at the 3′ end and the 5′ end, or a double-stranded nucleic acid having an overhang in only a sense strand (US 2012/0040459) may also be used as the double-stranded nucleic acid of the present invention.
• A nucleic acid having a base sequence identical to the base sequence of a target gene or identical to the base sequence of its complement strand may be used as the double-stranded nucleic acid constituting the nucleic acid conjugate used in the present invention. It is also possible to use a double-stranded nucleic acid having a nucleic acid obtained by deleting 1 to 4 bases at the 5′ end or the 3′ end of at least one strand of said nucleic acid and having a nucleic acid containing a base sequence complementary to the base sequence of said nucleic acid.
• The double-stranded nucleic acid constituting the nucleic acid conjugate used in the present invention may be a double-stranded RNA (dsRNA) formed from two strands of RNA, a double-stranded DNA (dsDNA) formed from two strands of DNA, or a hybrid nucleic acid formed from a strand of RNA and a strand of DNA. Alternatively, it may be a chimera nucleic acid in which one or both of the strands is formed from both DNA and RNA. Preferably it is double-stranded RNA (dsRNA).
• The second nucleotide from the 5′ end of the antisense strand of the nucleic acid conjugate of the present invention is preferably complementary to the second deoxyribonucleotide from the 3′ end of the target β2GPI mRNA sequence, more preferably the 2nd to 7th nucleotides from the 5′ end of the antisense strand are completely complimentary to the 2nd to 7th deoxyribonucleotides from the 3′ end of the target β2GPI mRNA sequence, and still more preferably the 2nd to 11th nucleotides from the 5′ end of the antisense strand are completely complimentary to the 2nd to 11th deoxyribonucleotides from the 3′ end of the target β2GPI mRNA sequence. Moreover, the 11th nucleotide from the 5′ end of the antisense strand in the nucleic acid of the present invention is preferably complementary to the 11th deoxyribonucleotide from the 3′ end of the target β2GPI mRNA sequence, more preferably the 9th to 13th nucleotides from the 5′ end of the antisense strand are completely complementary to the 9th to 13th deoxyribonucleotides from the 3′ end of the target β2GPI mRNA sequence, and still more preferably the 7th to 15th nucleotides from the 5′ end of the antisense strand are completely complementary to the 7th to 15th deoxyribonucleotides from the 3′ end of the target β2GPI mRNA sequence.
• The antisense strand and the sense strand of the nucleic acid conjugate of the present invention may be designed based on the base sequence (SEQ ID NO: 3541) of the cDNA (sense strand) of the full-length human β2GPI mRNA recorded as Genbank Accession No. NM_000042.
• Example of a nucleic acid having β2GPI expression-suppressing activity include a double-stranded nucleic acid having an antisense strand nucleic acid of the present invention containing a base sequence complementary to β2GPI mRNA and having a sense strand nucleic acid of the present invention containing a base sequence complementary to the base sequence of said nucleic acid, and having β2GPI expression-suppressing activity. The single-stranded nucleic acids constituting this double-stranded nucleic acid consist of normally 11 to 30 bases, preferably 15 to 29 bases, more preferably 15 to 27 bases, still more preferably 15 to 25 bases, yet more preferably 17 to 23 bases, and especially preferably 19 to 21 bases. The double-stranded nucleic acid has a duplex region consisting of normally 15 to 27 base pairs, preferably 15 to 25 base pairs, more preferably 15 to 23 base pairs, and still more preferably 15 to 21 base pairs.
• The double-stranded nucleic acid may be designed so as to interact with a target sequence in the β2GPI gene sequence.
• The sequence of one strand of the double-stranded nucleic acid is complementary to the above target sequence. The double-stranded nucleic acid can be chemically synthesized using methods described herein.
• RNA may be prepared by enzymatic or partial/total organic synthesis. Modified ribonucleotides may be introduced by enzymatic or organic synthesis in vitro. In one embodiment, each strand is prepared chemically. Methods for chemically synthesizing RNA molecules are well known in the technical field (see Nucleic Acids Research, 1998, Vol. 32, pp. 936-948). In general, double-stranded nucleic acids can be synthesized using solid-phase oligonucleotide synthesis methods (see for example Usman et al., U.S. Pat. No. 5,804,683 (Specification); U.S. Pat. No. 5,831,071 (Specification); U.S. Pat. No. 5,998,203 (Specification); U.S. Pat. No. 6,117,657 (Specification); U.S. Pat. No. 6,353,098 (Specification); U.S. Pat. No. 6,362,323 (Specification); U.S. Pat. No. 6,437,117 (Specification); U.S. Pat. No. 6,469,158 (Specification); Scaringe et al., U.S. Pat. No. 6,111,086 (Specification); U.S. Pat. No. 6,008,400 (Specification); and U.S. Pat. No. 6,111,086 (Specification)).
• The single-stranded nucleic acids are synthesized by the solid-phase phosphoramidite method (Nucleic Acids Research, 1993, Vol. 30, pp. 2435-2443), deprotected, and desalted on a NAP-5 column (Amersham Pharmacia Biotech, Piscataway, N.J.). The oligomers are purified by ion-exchange high-performance liquid chromatography (IE-HPLC) in an Amersham Source 15Q column-1.0 cm, height 0.25 cm (Amersham Pharmacia Biotech, Piscataway, N.J.) using a 15 minute process linear gradient. For the gradient, the buffer is changed from a 90:10 buffer A:B to a 52:48 buffer A:B, in which buffer A is 100 mmol/L Tris pH 8.5, and buffer B is 100 mmol/L Tris pH 8.5 (1 mol/L NaCl). Monitoring is performed at 260 nm, and peaks corresponding to full-length oligonucleotide species are collected, pooled, desalted on a NAP-5 column and freeze-dried.
• The purity of each single-stranded nucleic acid is determined by capillary electrophoresis (CE) in a Beckman PACE 5000 (Beckman Coulter, Inc., Fullerton, Calif.). The CE capillarity has an inner diameter of 100 μm, and contains ssDNA 100R Gel (Beckman-Coulter). Typically, about 0.6 nmol of the oligonucleotide is injected into the capillary, and detected by UV absorption at 260 nm in a 444 V/cm electrical field. A modified tris-boric acid-7 mol/L urea running buffer is purchased from Beckman-Coulter. A single-stranded nucleic acid with a purity of at least 90% in the CE evaluation is obtained for use in the tests described below. Compound identity is verified by matrix-assisted laser desorption/ionization-time of flight (MALD-TOF) mass spectrometry using a VoyagerDE® Biospectrometry workstation (Applied Biosystems, Inc., Foster City, Calif.) in accordance with the manufacturer's recommended protocols. A relative molecular mass of the single-stranded nucleic acid can be obtained within 0.2% of the predicted molecular mass.
• The single-stranded nucleic acids are re-suspended at a concentration of 100 μmol/L in a buffer with the pH of 7.5 consisting of 100 mmol/L potassium acetate and 30 mmol/L HEPES. The complementary sense strand and the antisense strand are mixed in the same molar amounts to obtain a final 50 μmol/L solution of the double-stranded nucleic acid. The sample is heated for 5 minutes at 95° C., and cooled to room temperature before use. The double-stranded nucleic acid is stored at −20° C. The single-stranded nucleic acids are either freeze-dried or stored at −80° C. in nuclease-free water.
• Examples of the double-stranded nucleic acid of the present invention consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs in which an oligonucleotide strand with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to the target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16, include a double-stranded nucleic acid containing a sequence selected from the group consisting of the antisense strands described in Tables 2-1 to 2-18 and 3-1 to 3-18 and 4-1 to 4-16 below, a double-stranded nucleic acid containing a sequence selected from the group consisting of the sense strands described in Tables 2-1 to 2-18 and 3-1 to 3-18 and 4-1 to 4-16 below, or a double-stranded nucleic acid containing the sequence of a pair of sense/antisense strands selected from the group consisting of the sense/antisense strands described in Tables 2-1 to 2-18 and 3-1 to 3-18 and 4-1 to 4-16 below. That is, specific examples of the double-stranded nucleic acid constituting the nucleic acid conjugate of the present invention are double-stranded nucleic acids consisting of the sense strand and the antisense strand from Tables 2-1 to 2-18 and 3-1 to 3-18 and 4-1 to 4-16 below. In Tables 3-1 to 3-18, N(M) represents 2′-O-methyl modified RNA, N(F) represents 2′-fluorine modified RNA, and A represents phosphorothioate.

• TABLE 2-1
  Double stranded	SEQ ID	Sense strand sequences	SEQ ID	Antisense strand sequence
  nucleic acid No.	NO.	(5′-3′)	NO.	(5′-3′)
  BH0033	No. 4001	UGGUAGUGCCAGUGUGACUCA	No. 4703	UGAGUCACACUGGCACUACCAAA
  BH0034	No. 4002	GGUAGUGCCAGUGUGACUCAU	No. 4704	AUGAGUCACACUGGCACUACCAA
  BH0035	No. 4003	GUAGUGCCAGUGUGACUCAUC	No. 4705	GAUGAGUCACACUGGCACUACCA
  BH0036	No. 4004	UAGUGCCAGUGUGACUCAUCC	No. 4706	GGAUGAGUCACACUGGCACUACC
  BH0037	No. 4005	AGUGCCAGUGUGACUCAUCCA	No. 4707	UGGAUGAGUCACACUGGCACUAC
  BH0038	No. 4006	GUGCCAGUGUGACUCAUCCAC	No. 4708	GUGGAUGAGUCACACUGGCACUA
  BH0039	No. 4007	UGCCAGUGUGACUCAUCCACA	No. 4709	UGUGGAUGAGUCACACUGGCACU
  BH0040	No. 4008	GCCAGUGUGACUCAUCCACAA	No. 4710	UUGUGGAUGAGUCACACUGGCAC
  BH0041	No. 4009	CCAGUGUGACUCAUCCACAAU	No. 4711	AUUGUGGAUGAGUCACACUGGCA
  BH0042	No. 4010	CAGUGUGACUCAUCCACAAUG	No. 4712	CAUUGUGGAUGAGUCACACUGGC
  BH0043	No. 4011	AGUGUGACUCAUCCACAAUGA	No. 4713	UCAUUGUGGAUGAGUCACACUGG
  BH0044	No. 4012	GUGUGACUCAUCCACAAUGAU	No. 4714	AUCAUUGUGGAUGAGUCACACUG
  BH0045	No. 4013	UGUGACUCAUCCACAAUGAUU	No. 4715	AAUCAUUGUGGAUGAGUCACACU
  BH0046	No. 4014	GUGACUCAUCCACAAUGAUUU	No. 4716	AAAUCAUUGUGGAUGAGUCACAC
  BH0047	No. 4015	UGACUCAUCCACAAUGAUUUC	No. 4717	GAAAUCAUUGUGGAUGAGUCACA
  BH0048	No. 4016	GACUCAUCCACAAUGAUUUCU	No. 4718	AGAAAUCAUUGUGGAUGAGUCAC
  BH0050	No. 4017	CUCAUCCACAAUGAUUUCUCC	No. 4719	GGAGAAAUCAUUGUGGAUGAGUC
  BH0051	No. 4018	UCAUCCACAAUGAUUUCUCCA	No. 4720	UGGAGAAAUCAUUGUGGAUGAGU
  BH0052	No. 4019	CAUCCACAAUGAUUUCUCCAG	No. 4721	CUGGAGAAAUCAUUGUGGAUGAG
  BH0053	No. 4020	AUCCACAAUGAUUUCUCCAGU	No. 4722	ACUGGAGAAAUCAUUGUGGAUGA
  BH0054	No. 4021	UCCACAAUGAUUUCUCCAGUG	No. 4723	CACUGGAGAAAUCAUUGUGGAUG
  BH0055	No. 4022	CCACAAUGAUUUCUCCAGUGC	No. 4724	GCACUGGAGAAAUCAUUGUGGAU
  BH0056	No. 4023	CACAAUGAUUUCUCCAGUGCU	No. 4725	AGCACUGGAGAAAUCAUUGUGGA
  BH0057	No. 4024	ACAAUGAUUUCUCCAGUGCUC	No. 4726	GAGCACUGGAGAAAUCAUUGUGG
  BH0058	No. 4025	CAAUGAUUUCUCCAGUGCUCA	No. 4727	UGAGCACUGGAGAAAUCAUUGUG
  BH0059	No. 4026	AAUGAUUUCUCCAGUGCUCAU	No. 4728	AUGAGCACUGGAGAAAUCAUUGU
  BH0060	No. 4027	AUGAUUUCUCCAGUGCUCAUC	No. 4729	GAUGAGCACUGGAGAAAUCAUUG
  BH0061	No. 4028	UGAUUUCUCCAGUGCUCAUCU	No. 4730	AGAUGAGCACUGGAGAAAUCAUU
  BH0062	No. 4029	GAUUUCUCCAGUGCUCAUCUU	No. 4731	AAGAUGAGCACUGGAGAAAUCAU
  BH0063	No. 4030	AUUUCUCCAGUGCUCAUCUUG	No. 4732	CAAGAUGAGCACUGGAGAAAUCA
  BH0064	No. 4031	UUUCUCCAGUGCUCAUCUUGU	No. 4733	ACAAGAUGAGCACUGGAGAAAUC
  BH0065	No. 4032	UUCUCCAGUGCUCAUCUUGUU	No. 4734	AACAAGAUGAGCACUGGAGAAAU
  BH0066	No. 4033	UCUCCAGUGCUCAUCUUGUUC	No. 4735	GAACAAGAUGAGCACUGGAGAAA
  BH0067	No. 4034	CUCCAGUGCUCAUCUUGUUCU	No. 4736	AGAACAAGAUGAGCACUGGAGAA
  BH0068	No. 4035	UCCAGUGCUCAUCUUGUUCUC	No. 4737	GAGAACAAGAUGAGCACUGGAGA
  BH0069	No. 4036	CCAGUGCUCAUCUUGUUCUCG	No. 4738	CGAGAACAAGAUGAGCACUGGAG
  BH0070	No. 4037	CAGUGCUCAUCUUGUUCUCGA	No. 4739	UCGAGAACAAGAUGAGCACUGGA
  BH0071	No. 4038	AGUGCUCAUCUUGUUCUCGAG	No. 4740	CUCGAGAACAAGAUGAGCACUGG
  BH0072	No. 4039	GUGCUCAUCUUGUUCUCGAGU	No. 4741	ACUCGAGAACAAGAUGAGCACUG
  BH0073	No. 4040	UGCUCAUCUUGUUCUCGAGUU	No. 4742	AACUCGAGAACAAGAUGAGCACU

• TABLE 2-2
  Double
  stranded
  nucleic	SEQ	Sense strand sequence	SEQ	Antsense strand
  acid No	ID NO.	(5′→3′)	ID NO	sequence (5′→3′)
  BH0074	No. 4041	GCUCAUCUUGUUCUCGAGUUU	No. 4743	AAACUCGAGAACAAGAUGAGCAC
  BH0075	No. 4042	CUCAUCUUGUUCUCGAGUUUU	No. 4744	AAAACUCGAGAACAAGAUGAGCA
  BH0076	No. 4043	UCAUCUUGUUCUCGAGUUUUC	No. 4745	GAAAACUCGAGAACAAGAUGAGC
  BH0077	No. 4044	CAUCUUGUUCUCGAGUUUUCU	No. 4746	AGAAAACUCGAGAACAAGAUGAG
  BH0078	No. 4045	AUCUUGUUCUCGAGUUUUCUC	No. 4747	GAGAAAACUCGAGAACAAGAUGA
  BH0079	No. 4046	UCUUGUUCUCGAGUUUUCUCU	No. 4748	AGAGAAAACUCGAGAACAAGAUG
  BH0080	No. 4047	CUUGUUCUCGAGUUUUCUCUG	No. 4749	CAGAGAAAACUCGAGAACAAGAU
  BH0081	No. 4048	UUGUUCUCGAGUUUUCUCUGG	No. 4750	GCAGAGAAAACUCGAGAACAAGA
  BH0083	No. 4049	GUUCUCGAGUUUUCUCUGCCA	No. 4751	UGGCAGAGAAAACUCGAGAACAA
  BH0084	No. 4050	UUCUCGAGUUUUCUCUGCCAU	No. 4752	AUGGCAGAGAAAACUCGAGAACA
  BH0085	No. 4051	UCUCGAGUUUUCUCUGCCAUG	No. 4753	CAUGGCAGAGAAAACUCGAGAAC
  BH0086	No. 4052	CUCGAGUUUUCUOUGCCAUGU	No. 4754	ACAUGGCAGAGAAAACUCGAGAA
  BH0087	No. 4053	UCGAGUUUUCUCUGCCAUGUU	No. 4755	AACAUGGCAGAGAAAACUCGAGA
  BH0088	No. 4054	CGAGUUUUCUCUGCCAUGUUG	No. 4756	CAACAUGGCAGAGAAAACUCGAG
  BH0089	No. 4055	GAGUUUUCUCUGGCAUGUUGC	No. 4757	GCAACAUGGCAGAGAAAACUCGA
  BH0090	No. 4056	AGUUUUCUCUGCCAUGUUGCU	No. 4758	AGCAACAUGGCAGAGAAAACUCG
  BH0091	No. 4057	GUUUUCUCUGCCAUGUUGCUA	No. 4759	UAGCAACAUGGCAGAGAAAACUC
  BH0092	No. 4058	UUUUCUCUGCCAUGUUGCUAU	No. 4760	AUAGCAACAUGGCAGAGAAAACU
  BH0093	No. 4059	UUUCUCUGCCAUGUUGCUAUU	No. 4761	AAUAGCAACAUGGCAGAGAAAAC
  BH0096	No. 4060	CUCUGCCAUGUUGCUAUUGCA	No. 4762	UGCAAUAGCAACAUGGCAGAGAA
  BH0097	No. 4061	UCUGCCAUGUUGCUAUUGCAG	No. 4763	CUGCAAUAGCAACAUGGCAGAGA
  BH0098	No. 4062	CUGCCAUGUUGCUAUUGCAGG	No. 4764	CCUGCAAUAGCAACAUGGCAGAG
  BH0099	No. 4063	UGCCAUGUUGCUAUUGCAGGA	No. 4765	UCCUGCAAUAGCAACAUGGCAGA
  BH0103	No. 4064	AUGUUGCUAUUGCAGGACGGA	No. 4766	UCCGUCCUGCAAUAGCAACAUGG
  BH0106	No. 4065	UUGCUAUUGCAGGACGGACCU	No. 4767	AGGUCCGUCCUGCAAUAGCAACA
  BH0107	No. 4066	UGCUAUUGCAGGACGGACCUG	No. 4768	CAGGUCCGUCCUGCAAUAGCAAC
  BH0108	No. 4067	GCUAUUGCAGGACGGACCUGU	No. 4769	ACAGGUCCGUCCUGCAAUAGCAA
  BH0109	No. 4068	CUAUUGCAGGACGGACCUGUC	No. 4770	GACAGGUCCGUCCUGCAAUAGCA
  BH0112	No. 4069	UUGCAGGACGGACCUGUCCCA	No. 4771	UGGGACAGGUCCGUCCUGCAAUA
  BH0114	No. 4070	GCAGGACGGACCUGUCCCAAG	No. 4772	CUUGGGACAGGUCCGUCCUGCAA
  BH0115	No. 4071	CAGGACGGACCUGUCCCAAGC	No. 4773	GCUUGGGACAGGUCCGUCCUGCA
  BH0117	No. 4072	GGACGGACCUGUCCCAAGCCA	No. 4774	UGGCUUGGGACAGGUCCGUCCUG
  BH0118	No. 4073	GACGGACCUGUCCCAAGCCAG	No. 4775	CUGGCUUGGGACAGGUCCGUCCU
  BH0119	No. 4074	ACGGACCUGUCCCAAGCCAGA	No. 4776	UCUGGCUUGGGACAGGUCCGUCC
  6H0120	No. 4075	CGGACCUGUCCCAAGCCAGAU	No. 4777	AUCUGGCUUGGGACAGGUCCGUC
  BH0121	No. 4076	GGACCUGUCCCAAGCCAGAUG	No. 4778	CAUCUGGCUUGGGACAGGUCCGU
  BH0122	No. 4077	GACCUGUCCCAAGCCAGAUGA	No. 4779	UCAUCUGGCUUGGGACAGGUCCG
  BH0123	No. 4078	ACCUGUCCCAAGCCAGAUGAU	No. 4780	AUCAUCUGGCUUGGGACAGGUCC
  BH0124	No. 4079	CCUGUCCCAAGOCAGAUGAUU	No. 4781	AAUCAUCUGGCUUGGGACAGGUC
  BH0125	No. 4080	CUGUCCCAAGCCAGAUGAUUU	No. 4782	AAAUCAUCUGGCUUGGGACAGGU

• TABLE 2-3
  Double
  stranded
  nucleic	SEQ	Sense strand sequence	SEQ	Antsense strand
  acid No	ID NO.	(5′→3′)	ID NO	sequence (5′→3′)
  BH0126	No. 4081	UGUCCCAAGCCAGAUGAUUUA	No. 4783	UAAAUCAUCUGGCUUGGGACAGG
  BH0127	No. 4082	GUCCCAAGCCAGAUGAUUUAC	No. 4784	GUAAAUCAUCUGGCUUGGGACAG
  BH0128	No. 4083	UCCCAAGCCAGAUGAUUUACC	No. 4785	GGUAAAUCAUCUGGCUUGGGACA
  BH0129	No. 4084	CCCAAGCCAGAUGAUUUACCA	No. 4786	UGGUAAAUCAUCUGGCUUGGGAC
  BH0130	No. 4085	CCAAGCCAGAUGAUUUACCAU	No. 4787	AUGGUAAAUCAUCUGGCUUGGGA
  BH0131	No. 4086	CAAGCCAGAUGAUUUACCAUU	No. 4788	AAUGGUAAAUCAUCUGGCUUGGG
  BH0132	No. 4087	AAGCCAGAUGAUUUACCAUUU	No. 4789	AAAUGGUAAAUCAUCUGGCUUGG
  BH0133	No. 4088	AGCCAGAUGAUUUACCAUUUU	No. 4790	AAAAUGGUAAAUCAUCUGGCUUG
  BH0134	No. 4089	GCCAGAUGAUUUACCAUUUUC	No. 4791	GAAAAUGGUAAAUCAUCUGGCUU
  BH0135	No. 4090	CCAGAUGAUUUACCAUUUUCC	No. 4792	GGAAAAUGGUAAAUCAUCUGGCU
  BH0136	No. 4091	CAGAUGAUUUACCAUUUUCCA	No. 4793	GUGGAAAAUGGUAAAUCAUCUGG
  BH0137	No. 4092	AGAUGAUUUACCAUUUUCCAC	No. 4794	UGUGGAAAAUGGUAAAUCAUCUG
  BH0138	No. 4093	GAUGAUUUACCAUUUUCCACA	No. 4795	UGUGGAAAAUGGUAAAUCAUCUG
  BH0139	No. 4094	AUGAUUUACCAUUUUCCACAG	No. 4796	CUGUGGAAAAUGGUAAAUCAUCU
  BH0143	No. 4095	UUUACCAUUUUCCACAGUGGU	No. 4797	ACCACUGUGGAAAAUGGUAAAUC
  BH0144	No. 4096	UUACCAUUUUCCACAGUGGUC	No. 4798	GACCACUGUGGAAAAUGGUAAAU
  BH0145	No. 4097	UACCAUUUUCCACAGUGGUCC	No. 4799	GGACCACUGUGGAAAAUGGUAAA
  BH0149	No. 4098	AUUUUCCACAGUGGUCCCGUU	No. 4800	AACGGGACCACUGUGGAAAAUGG
  BH0150	No. 4099	UUUUCCACAGUGGUCCCGUUA	No. 4801	UAACGGGACCACUGUGGAAAAUG
  BH0151	No. 4100	UUUCCACAGUGGUCCCGUUAA	No. 4802	UUAACGGGACCACUGUGGAAAAU
  BH0152	No. 4101	UUCCACAGUGGUCCCGUUAAA	No. 4803	UUUAACGGGACCACUGUGGAAAA
  BH0153	No. 4102	UCCACAGUGGUCCCGUUAAAA	No. 4804	UUUUAACGGGACCACUGUGGAAA
  BH0154	No. 4103	CCACAGUGGUCCCGUUAAAAA	No. 4805	UUUUUAACGGGACCACUGUGGAA
  BH0155	No. 4104	CACAGUGGUCCCGUUAAAAAC	No. 4806	GUUUUUAACGGGACCACUGUGGA
  BH0156	No. 4105	ACAGUGGUCCCGUUAAAAACA	No. 4807	UGUUUUUAACGGGACCACUGUGG
  BH0157	No. 4106	CAGUGGUCCCGUUAAAAACAU	No. 4808	AUGUUUUUAACGGGACCACUGUG
  BH0158	No. 4107	AGUGGUCCCGUUAAAAACAUU	No. 4809	AAUGUUUUUAACGGGACCACUGU
  BH0159	No. 4108	GUGGUCCCGUUAAAAACAUUC	No. 4810	GAAUGUUUUUAACGGGACCACUG
  BH0160	No. 4109	UGGUCCCGUUAAAAACAUUCU	No. 4811	AGAAUGUUUUUAACGGGACCACU
  BH0161	No. 4110	GGUCCCGUUAAAAACAUUCUA	No. 4812	UAGAAUGUUUUUAACGGGACCAC
  BH0162	No. 4111	GUCCCGUUAAAAACAUUCUAU	No. 4813	AUAGAAUGUUUUUAACGGGACCA
  BH0163	No. 4112	UCCCGUUAAAAACAUUCUAUG	No. 4814	CAUAGAAUGUUUUUAACGGGACC
  BH0164	No. 4113	CCCGUUAAAAACAUUCUAUGA	No. 4815	UCAUAGAAUGUUUUUAACGGGAC
  BH0173	No. 4114	AACAUUCUAUGAGCCAGGAGA	No. 4816	UCUCCUGGCUCAUAGAAUGUUUU
  BH0174	No. 4115	ACAUUCUAUGAGCCAGGAGAA	No. 4817	UUCUCCUGGCUCAUAGAAUGUUU
  BH0177	No. 4116	UUCUAUGAGCCAGGAGAAGAG	No. 4818	CUCUUCUCCUGGCUCAUAGAAUG
  BH0178	No. 4117	UCUAUGAGCCAGGAGAAGAGA	No. 4819	UCUCUUCUCCUGGCUCAUAGAAU
  BH0179	No. 4118	CUAUGAGCCAGGAGAAGAGAU	No. 4820	AUCUCUUCUCCUGGCUCAUAGAA
  BH0180	No. 4119	UAUGAGCCAGGAGAAGAGAUU	No. 4821	AAUCUCUUCUCCUGGCUCAUAGA
  BH0181	No. 4120	AUGAGCCAGGAGAAGAGAUUA	No. 4822	UAAUCUCUUCUCCUGGCUCAUAG

• TABLE 2-4
  Double
  stranded
  nucleic	SEQ	Sense strand sequence	SEQ	Antsense strand
  acid No	ID NO.	(5′→3′)	ID NO	sequence (5′→3′)
  BH0183	No. 4121	GAGCCAGGAGAAGAGAUUACG	No. 4823	CGUAAUCUCUUCUCCUGGCUCAU
  BH0184	No. 4122	AGCCAGGAGAAGAGAUUACGU	No. 4824	ACGUAAUCUCUUCUCCUGGCUCA
  BH0185	No. 4123	GCCAGGAGAAGAGAUUACGUA	No. 4825	UACGUAAUCUCUUCUCCUGGCUC
  BH0186	No. 4124	CCAGGAGAAGAGAUUACGUAU	No. 4826	AUACGUAAUCUCUUCUCCUGGCU
  BH0187	No. 4125	CAGGAGAAGAGAUUACGUAUU	No. 4827	AAUACGUAAUCUCUUCUCCUGGC
  BH0188	No. 4126	AGGAGAAGAGAUUACGUAUUC	No. 4828	GAAUACGUAAUCUCUUCUCCUGG
  BH0189	No. 4127	GGAGAAGAGAUUACGUAUUCC	No. 4829	GGAAUACGUAAUCUCUUCUCCUG
  BH0190	No. 4128	GAGAAGAGAUUACGUAUUCCU	No. 4830	AGGAAUACGUAAUCUCUUCUCCU
  BH0193	No. 4129	AAGAGAUUACGUAUUCCUGCA	No. 4831	UGCAGGAAUACGUAAUCUCUUCU
  BH0194	No. 4130	AGAGAUUACGUAUUCCUGCAA	No. 4832	UUGCAGGAAUACGUAAUCUCUUC
  BH0195	No. 4131	GAGAUUACGUAUUCCUGCAAG	No. 4833	CUUGCAGGAAUACGUAAUCUCUU
  BH0199	No. 4132	UUACGUAUUCCUGCAAGCCGG	No. 4834	CCGGCUUGCAGGAAUACGUAAUC
  BH0203	No. 4133	GUAUUCCUGCAAGCCGGGCUA	No. 4835	UAGCCCGGCUUGCAGGAAUACGU
  BH0207	No. 4134	UCCUGCAAGCCGGGCUAUGUG	No. 4836	CACAUAGCCCGGCUUGCAGGAAU
  BH0225	No. 4135	GUGUCCCGAGGAGGGAUGAGA	No. 4837	UCUCAUCCCUCCUCGGGACACAU
  BH0226	No. 4136	UGUCCCGAGGAGGGAUGAGAA	No. 4838	UUCUCAUCCCUCCUCGGGACACA
  BH0229	No. 4137	CCCGAGGAGGGAUGAGAAAGU	No. 4839	ACUUUCUCAUCCCUCCUCGGGAC
  BH0230	No. 4138	CCGAGGAGGGAUGAGAAAGUU	No. 4840	AACUUUCUCAUCCCUCCUCGGGA
  BH0231	No. 4139	CGAGGAGGGAUGAGAAAGUUU	No. 4841	AAACUUUCUCAUCCCUCCUCGGG
  BH0232	No. 4140	GAGGAGGGAUGAGAAAGUUUA	No. 4842	UAAACUUUCUCAUCCCUCCUCGG
  BH0233	No. 4141	AGGAGGGAUGAGAAAGUUUAU	No. 4843	AUAAACUUUCUCAUCCCUCCUCG
  BH0234	No. 4142	GGAGGGAUGAGAAAGUUUAUC	No. 4844	GAUAAACUUUCUCAUCCCUCCUC
  BH0235	No. 4143	GAGGGAUGAGAAAGUUUAUCU	No. 4845	AGAUAAACUUUCUCAUCCCUCCU
  BH0236	No. 4144	AGGGAUGAGAAAGUUUAUCUG	No. 4846	CAGAUAAACUUUCUCAUCCCUCC
  BH0242	No. 4145	GAGAAAGUUUAUCUGCCCUCU	No. 4847	AGAGGGCAGAUAAACUUUCUCAU
  BH0244	No. 4146	GAAAGUUUAUCUGCCCUCUCA	No. 4848	UGAGAGGGCAGAUAAACUUUCUC
  BH0255	No. 4147	UGCCCUCUCACAGGACUGUGG	No. 4849	CCACAGUCCUGUGAGAGGGCAGA
  BH0260	No. 4148	UCUCACAGGACUGUGGCCCAU	No. 4850	AUGGGCCACAGUCCUGUGAGAGG
  BH0262	No. 4149	UCACAGGACUGUGGCCCAUCA	No. 4851	UGAUGGGCCACAGUCCUGUGAGA
  BH0265	No. 4150	CAGGACUGUGGCCCAUCAACA	No. 4852	UGUUGAUGGGCCACAGUCCUGUG
  BH0266	No. 4151	AGGACUGUGGCCCAUCAACAC	No. 4853	GUGUUCAUGGGCCACAGUCCUGU
  BH0272	No. 4152	GUGGCCCAUCAACACUCUGAA	No. 4854	UUCAGAGUGUUGAUGGGCCACAG
  BH0274	No. 4153	GGCCCAUCAACACUCUGAAAU	No. 4855	AUUUCAGAGUGUUGAUGGGCCAC
  BH0275	No. 4154	GCCCAUCAACACUCUGAAAUG	No. 4856	CAUUUCAGAGUGUUGAUGGGCCA
  BH0276	No. 4155	CCCAUCAACACUCUGAAAUGU	No. 4857	ACAUUUCAGAGUGUUGAUGGGCC
  BH0277	No. 4156	CCAUCAACACUCUGAAAUGUA	No. 4858	UACAUUUCAGAGUGUUGAUGGGC
  BH0279	No. 4157	AUCAACACUCUGAAAUGUACA	No. 4859	UGUACAUUUCAGAGUGUUGAUGG
  BH0283	No. 4158	ACACUCUGAAAUGUACACCCA	No. 4860	UGGGUGUACAUUUCAGAGUGUUG
  BH0285	No. 4159	ACUCUGAAAUGUACACCCAGA	No. 4861	UCUGGGUGUACAUUUCAGAGUGU
  BH0288	No. 4160	CUGAAAUGUACACCCAGAGUA	No. 4862	UACUCUGGGUGUACAUUUCAGAG

• TABLE 2-5
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0289	No. 4161	UGAAAUGUACACCCAGAGUAU	No. 4863	AUACUCUGGGUGUACAUUUCAGA
  BH0291	No. 4162	AAAUGUACACCCAGAGUAUGU	No. 4864	ACAUACUCUGGGUGUACAUUUCA
  BH0294	No. 4163	UGUACACCCAGAGUAUGUCCU	No. 4865	AGGACAUACUCUGGGUGUACAUU
  BH0295	No. 4164	GUACACCCAGAGUAUGUCCUU	No. 4866	AAGGACAUACUCUGGGUGUACAU
  BH0296	No. 4165	UACACCCAGAGUAUGUCCUUU	No. 4867	AAAGGACAUACUCUGGGUGUACA
  BH0297	No. 4166	ACACCCAGAGUAUGUCCUUUU	No. 4868	AAAAGGACAUACUCUGGGUGUAC
  BH0298	No. 4167	CACCCAGAGUAUGUCCUUUUG	No. 4869	CAAAAGGACAUACUCUGGGUGUA
  BH0300	No. 4168	CCCAGAGUAUGUCCUUUUGCU	No. 4870	AGCAAAAGGACAUACUCUGGGUG
  BH0301	No. 4169	CCAGAGUAUGUCCUUUUGCUG	No. 4871	CAGCAAAAGGACAUACUCUGGGU
  BH0302	No. 4170	CAGAGUAUGUCCUUUUGCUGG	No. 4872	CCAGCAAAAGGACAUACUCUGGG
  BH0303	No. 4171	AGAGUAUGUCCUUUUGCUGGA	No. 4873	UCCAGCAAAAGGACAUACUCUGG
  BH0304	No. 4172	GAGUAUGUCCUUUUGCUGGAA	No. 4874	UUCCAGCAAAAGGACAUACUCUG
  BH0306	No. 4173	GUAUGUCCUUUUGCUGGAAUC	No. 4875	GAUUCCAGCAAAAGGACAUACUC
  BH0307	No. 4174	UAUGUCCUUUUGCUGGAAUCU	No. 4876	AGAUUCCAGCAAAAGGACAUACU
  BH0308	No. 4175	AUGUCCUUUUGCUGGAAUCUU	No. 4877	AAGAUUCCAGCAAAAGGACAUAC
  BH0309	No. 4176	UGUCCUUUUGCUGGAAUCUUA	No. 4878	UAAGAUUCCAGCAAAAGGACAUA
  BH0310	No. 4177	GUCCUUUUGCUGGAAUCUUAG	No. 4879	CUAAGAUUCCAGCAAAAGGACAU
  BH0311	No. 4178	UCCUUUUGCUGGAAUCUUAGA	No. 4880	UCUAAGAUUCCAGCAAAAGGACA
  BH0314	No. 4179	UUUUGCUGGAAUCUUAGAAAA	No. 4881	UUUUCUAAGAUUCCAGCAAAAGG
  BH0315	No. 4180	UUUGCUGGAAUCUUAGAAAAU	No. 4882	AUUUUCUAAGAUUCCAGCAAAAG
  BH0316	No. 4181	UUGCUGGAAUCUUAGAAAAUG	No. 4883	CAUUUUCUAAGAUUCCAGCAAAA
  BH0317	No. 4182	UGCUGGAAUCUUAGAAAAUGG	No. 4884	CCAUUUUCUAAGAUUCCAGCAAA
  BH0318	No. 4183	GCUGGAAUCUUAGAAAAUGGA	No. 4885	UCCAUUUUCUAAGAUUCCAGCAA
  BH0319	No. 4184	CUGGAAUCUUAGAAAAUGGAG	No. 4886	CUCCAUUUUCUAAGAUUCCAGCA
  BH0324	No. 4185	AUCUUAGAAAAUGGAGCCGUA	No. 4887	UACGGCUCCAUUUUCUAAGAUUC
  BH0327	No. 4186	UUAGAAAAUGGAGCCGUACGC	No. 4888	GCGUACGGCUCCAUUUUCUAAGA
  BH0328	No. 4187	UAGAAAAUGGAGCCGUACGCU	No. 4889	AGCGUACGGCUCCAUUUUCUAAG
  BH0329	No. 4188	AGAAAAUGGAGCCGUACGCUA	No. 4890	UAGCGUACGGCUCCAUUUUCUAA
  BH0330	No. 4189	GAAAAUGGAGCCGUACGCUAU	No. 4891	AUAGCGUACGGCUCCAUUUUCUA
  BH0331	No. 4190	AAAAUGGAGCCGUACGCUAUA	No. 4892	UAUAGCGUAGGGCUCCAUUUUCU
  BH0334	No. 4191	AUGGAGCCGUACGCUAUACGA	No. 4893	UCGUAUAGCGUACGGCUCCAUUU
  BH0335	No. 4192	UGGAGCCGUACGCUAUACGAC	No. 4894	GUCGUAUAGCGUACGGCUCCAUU
  BH0336	No. 4103	GGAGCCGUACGCUAUACGACU	No. 4895	AGUCGUAUAGCGUACGGCUCCAU
  BH0337	No. 4194	GAGCCGUACGCUAUACGACUU	No. 4896	AAGUCGUAUAGCGUACGGCUCCA
  BH0338	No. 4195	AGCCGUACGCUAUACGACUUU	No. 4897	AAAGUCGUAUAGCGUACGGCUCC
  BH0339	No. 4196	GCCGUACGCUAUACGACUUUU	No. 4898	AAAAGUGGUAUAGCGUACGGCUC
  BH0340	No. 4197	CCGUACGCUAUACGACUUUUG	No. 4899	CAAAAGUCGUAUAGCGUACGGCU
  BH0341	No. 4198	CGUACGCUAUACGACUUUUGA	No. 4900	UCAAAAGUCGUAUAGCGUACGGC
  BH0342	No. 4199	GUACGCUAUACGACUUUUGAA	No. 4901	UUCAAAAGUCGUAUAGCGUACGG
  BH0343	No. 4200	UACGCUAUACGACUUUUGAAU	No. 4902	AUUCAAAAGUCGUAUAGCGUACG

• TABLE 2-6
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0345	No. 4201	CGCUAUACGACUUUUGAAUAU	No. 4903	AUAUUCAAAAGUCGUAUAGCGUA
  BH0346	No. 4202	GCUAUACGACUUUUGAAUAUC	No. 4904	GAUAUUCAAAAGUCGUAUAGCGU
  BH0349	No. 4203	AUACGACUUUUGAAUAUCCCA	No. 4905	UGGGAUAUUCAAAAGUCGUAUAG
  BH0350	No. 4204	UACGACUUUUGAAUAUCCCAA	No. 4906	UUGGGAUAUUCAAAAGUCGUAUA
  BH0351	No. 4205	ACGACUUUUGAAUAUCCCAAC	No. 4907	GUUGGGAUAUUCAAAAGUCGUAU
  BH0352	No. 4206	CGACUUUUGAAUAUCCCAACA	No. 4908	UGUUGGGAUAUUCAAAAGUCGUA
  BH0355	No. 4207	CUUUUGAAUAUCCCAACACGA	No. 4909	UCGUGUUGGGAUAUUCAAAAGUC
  BH0356	No. 4208	UUUUGAAUAUCCCAACACGAU	No. 4910	AUCGUGUUGGGAUAUUCAAAAGU
  BH0357	No. 4209	UUUGAAUAUCCCAACACGAUC	No. 4911	GAUCGUGUUGGGAUAUUCAAAAG
  BH0358	No. 4210	UUGAAUAUCCCAACACGAUCA	No. 4912	UGAUCGUGUUGGGAUAUUCAAAA
  BH0361	No. 4211	AAUAUCCCAACACGAUCAGUU	No. 4913	AACUGAUCGUGUUGGGAUAUUCA
  BH0362	No. 4212	AUAUCCCAACACGAUCAGUUU	No. 4914	AAACUGAUCGUGUUGGGAUAUUC
  BH0363	No. 4213	UAUCCCAACACGAUCAGUUUU	No. 4915	AAAACUGAUCGUGUUGGGAUAUU
  BH0364	No. 4214	AUCCCAACACGAUCAGUUUUU	No. 4916	AAAAACUGAUCGUGUUGGGAUAU
  BH0365	No. 4215	UCCCAACACGAUCAGUUUUUC	No. 4917	GAAAAACUGAUCGUGUUGGGAUA
  BH0366	No. 4216	CCCAACACGAUCAGUUUUUCU	No. 4918	AGAAAAACUGAUCGUGUUGGGAU
  BH0367	No. 4217	CCAAGACGAUCAGUUUUUCUU	No. 4919	AAGAAAAACUGAUCGUGUUGGGA
  BH0369	No. 4218	AACACGAUCAGUUUUUCUUGU	No. 4920	ACAAGAAAAACUGAUCGUGUUGG
  BH0370	No. 4219	ACACGAUCAGUUUUUCUUGUA	No. 4921	UACAAGAAAAACUGAUCGUGUUG
  BH0371	No. 4220	CACGAUCAGUUUUUCUUGUAA	No. 4922	UUACAAGAAAAACUGAUCGUGUU
  BH0372	No. 4221	ACGAUCAGUUUUUCUUGUAAC	No. 4923	GUUACAAGAAAAACUGAUCGUGU
  BH0373	No. 4222	CGAUCAGUUUUUCUUGUAACA	No. 4924	UGUUACAAGAAAAACUGAUCGUG
  BH0375	No. 4223	AUCAGUUUUUCUUGUAACACU	No. 4925	AGUGUUACAAGAAAAACUGAUCG
  BH0376	No. 4224	UCAGUUUUUCUUGUAACACUG	No. 4926	CAGUGUUACAAGAAAAACUGAUC
  BH0382	No. 4225	UUUCUUGUAACACUGGGUUUU	No. 4927	AAAACCCAGUGUUACAAGAAAAA
  BH0383	No. 4226	UUCUUGUAACACUGGGUUUUA	No. 4928	UAAAACCCAGUGUUACAAGAAAA
  BH0384	No. 4227	UCUUGUAACACUGGGUUUUAU	No. 4929	AUAAAACCCAGUGUUACAAGAAA
  BH0385	No. 4228	CUUGUAACACUGGGUUUUAUC	No. 4930	GAUAAAACCCAGUGUUACAAGAA
  BH0386	No. 4229	UUGUAACACUGGGUUUUAUCU	No. 4931	AGAUAAAACCCAGUGUUACAAGA
  BH0388	No. 4230	GUAACACUGGGUUUUAUCUGA	No. 4932	UCAGAUAAAACCCAGUGUUACAA
  BH0389	No. 4231	UAACACUGGGUUUUAUCUGAA	No. 4933	UUCAGAUAAAACCCAGUGUUACA
  BH0390	No. 4232	AACACUGGGUUUUAUCUGAAU	No. 4934	AUUCAGAUAAAACCCAGUGUUAC
  BH0392	No. 4233	CACUGGGUUUUAUCUGAAUGG	No. 4935	CCAUUCAGAUAAAACCCAGUGUU
  BH0394	No. 4234	CUGGGUUUUAUCUGAAUGGCG	No. 4936	CGCCAUUCAGAUAAAACCCAGUG
  BH0395	No. 4235	UGGGUUUUAUCUGAAUGGCGC	No. 4937	GCGCCAUUCAGAUAAAACCCAGU
  BH0396	No. 4236	GGGUUUUAUCUGAAUGGCGCU	No. 4938	AGCGCCAUUCAGAUAAAACCCAG
  BH0399	No. 4237	UUUUAUCUGAAUGGCGCUGAU	No. 4939	AUCAGCGCCAUUCAGAUAAAACC
  BH0402	No. 4238	UAUCUGAAUGGCGCUGAUUCU	No. 4940	AGAAUCAGCGCCAUUCAGAUAAA
  BH0406	No. 4239	UGAAUGGCGCUGAUUCUGCCA	No. 4941	UGGCAGAAUCAGCGCCAUUCAGA
  BH0409	No. 4240	AUGGCGCUGAUUCUGCCAAGU	No. 4942	ACUUGGCAGAAUCAGCGCCAUUC

• TABLE 2-7
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0410	No. 4241	UGGCGCUGAUUCUGCCAAGUG	No. 4943	CACUUGGCAGAAUCAGCGCCAUU
  BH0411	No. 4242	GGCGCUGAUUCUGCCAAGUGC	No. 4944	GCACUUGGCAGAAUCAGCGCCAU
  BH0412	No. 4243	GCGCUGAUUCUGCCAAGUGCA	No. 4945	UGCACUUGGCAGAAUCAGCGCCA
  BH0413	No. 4244	CGCUGAUUCUGCCAAGUGCAC	No. 4946	GUGCACUUGGCAGAAUCAGCGCC
  BH0414	No. 4245	GCUGAUUCUGCCAAGUGCACU	No. 4947	AGUGCACUUGGCAGAAUCAGCGC
  BH0415	No. 4246	CUGAUUCUGCCAAGUGCACUG	No. 4948	CAGUGCACUUGGCAGAAUCAGCG
  BH0419	No. 4247	UUCUGCCAAGUGCACUGAGGA	No. 4949	UCCUCAGUGCACUUGGCAGAAUC
  BH0420	No. 4248	UCUGCCAAGUGCACUGAGGAA	No. 4950	UUCCUCAGUGCACUUGGCAGAAU
  BH0422	No. 4249	UGCCAAGUGCACUGAGGAAGG	No. 4951	CCUUCCUCAGUGCACUUGGCAGA
  BH0428	No. 4250	GCCAAGUGCACUGAGGAAGGA	No. 4952	UCCUUCCUCAGUGCACUUGGCAG
  BH0424	No. 4251	CCAAGUGCACUGAGGAAGGAA	No. 4953	UUCCUUCCUCAGUGCACUUGGCA
  BH0425	No. 4252	CAAGUGCACUGAGGAAGGAAA	No. 4954	UUUCCUUCCUCAGUGCACUUGGC
  BH0426	No. 4253	AAGUGCACUGAGGAAGGAAAA	No. 4955	UUUUCCUUCCUCAGUGCACUUGG
  BH0427	No. 4254	AGUGCACUGAGGAAGGAAAAU	No. 4956	AUUUUCCUUCCUCAGUGCACUUG
  BH0436	No. 4255	AGGAAGGAAAAUGGAGCCCGG	No. 4957	CCGGGCUCCAUUUUCCUUCCUCA
  BH0449	No. 4256	GAGCCCGGAGCUUCCUGUCUG	No. 4958	CAGACAGGAAGCUCCGGGCUCCA
  BH0450	No. 4257	AGCCCGGAGCUUCCUGUCUGU	No. 4959	ACAGACAGGAAGCUCCGGGCUCC
  BH0453	No. 4258	CCGGAGCUUCCUGUCUGUGCU	No. 4960	AGCACAGACAGGAAGCUCCGGGC
  BH0454	No. 4259	CGGAGCUUCCUGUCUGUGCUC	No. 4961	GAGCACAGACAGGAAGCUCCGGG
  BH0457	No. 4260	AGCUUCCUGUCUGUGCUCCCA	No. 4962	UGGGAGCACAGACAGGAAGCUCC
  BH0461	No. 4261	UCCUGUCUGUGCUCCCAUCAU	No. 4963	AUGAUGGGAGCACAGACAGGAAG
  BH0463	No. 4262	CUGUCUGUGCUCCCAUCAUCU	No. 4964	AGAUGAUGGGAGCACAGACAGGA
  BH0472	No. 4263	CUCCCAUCAUCUGCCCUCCAC	No. 4965	GUGGAGGGCAGAUGAUGGGAGCA
  BH0475	No. 4264	CCAUCAUCUGCCCUCCACCAU	No. 4966	AUGGUGGAGGGCAGAUGAUGGGA
  BH0476	No. 4265	CAUCAUCUGCCCUCCACCAUC	No. 4967	GAUGGUGGAGGGCAGAUGAUGGG
  BH0480	No. 4266	AUCUGCCCUCCACCAUCCAUA	No. 4968	UAUGGAUGGUGGAGGGCAGAUGA
  BH0484	No. 4267	GCCCUCCACCAUCCAUACCUA	No. 4969	UAGGUAUGGAUGGUGGAGGGCAG
  BH0487	No. 4268	CUCCACCAUCCAUACCUACGU	No. 4970	ACGUAGGUAUGGAUGGUGGAGGG
  BH0488	No. 4269	UCCACCAUCCAUACCUACGUU	No. 4971	AACGUAGGUAUGGAUGGUGGAGG
  BH0489	No. 4270	CCACCAUCCAUACCUACGUUU	No. 4972	AAACGUAGGUAUGGAUGGUGGAG
  BH0490	No. 4271	CACCAUCCAUACCUACGUUUG	No. 4973	CAAACGUAGGUAUGGAUGGUGGA
  BH0491	No. 4272	ACCAUCCAUACCUACGUUUGC	No. 4974	GCAAACGUAGGUAUGGAUGGUGG
  BH0492	No. 4273	CCAUCCAUACCUACGUUUGCA	No. 4975	UGCAAACGUAGGUAUGGAUGGUG
  BH0483	No. 4274	CAUCCAUACCUACGUUUGCAA	No. 4976	UUGCAAACGUAGGUAUGGAUGGU
  BH0495	No. 4273	UCCAUACCUACGUUUGCAACA	No. 4977	UGUUGCAAACGUAGGUAUGGAUG
  BH0498	No. 4276	AUACCUACGUUUGGAACACUU	No. 4978	AAGUGUUGCAAACGUAGGUAUGG
  BH0499	No. 4277	UACCUACGUUUGCAACACUUC	No. 4979	GAAGUGUUGCAAACGUAGGUAUG
  BH0500	No. 4278	ACCUACGUUUGCAACACUUCG	No. 4980	CGAAGUGUUGCAAACGUAGGUAU
  BH0501	No. 4279	CCUACGUUUGCAACACUUCGU	No. 4981	ACGAAGUGUUGCAAACGUAGGUA
  BH0502	No. 4280	CUACGUUUGCAACACUUCGUG	No. 4982	CACGAAGUGUUGCAAACGUAGGU

• TABLE 2-8
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0503	No. 4281	UACGUUUGCAACACUUCGUGU	No. 4983	ACACGAAGUGUUGCAAACGUAGG
  BH0504	No. 4282	ACGUUUGCAACACUUCGUGUU	No. 4984	AACACGAAGUGUUGCAAACGUAG
  BH0505	No. 4283	CGUUUGCAACACUUCGUGUUU	No. 4985	AAACACGAAGUGUUGCAAACGUA
  BH0506	No. 4284	GUUUGCAACACUUCGUGUUUA	No. 4986	UAAACACGAAGUGUUGCAAACGU
  BH0507	No. 4285	UUUGCAACACUUCGUGUUUAU	No. 4987	AUAAACACGAAGUGUUGCAAACG
  BH0508	No. 4286	UUGCAACACUUCGUGUUUAUA	No. 4988	UAUAAACACGAAGUGUUGCAAAC
  BH0509	No. 4287	UGCAACACUUCGUGUUUAUAA	No. 4989	UUAUAAACACGAAGUGUUGCAAA
  BH0510	No. 4288	GCAACACUUCGUGUUUAUAAG	No. 4990	CUUAUAAACACGAAGUGUUGCAA
  BH0513	No. 4289	ACACUUCGUGUUUAUAAGCCA	No. 4991	UGGCUUAUAAACACGAAGUGUUG
  BH0514	No. 4290	CACUUCGUGUUUAUAAGCCAU	No. 4992	AUGGCUUAUAAACACGAAGUGUU
  BH0518	No. 4291	UCGUGUUUAUAAGCCAUCAGC	No. 4993	GCUGAUGGCUUAUAAACACGAAG
  BH0519	No. 4292	CGUGUUUAUAAGCCAUCAGCU	No. 4994	AGCUGAUGGCUUAUAAACACGAA
  BH0520	No. 4293	GUGUUUAUAAGCCAUCAGCUG	No. 4995	CAGCUGAUGGCUUAUAAACACGA
  BH0526	No. 4294	AUAAGCCAUCAGCUGGAAACA	No. 4996	UGUUUCCAGCUGAUGGCUUAUAA
  BH0527	No. 4295	UAAGCCAUCAGCUGGAAACAA	No. 4997	UUGUUUCCAGCUGAUGGCUUAUA
  BH0528	No. 4296	AAGCCAUCAGCUGGAAACAAU	No. 4998	AUUGUUUCCAGCUGAUGGCUUAU
  BH0529	No. 4297	AGCCAUCAGCUGGAAACAAUU	No. 4999	AAUUGUUUCCAGCUGAUGGCUUA
  BH0530	No. 4298	GCCAUCAGCUGGAAACAAUUC	No. 5000	GAAUUGUUUCCAGCUGAUGGCUU
  BH0534	No. 4299	UCAGCUGGAAACAAUUCCCUC	No. 5001	GAGGGAAUUGUUUCCAGCUGAUG
  BH0535	No. 4300	CAGCUGGAAACAAUUCCCUCU	No. 5002	AGAGGGAAUUGUUUCCAGCUGAU
  BH0538	No. 4301	CUGGAAACAAUUCCCUCUAUC	No. 5003	GAUAGAGGGAAUUGUUUCCAGCU
  BH0542	No. 4302	AAACAAUUCCCUCUAUCGGGA	No. 5004	UCCCGAUAGAGGGAAUUGUUUCC
  BH0549	No. 4303	UCCCUCUAUCGGGACACAGCA	No. 5005	UGCUGUGUCCCGAUAGAGGGAAU
  BH0552	No. 4304	CUCUAUCGGGACACAGCAGUU	No. 5006	AACUGCUGUGUCCCGAUAGAGGG
  BH0553	No. 4305	UCUAUCGGGACACAGCAGUUU	No. 5007	AAACUGCUGUGUCCCGAUAGAGG
  BH0554	No. 4306	CUAUCGGGACACAGCAGUUUU	No. 5008	AAAACUGCUGUGUCCCGAUAGAG
  BH0555	No. 4307	UAUCGGGACACAGCAGUUUUU	No. 5009	AAAAACUGCUGUGUCCCGAUAGA
  BH0557	No. 4308	UCGGGACACAGCAGUUUUUGA	No. 5010	UCAAAAACUGCUGUGUCCCGAUA
  BH0558	No. 4309	CGGGACACAGCAGUUUUUGAA	No. 5011	UUCAAAAACUGCUGUGUCCCGAU
  BH0559	No. 4310	GGGACACAGCAGUUUUUGAAU	No. 5012	AUUCAAAAACUGCUGUGUCCCGA
  BH0561	No. 4311	GACACAGCAGUUUUUGAAUGU	No. 5013	ACAUUCAAAAACUGCUGUGUCCC
  5H0562	No. 4312	ACACAGCAGUUUUUGAAUGUU	No. 5014	AACAUUCAAAAACUGCUGUGUCC
  BH0563	No. 4313	CACAGCAGUUUUUGAAUGUUU	No. 5015	AAACAUUCAAAAACUGCUGUGUC
  BH0564	No. 4314	ACAGCAGUUUUUGAAUGUUUG	No. 5016	CAAACAUUCAAAAACUGCUGUGU
  BH0565	No. 4315	CAGCAGUUUUUGAAUGUUUGC	No. 5017	GCAAACAUUCAAAAACUGCUGUG
  BH0567	No. 4316	GCAGUUUUUGAAUGUUUGCCA	No. 5018	UGGCAAACAUUCAAAAACUGCUG
  BH0568	No. 4317	CAGUUUUUGAAUGUUUGCCAC	No. 5019	GUGGCAAACAUUCAAAAACUGCU
  BH0570	No. 4318	GUUUUUGAAUGUUUGCCACAA	No. 5020	UUGUGGCAAACAUUCAAAAACUG
  BH0572	No. 4319	UUUUGAAUGUUUGCCACAACA	No. 5021	UGUUGUGGCAAACAUUCAAAAAC
  BH0573	No. 4320	UUUGAAUGUUUGCCACAACAU	No. 5022	AUGUUGUGGCAAACAUUCAAAAA

• TABLE 2-9
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0574	No. 4321	UUGAAUGUUUGCCACAACAUG	No. 5023	CAUGUUGUGGCAAACAUUCAAAA
  BH0578	No. 4322	AUGUUUGCCACAACAUGCGAU	No. 5024	AUCGCAUGUUGUGGCAAACAUUC
  BH0582	No. 4323	UUGCCACAACAUGCGAUGUUU	No. 5025	AAACAUCGCAUGUUGUGGCAAAC
  BH0583	No. 4324	UGCCACAACAUGCGAUGUUUG	No. 5026	CAAACAUCGCAUGUUGUGGCAAA
  BH0585	No. 4325	CCACAACAUGCGAUGUUUGGA	No. 5027	UCCAAACAUCGCAUGUUGUGGCA
  BH0586	No. 4326	CACAACAUGCGAUGUUUGGAA	No. 5028	UUCCAAACAUCGCAUGUUGUGGC
  BH0588	No. 4327	CAACAUGCGAUGUUUGGAAAU	No. 5029	AUUUCCAAACAUCGCAUGUUGUG
  BH0590	No. 4328	ACAUGCGAUGUUUGGAAAUGA	No. 5030	UCAUUUCCAAACAUCGCAUGUUG
  BH0591	No. 4329	CAUGGGAUGUUUGGAAAUGAU	No. 5031	AUCAUUUCCAAACAUCGCAUGUU
  BH0592	No. 4330	AUGCGAUGUUUGGAAAUGAUA	No. 5032	UAUCAUUUCCAAACAUCGCAUGU
  BH0593	No. 4331	UGCGAUGUUUGGAAAUGAUAC	No. 5033	GUAUCAUUUCCAAACAUCGCAUG
  BH0594	No. 4332	GCGAUGUUUGGAAAUGAUACA	No. 5034	UGUAUCAUUUCCAAACAUCGCAU
  BH0595	No. 4333	CGAUGUUUGGAAAUGAUACAA	No. 5035	UUGUAUCAUUUCCAAACAUCGCA
  BH0597	No. 4334	AUGUUUGGAAAUGAUACAAUU	No. 5036	AAUUGUAUCAUUUCCAAACAUCG
  BH0598	No. 4335	UGUUUGGAAAUGAUACAAUUA	No. 5037	UAAUUGUAUCAUUUCCAAACAUC
  BH0601	No. 4336	UUGGAAAUGAUACAAUUACCU	No. 5038	AGGUAAUUGUAUCAUUUCCAAAC
  BH0607	No. 4337	AUGAUACAAUUACCUGGACGA	No. 5039	UCGUGCAGGUAAUUGUAUCAUUU
  BH0609	No. 4338	GAUACAAUUACCUGCACGACA	No. 5040	UGUCGUGCAGGUAAUUGUAUCAU
  BH0610	No. 4339	AUACAAUUACCUGCACGACAC	No. 5041	GUGUCGUGCAGGUAAUUGUAUCA
  BH0611	No. 4340	UACAAUUACCUGCACGACACA	No. 5042	UGUGUCGUGCAGGUAAUUGUAUC
  BH0612	No. 4341	ACAAUUACCUGCACGACACAU	No. 5043	AUGUGUCGUGCAGGUAAUUGUAU
  BH0616	No. 4342	UUACCUGCACGACACAUGGAA	No. 5044	UUCCAUGUGUCGUGCAGGUAAUU
  BH0617	No. 4343	UACCUGCACGACACAUGGAAA	No. 5045	UUUCCAUGUGUCGUGCAGGUAAU
  BH0618	No. 4344	ACCUGCACGACACAUGGAAAU	No. 5046	AUUUCCAUGUGUCGUGCAGGUAA
  BH0622	No. 4345	GCACGACACAUGGAAAUUGGA	No. 5047	UCCAAUUUCCAUGUGUCGUGCAG
  BH0624	No. 4346	ACGACACAUGGAAAUUGGACU	No. 5048	AGUCCAAUUUCCAUGUGUCGUGC
  BH0625	No. 4347	CGACACAUGGAAAUUGGACUA	No. 5049	UAGUCCAAUUUCCAUGUGUCGUG
  BH0627	No. 4348	ACACAUGGAAAUUGGACUAAA	No. 5050	UUUAGUCCAAUUUCCAUGUGUCG
  BH0628	No. 4349	CACAUGGAAAUUGGACUAAAU	No. 5051	AUUUAGUCCAAUUUCCAUGUGUC
  BH0629	No. 4350	ACAUGGAAAUUGGACUAAAUU	No. 5052	AAUUUAGUCCAAUUUCCAUGUGU
  BH0630	No. 4351	CAUGGAAAUUGGACUAAAUUA	No. 5053	UAAUUUAGUCCAAUUUCCAUGUG
  BH0631	No. 4352	AUGGAAAUUGGACUAAAUUAC	No. 5054	GUAAUUUAGUCCAAUUUCCAUGU
  BH0633	No. 4353	GGAAAUUGGACUAAAUUACCA	No. 5055	UGGUAAUUUAGUCCAAUUUCCAU
  BH0638	No. 4354	UUGGACUAAAUUACCAGAAUG	No. 5056	CAUUCUGGUAAUUUAGUCCAAUU
  BH0649	No. 4355	UACCAGAAUGCAGGGAAGUAA	No. 5057	UUACUUCCCUGCAUUCUGGUAAU
  BH0650	No. 4356	ACCAGAAUGCAGGGAAGUAAA	No. 5058	UUUACUUCCCUGCAUUCUGGUAA
  BH0651	No. 4357	CCAGAAUGCAGGGAAGUAAAA	No. 5059	UUUUACUUCCCUGCAUUCUGGUA
  BH0652	No. 4358	CAGAAUGCAGGGAAGUAAAAU	No. 5060	AUUUUACUUCCCUGCAUUCUGGU
  BH0653	No. 4359	AGAAUGCAGGGAAGUAAAAUG	No. 5061	CAUUUUACUUCCCUGCAUUCUGG
  BH0657	No. 4360	UGCAGGGAAGUAAAAUGCCCA	No. 5062	UGGGCAUUUUACUUCCCUGCAUU

• TABLE 2-10
  Double stranded		Sense stand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0661	No. 4361	GGGAAGUAAAAUGCCCAUUCC	No. 5063	GGAAUGGGCAUUUUACUUCCCUG
  BH0664	No. 4362	AAGUAAAAUGCCCAUUCCCAU	No. 5064	AUGGGAAUGGGCAUUUUACUUCC
  BH0669	No. 4363	AAAUGCCCAUUCCCAUCAAGA	No. 5065	UCUUGAUGGGAAUGGGCAUUUUA
  BH0670	No. 4364	AAUGCCCAUUCCCAUCAAGAC	No. 5066	GUCUUGAUGGGAAUGGGCAUUUU
  BH0672	No. 4365	UGCCCAUUCCCAUCAAGACCA	No. 5067	UGGUCUUGAUGGGAAUGGGCAUU
  BH0673	No. 4366	GCCCAUUCCCAUCAAGACCAG	No. 5068	CUGGUCUUGAUGGGAAUGGGCAU
  BH0674	No. 4367	CCCAUUCCCAUCAAGACCAGA	No. 5069	UCUGGUCUUGAUGGGAAUGGGCA
  BH0678	No. 4368	UUCCCAUCAAGACCAGACAAU	No. 5070	AUUGUCUGGUCUUGAUGGGAAUG
  BH0679	No. 4369	UCCCAUCAAGACCAGACAAUG	No. 5071	CAUUGUCUGGUCUUGAUGGGAAU
  BH0680	No. 4370	CCCAUCAAGACCAGACAAUGG	No. 5072	CCAUUGUCUGGUCUUGAUGGGAA
  BH0681	No. 4371	CCAUCAAGACCAGACAAUGGA	No. 5073	UCCAUUGUCUGGUCUUGAUGGGA
  BH0682	No. 4372	CAUCAAGACCAGACAAUGGAU	No. 5074	AUCCAUUGUCUGGUCUUGAUGGG
  BH0683	No. 4373	AUCAAGACCAGACAAUGGAUU	No. 5075	AAUCCAUUGUCUGGUCUUGAUGG
  BH0684	No. 4374	UCAAGACCAGACAAUGGAUUU	No. 5076	AAAUCCAUUGUCUGGUCUUGAUG
  BH0685	No. 4375	CAAGACCAGACAAUGGAUUUG	No. 5077	CAAAUCCAUUGUCUGGUCUUGAU
  BH0687	No. 4376	AGACCAGACAAUGGAUUUGUG	No. 5078	CACAAAUCCAUUGUCUGGUCUUG
  BH0688	No. 4377	GACCAGACAAUGGAUUUGUGA	No. 5079	UCACAAAUCCAUUGUCUGGUCUU
  BH0689	No. 4378	ACCAGACAAUGGAUUUGUGAA	No. 5080	UUCACAAAUCCAUUGUCUGGUCU
  BH0690	No. 4379	CCAGACAAUGGAUUUGUGAAC	No. 5081	GUUCACAAAUCCAUUGUCUGGUC
  BH0692	No. 4380	AGACAAUGGAUUUGUGAACUA	No. 5082	UAGUUCACAAAUCCAUUGUCUGG
  BH0693	No. 4381	GACAAUGGAUUUGUGAACUAU	No. 5083	AUAGUUCACAAAUCCAUUGUCUG
  BH0694	No. 4382	ACAAUGGAUUUGUGAACUAUC	No. 5084	GAUAGUUCACAAAUCCAUUGUCU
  BH0697	No. 4383	AUGGAUUUGUGAACUAUCCUG	No. 5085	CAGGAUAGUUCACAAAUCCAUUG
  BH0699	No. 4384	GGAUUUGUGAACUAUCCUGCA	No. 5086	UGCAGGAUAGUUCACAAAUCCAU
  BH0700	No. 4385	GAUUUGUGAACUAUCCUGCAA	No. 5087	UUGCAGGAUAGUUCACAAAUCCA
  BH0701	No. 4386	AUUUGUGAACUAUCCUGCAAA	No. 5088	UUUGCAGGAUAGUUCACAAAUCC
  BH0702	No. 4387	UUUGUGAACUAUCCUGCAAAA	No. 5089	UUUUGCAGGAUAGUUCACAAAUC
  BH0705	No. 4388	GUGAACUAUCCUGCAAAACCA	No. 5090	UGGUUUUGCAGGAUAGUUCACAA
  BH0706	No. 4389	UGAACUAUCCUGCAAAACCAA	No. 5091	UUGGUUUUGCAGGAUAGUUCACA
  BH0708	No. 4390	AACUAUCCUGCAAAACCAACA	No. 5092	UGUUGGUUUUGCAGGAUAGUUCA
  BH0709	No. 4391	ACUAUCCUGCAAAACCAACAC	No. 5093	GUGUUGGUUUUGCAGGAUAGUUC
  BH0711	No. 4392	UAUCCUGCAAAACCAACACUU	No. 5094	AAGUGUUGGUUUUGCAGGAUAGU
  BH0712	No. 4393	AUCCUGCAAAACCAACACUUU	No. 5095	AAAGUGUUGGUUUUGCAGGAUAG
  BH0713	No. 4394	UCCUGCAAAACCAACACUUUA	No. 5096	UAAAGUGUUGGUUUUGCAGGAUA
  BH0714	No. 4395	CCUGCAAAACCAACACUUUAU	No. 5097	AUAAAGUGUUGGUUUUGCAGGAU
  BH0715	No. 4396	CUGCAAAACCAACACUUUAUU	No. 5098	AAUAAAGUGUUGGUUUUGCAGGA
  BH0716	No. 4397	UGCAAAACCAACACUUUAUUA	No. 5099	UAAUAAAGUGUUGGUUUUCCAGG
  BH0718	No. 4398	CAAAACCAACACUUUAUUACA	No. 5100	UGUAAUAAAGUGUUGGUUUUGCA
  BH0719	No. 4399	AAAACCAACACUUUAUUACAA	No. 5101	UUGUAAUAAAGUGUUGGUUUUGC
  BH0721	No. 4400	AACCAACACUUUAUUACAAGG	No. 5102	CCUUGUAAUAAAGUGUUGGUUUU

• TABLE 2-11
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0723	No. 4401	CCAACACUUUAUUACAAGGAU	No. 5103	AUCCUUGUAAUAAAGUGUUGGUU
  BH0724	No. 4402	CAACACUUUAUUACAAGGAUA	No. 5104	UAUCCUUGU UAAAGUGUUGGU
  BH0725	No. 4403	AACACUUUAUUACAAGGAUAA	No. 5105	UUAUCCUUGUAAUAAAGUGUUGG
  BH0735	No. 4404	UACAAGGAUAAAGCCACAUUU	No. 5106	AAAUGUGGCUUUAUCCUUGUAAU
  BH0737	No. 4405	CAAGGAUAAAGCCACAUUUGG	No. 5107	GCAAAUGUGGCUUUAUCCUUGUA
  BH0739	No. 4406	AGGAUAAAGCCACAUUUGGCU	No. 5108	AGCCAAAUGUGGCUUUAUCCUUG
  BH0743	No. 4407	UAAAGCCACAUUUGGCUGCCA	No. 5109	UGGCAGCCAAAUGUGGCUUUAUC
  BH0744	No. 4408	AAAGCCACAUUUGGCUGCCAU	No. 5110	AUGGCAGCCAAAUGUGGCUUUAU
  BH0745	No. 4409	AAGCCACAUUUGGCUGCCAUG	No. 5111	CAUGGCAGCCAAAUGUGGCUUUA
  BH0746	No. 4410	AGCCACAUUUGGCUGCCAUGA	No. 5112	UCAUGGCAGCCAAAUGUGGCUUU
  BH0747	No. 4411	GCCACAUUUGGCUGCCAUGAU	No. 5113	AUCAUGGCAGCCAAAUGUGGCUU
  BH0748	No. 4412	CCACAUUUGGCUGCCAUGAUG	No. 5114	CAUCAUGGCAGCCAAAUGUGGCU
  BH0749	No. 4413	CACAUUUGGCUGCCAUGAUGG	No. 5115	CCAUCAUGGCAGCCAAAUGUGGC
  BH0750	No. 4414	ACAUUUGGCUGCCAUGAUGGA	No. 5116	UCCAUCAUGGCAGCCAAAUGUGG
  BH0753	No. 4415	UUUGGCUGCCAUGAUGGAUAU	No. 5117	AUAUCCAUCAUGGCAGCCAAAUG
  BH0754	No. 4416	UUGGCUGCCAUGAUGGAUAUU	No. 5118	AAUAUCCAUCAUGGCAGCCAAAU
  BH0756	No. 4417	GGCUGCCAUGAUGGAUAUUCU	No. 5119	AGAAUAUCCAUCAUGGCAGCCAA
  BH0757	No. 4418	GCUGCCAUGAUGGAUAUUCUC	No. 5120	GAGAAUAUCCAUCAUGGCAGCCA
  BH0759	No. 4419	UGCCAUGAUGGAUAUUCUCUG	No. 5121	CAGAGAAUAUCCAUCAUGGCAGC
  BH0760	No. 4420	GCCAUGAUGGAUAUUCUCUGG	No. 5122	CCAGAGAAUAUCCAUCAUGGCAG
  BH0762	No. 4421	CAUGAUGGAUAUUCUCUGGAU	No. 5123	AUCCAGAGAAUAUCCAUCAUGGC
  BH0763	No. 4422	AUGAUGGAUAUUCUCUGGAUG	No. 5124	CAUCCAGAGAAUAUCCAUCAUGG
  BH0766	No. 4423	AUGGAUAUUCUCUGGAUGGCC	No. 5125	GGCCAUCCAGAGAAUAUCCAUCA
  BH0771	No. 4424	UAUUCUCUGGAUGGCCCGGAA	No. 5126	UUCCGGGCCAUCCAGAGAAUAUC
  BH0773	No. 4425	UUCUCUGGAUGGCCCGGAAGA	No. 5127	UCUUCCGGGCCAUCCAGAGAAUA
  BH0774	No. 4426	UCUCUGGAUGGCCCGGAAGAA	No. 5128	UUCUUCCGGGCCAUCCAGAGAAU
  BH0775	No. 4427	CUCUGGAUGGCCCGGAAGAAA	No. 5129	UUUCUUCCGGGCCAUCCAGAGAA
  BH0776	No. 4428	UCUGGAUGGCCCGGAAGAAAU	No. 5130	AUUUCUUCCGGGCCAUCCAGAGA
  BH0777	No. 4429	CUGGAUGGCCCGGAAGAAAUA	No. 5131	UAUUUCUUCCGGGCCAUCCAGAG
  BH0779	No. 4430	GGAUGGCCCGGAAGAAAUAGA	No. 5132	UCUAUUUCUUCCGGGCCAUCCAG
  BH0780	No. 4431	GAUGGCCCGGAAGAAAUAGAA	No. 5133	UUCUAUUUCUUCCGGGCCAUCCA
  BH0781	No. 4432	AUGGCCCGGAAGAAAUAGAAU	No. 5134	AUUCUAUUUCUUCCGGGCCAUCC
  BH0782	No. 4433	UGGCCCGGAAGAAAUAGAAUG	No. 5135	CAUUCUAUUUCUUCCGGGCCAUC
  BH0783	No. 4434	GGCCCGGAAGAAAUAGAAUGU	No. 5136	ACAUUCUAUUUCUUCCGGGCCAU
  BH0785	No. 4435	CCCGGAAGAAAUAGAAUGUAC	No. 5137	GUACAUUCUAUUUCUUCCGGGCC
  BH0786	No. 4436	CCGGAAGAAAUAGAAUGUACC	No. 5138	GGUACAUUCUAUUUCUUCCGGGC
  BH0787	No. 4437	CGGAAGAAAUAGAAUGUACCA	No. 5139	UGGUACAUUCUAUUUCUUCCGGG
  BH0790	No. 4438	AAGAAAUAGAAUGUACCAAAC	No. 5140	GUUUGGUACAUUCUAUUUCUUCC
  BH0795	No. 4439	AUAGAAUGUACCAAACUGGGA	No. 5141	UCCCAGUUUGGUACAUUCUAUUU
  BH0796	No. 4440	UAGAAUGUACCAAACUGGGAA	No. 5142	UUCCCAGUUUGGUACAUUCUAUU

• TABLE 2-12
  Double stranded		Sense strand sequence		Annsense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0797	No. 4441	AGAAUGUACCAAACUGGGAAA	No. 5143	UUUCCCAGUUUGGUACAUUCUAU
  BH0800	No. 4442	AUGUACCAAACUGGGAAACUG	No. 5144	CAGUUUCCCAGUUUGGUACAUUC
  BH0804	No. 4443	ACCAAACUGGGAAACUGGUCU	No. 5145	AGACCAGUUUCCCAGUUUGGUAC
  BH0805	No. 4444	CCAAACUGGGAAACUGGUCUG	No. 5146	CAGACCAGUUUCCCAGUUUGGUA
  BH0808	No. 4445	AACUGGGAAACUGGUCUGCCA	No. 5147	UGGCAGACCAGUUUCCCAGUUUG
  BH0809	No. 4446	ACUGGGAAACUGGUCUGCCAU	No. 5148	AUGGCAGACCAGUUUCCCAGUUU
  BH0810	No. 4447	CUGGGAAACUGGUCUGCCAUG	No. 5149	CAUGGCAGACCAGUUUCCCAGUU
  BH0811	No. 4448	UGGGAAACUGGUCUGCCAUGC	No. 5150	GCAUGGCAGACCAGUUUCCCAGU
  BH0813	No. 4449	GGAAACUGGUCUGCCAUGCCA	No. 5151	UGGCAUGGCAGACCAGUUUCCCA
  BH0814	No. 4450	GAAACUGGUCUGCCAUGCCAA	No. 5152	UUGGCAUGGCAGACCAGUUUCCC
  BH0815	No. 4451	AAACUGGUCUGCCAUGCCAAG	No. 5153	CUUGGCAUGGCAGACCAGUUUCC
  BH0816	No. 4452	AACUGGUCUGCCAUGCCAAGU	No. 5154	ACUUGGCAUGGCAGACCAGUUUC
  BH0817	No. 4453	ACUGGUCUGCCAUGCCAAGUU	No. 5165	AACUUGGCAUGGCAGACCAGUUU
  BH0818	No. 4454	CUGGUCUGCCAUGCCAAGUUG	No. 5156	CAACUUGGCAUGGCAGACCAGUU
  BH0819	No. 4455	UGGUCUGCCAUGCCAAGUUGU	No. 5157	ACAACUUGGCAUGGCAGACCAGU
  BH0820	No. 4456	GGUCUGCCAUGCCAAGUUGUA	No. 5158	UACAACUUGGCAUGGCAGACCAG
  BH0821	No. 4457	GUCUGCCAUGCCAAGUUGUAA	No. 5158	UUACAACUUGGCAUGGCAGACCA
  BH0822	No. 4458	UCUGCCAUGCCAAGUUGUAAA	No. 5160	UUUACAACUUGGCAUGGCAGACC
  BH0823	No. 4459	CUGCCAUGCCAAGUUGUAAAG	No. 5161	CUUUACAACUUGGCAUGGCAGAC
  BH0825	No. 4460	GCCAUGCCAAGUUGUAAAGCA	No. 5162	UGCUUUACAACUUGGCAUGGCAG
  BH0826	No. 4461	CCAUGCCAAGUUGUAAAGCAU	No. 5163	AUGCUUUACAACUUGGCAUGGCA
  BH0827	No. 4462	CAUGCCAAGUUGUAAAGCAUC	No. 5164	GAUGCUUUACAACUUGGCAUGGC
  BH0828	No. 4463	AUGCCAAGUUGUAAAGCAUCU	No. 5165	AGAUGCUUUACAACUUGGCAUGG
  BH0829	No. 4464	UGCCAAGUUGUAAAGCAUCUU	No. 5166	AAGAUGCUUUACAACUUGGCAUG
  BH0830	No. 4465	GCCAAGUUGUAAAGCAUCUUG	No. 5167	CAAGAUGCUUUACAACUUGGCAU
  BH0831	No. 4466	CCAAGUUGUAAAGCAUCUUGU	No. 5168	ACAAGAUGCUUUACAACUUGGCA
  BH0832	No. 4467	CAAGUUGUAAAGCAUCUUGUA	No. 5169	UACAAGAUGCUUUACAACUUGGC
  BH0833	No. 4468	AAGUUGUAAAGCAUCUUGUAA	No. 5170	UUACAAGAUGCUUUACAACUUGG
  BH0834	No. 4469	AGUUGUAAAGCAUCUUGUAAA	No. 5171	UUUACAAGAUGCUUUACAACUUG
  BH0835	No. 4470	GUUGUAAAGCAUCUUGUAAAG	No. 5172	CUUUACAAGAUGCUUUACAACUU
  BH0837	No. 4471	UGUAAAGCAUCUUGUAAAGUA	No. 5173	UACUUUACAAGAUGCUUUACAAC
  BH0838	No. 4472	GUAAAGCAUCUUGUAAAGUAC	No. 5174	GUACUUUACAAGAUGCUUUACAA
  BH0840	No. 4473	AAAGCAUCUUGUAAAGUACCU	No. 5175	AGGUACUUUACAAGAUGCUUUAC
  BH0842	No. 4474	AGCAUCUUGUAAAGUACCUGU	No. 5176	ACAGGUACUUUACAAGAUGCUUU
  BH0845	No. 4475	AUCUUGUAAAGUACCUGUGAA	No. 5177	UUCACAGGUACUUUACAAGAUGC
  BH0846	No. 4476	UCUUGUAAAGUACCUGUGAAA	No. 5178	UUUCACAGGUACUUUACAAGAUG
  BH0847	No. 4477	CUUGUAAAGUACCUGUGAAAA	No. 5179	UUUUCACAGGUACUUUACAAGAU
  BH0852	No. 4478	AAAGUACCUGUGAAAAAAGCC	No. 5180	GGCUUUUUUCACAGGUACUUUAC
  BH0853	No. 4479	AAGUACCUGUGAAAAAAGCCA	No. 5181	UGGCUUUUUUCACAGGUACUUUA
  BH0854	No. 4480	AGUACCUGUGAAAAAAGCCAC	No. 5182	GUGGCUUUUUUCACAGGUACUUU

• TABLE 2-13
  Double stranded		Sense strand sequence		Anttserise strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0855	No. 4481	GUACCUGUGAAAAAAGCCACU	No.5183	AGUGGCUUUUUUCACAGGUACUU
  BH0857	No. 4482	ACCUGUGAAAAAAGCCACUGU	No. 6184	ACAGUGGCUUUUUUCACAGGUAC
  BH0858	No. 4483	CCUGUGAAAAAAGCCACUGUG	No. 5185	CACAGUGGCUUUUUUCACAGGUA
  BH0859	No. 4484	CUGUGAAAAAAGCCACUGUGG	No. 5186	CCACAGUGGCUUUUUUCACAGGU
  BH0860	No. 4485	UGUGAAAAAAGCCACUGUGGU	No. 5187	ACCACAGUGGCUUUUUUCACAGG
  BH0861	No. 4486	GUGAAAAAAGCCACUGUGGUG	No. 5188	CACCACAGUGGCUUUUUUCACAG
  BH0863	No. 4487	GAAAAAAGCCACUGUGGUGUA	No. 5189	UACACCACAGUGGCUUUUUUCAC
  BH0864	No. 4488	AAAAAAGCCACUGUGGUGUAC	No. 5190	GUACACCACAGUGGCUUUUUUCA
  BH0866	No. 4489	AAAAGCCACUGUGGUGUACCA	No. 5191	UGGUACACCACAGUGGCUUUUUU
  BH0867	No. 4490	AAAGCCACUGUGGUGUACCAA	No. 5192	UUGGUACACCACAGUGGCUUUUU
  BH0868	No. 4491	AAGCCACUGUGGUGUACCAAG	No. 5193	CUUGGUACACCACAGUGGCUUUU
  BH0870	No. 4492	GCCACUGUGGUGUACCAAGGA	No. 5194	UCCUUGGUACACCACAGUGGCUU
  BH0872	No. 4493	CACUGUGGUGUACCAAGGAGA	No. 5195	UCUCCUUGGUACACCACAGUGGC
  BH0873	No. 4494	ACUGUGGUGUACCAAGGAGAG	No. 5196	CUCUCCUUGGUACACCACAGUGG
  BH0874	No. 4495	CUGUGGUGUACCAAGGAGAGA	No. 5197	UCUCUCCUUGGUACACCACAGUG
  BH0875	No. 4496	UGUGGUGUACCAAGGAGAGAG	No. 5198	CUCUCUCCUUGGUACACCACAGU
  BH0876	No. 4497	GUGGUGUACCAAGGAGAGAGA	No. 5199	UCUCUCUCCUUGGUACACCACAG
  BH0877	No. 4498	UGGUGUACCAAGGAGAGAGAG	No. 5200	CUCUCUCUCCUUGGUACACCACA
  BH0879	No. 4499	GUGUACCAAGGAGAGAGAGUA	No. 5201	UACUCUCUCUCCUUGGUACACCA
  BH0880	No. 4500	UGUACCAAGGAGAGAGAGUAA	No. 5202	UUACUCUCUCUCCUUGGUACACC
  BH0881	No. 4501	GUACCAAGGAGAGAGAGUAAA	No. 5203	UUUACUCUCUCUCCUUGGUACAC
  BH0882	No. 4502	UACCAAGGAGAGAGAGUAAAG	No. 5204	CUUUACUCUCUCUCCUUGGUACA
  BH0883	No. 4503	ACCAAGGAGAGAGAGUAAAGA	No. 5205	UCUUUACUCUCUCUCCUUGGUAC
  BH0884	No. 4504	CCAAGGAGAGAGAGUAAAGAU	No. 5206	AUCUUUACUCUCUCUCCUUGGUA
  BH0885	No. 4505	CAAGGAGAGAGAGUAAAGAUU	No. 5207	AAUCUUUACUCUCUCUCCUUGGU
  BH0886	No. 4506	AAGGAGAGAGAGUAAAGAUUC	No. 5208	GAAUCUUUACUCUCUCUCCUUGG
  BH0887	No. 4507	AGGAGAGAGAGUAAAGAUUCA	No. 5209	UGAAUCUUUACUCUCUCUCCUUG
  BH0888	No. 4508	GGAGAGAGAGUAAAGAUUCAG	No. 5210	CUGAAUCUUUACUCUCUCUCCUU
  BH0890	No. 4509	AGAGAGAGUAAAGAUUCAGGA	No. 5211	UCCUGAAUCUUUACUCUCUCUCC
  BH0891	No. 4510	GAGAGAGUAAAGAUUCAGGAA	No. 5212	UUCCUGAAUCUUUACUCUCUCUC
  BH0892	No. 4511	AGAGAGUAAAGAUUCAGGAAA	No. 5213	UUUCCUGAAUCUUUACUCUCUCU
  BH0893	No. 4512	GAGAGUAAAGAUUCAGGAAAA	No. 5214	UUUUCCUGAAUCUUUACUCUCUC
  BH0894	No. 4513	AGAGUAAAGAUUCAGGAAAAA	No. 5216	UUUUUCCUGAAUCUUUACUCUCU
  BH0895	No. 4514	GAGUAAAGAUUCAGGAAAAAU	No. 5216	AUUUUUCCUGAAUCUUUACUCUC
  BH0896	No. 4516	AGUAAAGAUUCAGGAAAAAUU	No. 5217	AAUUUUUCCUGAAUCUUUACUCU
  BH0897	No. 4516	GUAAAGAUUCAGGAAAAAUUU	No. 5218	AAAUUUUUCCUGAAUCUUUACUC
  BH0898	No. 4517	UAAAGAUUCAGGAAAAAUUUA	No. 5219	UAAAUUUUUCCUGAAUCUUUACU
  BH0899	No. 4518	AAAGAUUCAGGAAAAAUUUAA	No. 5220	UUAAAUUUUUCCUGAAUCUUUAC
  BH0905	No. 4619	UCAGGAAAAAUUUAAGAAUGG	No. 5221	CCAUUCUUAAAUUUUUCCUGAAU
  BH0906	No. 4520	CAGGAAAAAUUUAAGAAUGGA	No. 5222	UCCAUUCUUAAAUUUUUCCUGAA

• TABLE 2-14
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0907	No. 4521	AGGAAAAAUUUAAGAAUGGAA	No. 5223	UUCCAUUCUUAAAUUUUUCCUGA
  BH0912	No. 4522	AAAUUUAAGAAUGGAAUGCUA	No. 5224	UAGCAUUCCAUUCUUAAAUUUUU
  BH0914	No. 4523	AUUUAAGAAUGGAAUGCUACA	No. 5225	UGUAGCAUUCCAUUCUUAAAUUU
  BH0917	No. 4524	UAAGAAUGGAAUGCUACAUGG	No. 5226	CCAUGUAGCAUUCCAUUCUUAAA
  BH0918	No. 4525	AAGAAUGGAAUGCUACAUGGU	No. 5227	ACCAUGUAGCAUUCCAUUCUUAA
  BH0919	No. 4626	AGAAUGGAAUGCUACAUGGUG	No. 5228	CACCAUGUAGCAUUCCAUUCUUA
  BH0920	No. 4527	GAAUGGAAUGCUACAUGGUGA	No. 5229	UCACCAUGUAGCAUUCCAUUCUU
  BH0921	No. 4528	AAUGGAAUGCUACAUGGUGAU	No. 5230	AUCACCAUGUAGCAUUCCAUUCU
  BH0922	No. 4529	AUGGAAUGCUACAUGGUGAUA	No. 5231	UAUCACCAUGUAGCAUUCCAUUC
  BH0923	No. 4530	UGGAAUGCUACAUGGUGAUAA	No. 5232	UUAUCACCAUGUAGCAUUCCAUU
  BH0924	No. 4531	GGAAUGCUACAUGGUGAUAAA	No. 5233	UUUAUCACCAUGUAGCAUUCCAU
  BH0926	No. 4532	AAUGCUACAUGGUGAUAAAGU	No. 5234	ACUUUAUCACCAUGUAGCAUUCC
  BH0927	No. 4533	AUGCUACAUGGUGAUAAAGUU	No. 5235	AACUUUAUCACCAUGUAGCAUUC
  BH0928	No. 4534	UGCUACAUGGUGAUAAAGUUU	No. 5236	AAACUUUAUCACCAUGUAGCAUU
  BH0930	No. 4535	CUACAUGGUGAUAAAGUUUCU	No. 5237	AGAAACUUUAUCACCAUGUAGCA
  BH0932	No. 4536	ACAUGGUGAUAAAGUUUCUUU	No. 5238	AAAGAAACUUUAUCACCAUGUAG
  BH0934	No. 4537	AUGGUGAUAAAGUUUCUUUCU	No. 5239	AGAAAGAAACUUUAUCACCAUGU
  BH0935	No. 4538	UGGUGAUAAAGUUUCUUUCUU	No. 5240	AAGAAAGAAACUUUAUCACCAUG
  BH0936	No. 4539	GGUGAUAAAGUUUCUUUCUUC	No. 5241	GAAGAAAGAAACUUUAUCACCAU
  BH0937	No. 4540	GUGAUAAAGUUUCUUUCUUCU	No. 5242	AGAAGAAAGAAACUUUAUCACCA
  BH0940	No. 4541	AUAAAGUUUCUUUCUUCUGCA	No. 5243	UGCAGAAGAAAGAAACUUUAUCA
  BH0941	No. 4542	UAAAGUUUCUUUCUUCUGCAA	No. 5244	UUGCAGAAGAAAGAAACUUUAUC
  BH0942	No. 4543	AAAGUUUCUUUCUUCUGCAAA	No. 5245	UUUGCAGAAGAAAGAAACUUUAU
  BH0943	No. 4544	AAGUUUCUUUCUUCUGCAAAA	No. 5246	UUUUGCAGAAGAAAGAAACUUUA
  BH0944	No. 4545	AGUUUCUUUCUUCUGCAAAAA	No. 5247	UUUUUGCAGAAGAAAGAAACUUU
  BH0945	No. 4546	GUUUCUUUCUUCUGCAAAAAU	No. 5248	AUUUUUGCAGAAGAAAGAAACUU
  BH0946	No. 4547	UUUCUUUCUUCUGCAAAAAUA	No. 5249	UAUUUUUGCAGAAGAAAGAAACU
  BH0947	No. 4548	UUCUUUCUUCUGCAAAAAUAA	No. 5250	UUAUUUUUGCAGAAGAAAGAAAC
  BH0948	No. 4549	UCUUUCUUCUGCAAAAAUAAG	No. 5251	CUUAUUUUUGCAGAAGAAAGAAA
  BH0953	No. 4550	CUUCUGCAAAAAUAAGGAAAA	No. 5252	UUUUCCUUAUUUUUGCAGAAGAA
  BH0955	No. 4551	UCUGCAAAAAUAAGGAAAAGA	No. 5253	UCUUUUCCUUAUUUUUGCAGAAG
  BH0956	No. 4552	CUGCAAAAAUAAGGAAAAGAA	No. 5254	UUCUUUUCCUUAUUUUUGCAGAA
  BH0957	No. 4553	UGCAAAAAUAAGGAAAAGAAG	No. 5255	CUUCUUUUCCUUAUUUUUGCAGA
  BH0964	No. 4554	AUAAGGAAAAGAAGUGUAGCU	No. 5256	AGCUACACUUCUUUUCCUUAUUU
  BH0965	No. 4555	UAAGGAAAAGAAGUGUAGCUA	No. 5257	UAGCUACACUUCUUUUCCUUAUU
  BH0966	No. 4556	AAGGAAAAGAAGUGUAGCUAU	No. 5258	AUAGCUACACUUCUUUUCCUUAU
  BH0967	No. 4557	AGGAAAAGAAGUGUAGCUAUA	No. 5259	UAUAGCUACACUUCUUUUCCUUA
  BH0969	No. 4558	GAAAAGAAGUGUAGCUAUACA	No. 5260	UGUAUAGCUACACUUCUUUUCCU
  BH0972	No. 4559	AAGAAGUGUAGCUAUACAGAG	No. 5261	CUCUGUAUAGCUACACUUCUUUU
  BH0974	No. 4560	GAAGUGUAGCUAUACAGAGGA	No. 5262	UCCUCUGUAUAGCUACACUUCUU

• TABLE 2-15
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH0975	No. 4561	AAGUGUAGCUAUACAGAGGAU	No. 5263	AUCCUCUGUAUAGCUACACUUCU
  BH0977	No. 4562	GUGUAGCUAUACAGAGGAUGC	No. 5264	GCAUCCUCUGUAUAGCUACACUU
  BH0978	No. 4563	UGUAGCUAUACAGAGGAUGCU	No. 5265	AGCAUCCUCUGUAUAGCUACACU
  BH0980	No. 4564	UAGCUAUACAGAGGAUGCUCA	No. 5266	UGAGCAUCCUCUGUAUAGCUACA
  BH0981	No. 4565	AGCUAUACAGAGGAUGCUCAG	No. 5267	CUGAGCAUCCUCUGUAUAGCUAC
  BH0985	No. 4566	AUACAGAGGAUGCUCAGUGUA	No. 5268	UACACUGAGCAUCCUCUGUAUAG
  BH0987	No. 4567	ACAGAGGAUGCUCAGUGUAUA	No. 5269	UAUACACUGAGCAUCCUCUGUAU
  BH0988	No. 4568	CAGAGGAUGCUCAGUGUAUAG	No. 5270	CUAUACACUGAGCAUCCUCUGUA
  BH0989	No. 4569	AGAGGAUGCUCAGUGUAUAGA	No. 5271	UCUAUACACUGAGCAUCCUCUGU
  BH0990	No. 4570	GAGGAUGCUCAGUGUAUAGAU	No. 5272	AUCUAUACACUGAGCAUCCUCUG
  BH0991	No. 4571	AGGAUGCUCAGUGUAUAGAUG	No. 5273	CAUCUAUACACUGAGCAUCCUCU
  BH0996	No. 4572	GCUCAGUGUAUAGAUGGCACU	No. 5274	AGUGCCAUCUAUACACUGAGCAU
  BH0997	No. 4573	CUCAGUGUAUAGAUGGCACUA	No. 5275	UAGUGCCAUCUAUACACUGAGCA
  BH0998	No. 4574	UCAGUGUAUAGAUGGCACUAU	No. 5276	AUAGUGCCAUCUAUACACUGAGC
  BH0999	No. 4575	CAGUGUAUAGAUGGCACUAUC	No. 5277	GAUAGUGCCAUCUAUACACUGAG
  BH1000	No. 4576	AGUGUAUAGAUGGCACUAUCG	No. 5278	CGAUAGUGCCAUCUAUACACUGA
  BH1001	No. 4577	GUGUAUAGAUGGCACUAUCGA	No. 5279	UCGAUAGUGCCAUCUAUACACUG
  BH1002	No. 4578	UGUAUAGAUGGCACUAUCGAA	No. 5280	UUCGAUAGUGCCAUCUAUACACU
  BH1003	No. 4579	GUAUAGAUGGCACUAUCGAAG	No. 5281	CUUCGAUAGUGCCAUCUAUACAC
  BH1005	No. 4580	AUAGAUGGCACUAUCGAAGUC	No. 5282	GACUUCGAUAGUGCCAUCUAUAC
  BH1007	No. 4581	AGAUGGCACUAUCGAAGUCCC	No. 5283	GGGACUUCGAUAGUGCCAUCUAU
  BH1009	No. 4582	AUGGCACUAUCGAAGUCCCCA	No. 5284	UGGGGACUUCGAUAGUGCCAUCU
  BH1010	No. 4583	UGGCACUAUCGAAGUCCCCAA	No. 5285	UUGGGGACUUCGAUAGUGCCAUC
  BH1011	No. 4584	GGCACUAUCGAAGUCCCCAAA	No. 5286	UUUGGGGACUUCGAUAGUGCCAU
  BH1013	No. 4585	CACUAUCGAAGUCCCCAAAUG	No. 5287	CAUUUGGGGACUUCGAUAGUGCC
  BH1015	No. 4586	CUAUCGAAGUCCCCAAAUGCU	No. 5288	AGCAUUUGGGGACUUCGAUAGUG
  BH1016	No. 4587	UAUCGAAGUCCCCAAAUGCUU	No. 5289	AAGCAUUUGGGGACUUCGAUAGU
  BH1017	No. 4588	AUCGAAGUCCCCAAAUGCUUC	No. 5290	GAAGCAUUUGGGGACUUCGAUAG
  BH1018	No. 4589	UCGAAGUCCCCAAAUGCUUCA	No. 5291	UGAAGCAUUUGGGGACUUCGAUA
  BH1021	No. 4590	AAGUCCCCAAAUGCUUCAAGG	No. 5292	CCUUGAAGCAUUUGGGGACUUCG
  BH1022	No. 4591	AGUCCCCAAAUGCUUCAAGGA	No. 5293	UCCUUGAAGCAUUUGGGGACUUC
  BH1023	No. 4592	GUCCCCAAAUGCUUCAAGGAA	No. 5294	UUCCUUGAAGCAUUUGGGGACUU
  BH1024	No. 4593	UCCCCAAAUGCUUCAAGGAAC	No. 5295	GUUCCUUGAAGCAUUUGGGGACU
  BH1025	No. 4594	CCCCAAAUGCUUCAAGGAACA	No. 5296	UGUUCCUUGAAGCAUUUGGGGAC
  BH1026	No. 4595	CCCAAAUGCUUCAAGGAACAC	No. 5297	GUGUUCCUUGAAGCAUUUGGGGA
  BH1027	No. 4596	CCAAAUCCUUCAAGGAACACA	No. 5298	UGUGUUCCUUGAAGCAUUUGGGG
  BH1028	No. 4597	CAAAUCCUUCAAGGAACACAG	No. 5299	CUGUGUUCCUUGAAGCAUUUGGG
  BH1029	No. 4598	AAAUGCUUCAAGGAACACAGU	No. 5300	ACUGUGUUCCUUGAAGCAUUUGG
  BH1030	No. 4599	AAUGCUUCAAGGAACACAGUU	No. 5301	AACUGUGUUCCUUGAAGCAUUUG
  BH1031	No. 4600	AUGCUUCAAGGAACACAGUUC	No. 5302	GAACUGUGUUCCUUGAAGCAUUU

• TABLE 2-16
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH1032	No. 4601	UGCUUCAAGGAACACAGUUCU	No. 5303	AGAACUGUGUUCCUUGAAGCAUU
  BH1034	No. 4602	CUUCAAGGAACACAGUUCUCU	No. 5304	AGAGAACUGUGUUCCUUGAAGCA
  BH1035	No. 4603	UUCAAGGAACACAGUUCUCUG	No. 5305	CAGAGAACUGUGUUCCUUGAAGC
  BH1038	No. 4604	AAGGAACACAGUUCUCUGGCU	No. 5306	AGCCAGAGAACUGUGUUCCUUGA
  BH1039	No. 4605	AGGAACACAGUUCUCUGGCUU	No. 5307	AAGCCAGAGAACUGUGUUCCUUG
  BH1040	No. 4606	GGAACACAGUUCUCUGGCUUU	No. 5308	AAAGCCAGAGAACUGUGUUCCUU
  BH1041	No. 4607	GAACACAGUUCUCUGGCUUUU	No. 5309	AAAAGCCAGAGAACUGUGUUCCU
  BH1042	No. 4608	AACACAGUUCUCUGGCUUUUU	No. 5310	AAAAAGCCAGAGAACUGUGUUCC
  BH1043	No. 4609	ACACAGUUCUCUGGCUUUUUG	No. 5311	CAAAAAGCCAGAGAACUGUGUUC
  BH1044	No. 4610	CACAGUUCUCUGGCUUUUUGG	No. 5312	CCAAAAAGCCAGAGAACUGUGUU
  BH1045	No. 4611	ACAGUUCUCUGGCUUUUUGGA	No. 5313	UCCAAAAAGCCAGAGAACUGUGU
  BH1046	No. 4612	CAGUUCUCUGGCUUUUUGGAA	No. 5314	UUCCAAAAAGCCAGAGAACUGUG
  BH1047	No. 4613	AGUUCUCUGGCUUUUUGGAAA	No. 5315	UUUCCAAAAAGCCAGAGAACUGU
  BH1048	No. 4614	GUUCUCUGGCUUUUUGGAAAA	No. 5316	UUUUCCAAAAAGCCAGAGAACUG
  BH1051	No. 4615	CUCUGGCUUUUUGGAAAACUG	No. 5317	CAGUUUUCCAAAAAGCCAGAGAA
  BH1052	No. 4616	UCUGGCUUUUUGGAAAACUGA	No. 5318	UCAGUUUUCCAAAAAGCCAGAGA
  BH1053	No. 4617	CUGGCUUUUUGGAAAACUGAU	No. 5319	AUCAGUUUUCCAAAAAGCCAGAG
  BH1054	No. 4618	UGGCUUUUUGGAAAACUGAUG	No. 5320	CAUCAGUUUUCCAAAAAGCCAGA
  BH1056	No. 4619	GCUUUUUGGAAAACUGAUGCA	No. 5321	UGCAUCAGUUUUCCAAAAAGCCA
  BH1057	No. 4620	CUUUUUGGAAAACUGAUGCAU	No. 5322	AUGCAUCAGUUUUCCAAAAAGCC
  BH1061	No. 4621	UUGGAAAACUGAUGCAUCCGA	No. 5323	UCGGAUGCAUCAGUUUUCCAAAA
  BH1062	No. 4622	UGGAAAACUGAUGCAUCCGAU	No. 5324	AUCGGAUGCAUCAGUUUUCCAAA
  BH1063	No. 4623	GGAAAACUGAUGCAUCCGAUG	No. 5325	CAUCGGAUGCAUCAGUUUUCCAA
  BH1064	No. 4624	GAAAACUGAUGCAUCCGAUGU	No. 5326	ACAUCGGAUGCAUCAGUUUUCCA
  BH1065	No. 4625	AAAACUGAUGCAUCCGAUGUA	No. 5327	UACAUCGGAUGCAUCAGUUUUCC
  BH1067	No. 4626	AACUGAUGCAUCCGAUGUAAA	No. 5328	UUUACAUCGGAUGCAUCAGUUUU
  BH1068	No. 4627	ACUGAUGCAUCCGAUGUAAAG	No. 5329	CUUUACAUCGGAUGCAUCAGUUU
  BH1072	No. 4628	AUGCAUCCGAUGUAAAGCCAU	No. 5330	AUGGCUUUACAUCGGAUGCAUCA
  BH1073	No. 4629	UGCAUCCGAUGUAAAGCCAUG	No. 5331	CAUGGCUUUACAUCGGAUGCAUC
  BH1076	No. 4630	AUCCGAUGUAAAGCCAUGCUA	No. 5332	UAGCAUGGCUUUACAUCGGAUGC
  BH1077	No. 4631	UCCGAUGUAAAGCCAUGCUAA	No. 5333	UUAGCAUGGCUUUACAUCGGAUG
  BH1078	No. 4632	CCGAUGUAAAGCCAUGCUAAG	No. 5334	CUUAGCAUGGCUUUACAUCGGAU
  BH1083	No. 4633	GUAAAGCCAUGCUAAGGUGGU	No. 5335	ACCACCUUAGCAUGGCUUUACAU
  BH1084	No. 4634	UAAAGCCAUGCUAAGGUGGUU	No. 5336	AACCACCUUAGCAUGGCUUUACA
  BH1085	No. 4635	AAAGCCAUGCUAAGGUGGUUU	No. 5337	AAACCACCUUAGCAUGGCUUUAC
  BH1086	No. 4636	AAGCCAUGCUAAGGUGGUUUU	No. 5338	AAAACCACCUUAGCAUGGCUUUA
  BH1087	No. 4637	AGCCAUGCUAAGGUGGUUUUC	No. 5339	GAAAACCACCUUAGCAUGGCUUU
  BH1088	No. 4638	GCCAUGCUAAGGUGGUUUUCA	No. 5340	UGAAAACCACCUUAGCAUGGCUU
  BH1089	No. 4639	CCAUGCUAAGGUGGUUUUCAG	No. 5341	CUGAAAACCACCUUAGCAUGGCU
  BH1090	No. 4640	CAUGCUAAGGUGGUUUUCAGA	No. 5342	UCUGAAAACCACCUUAGCAUGGC

• TABLE 2-17
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH1092	No. 4641	UGCUAAGGUGGUUUUCAGAUU	No. 5343	AAUCUGAAAACCACCUUAGCAUG
  BH1093	No. 4642	GCUAAGGUGGUUUUCAGAUUC	No. 5344	GAAUCUGAAAACCACCUUAGCAU
  BH1095	No. 4643	UAAGGUGGUUUUCAGAUUCCA	No. 5345	UGGAAUCUGAAAACCACCUUAGC
  BH1096	No. 4644	AAGGUGGUUUUCAGAUUCCAC	No. 5346	GUGGAAUCUGAAAACCACCUUAG
  BH1097	No. 4645	AGGUGGUUUUCAGAUUCCACA	No. 5347	UGUGGAAUCUGAAAACCACCUUA
  BH1099	No. 4646	GUGGUUUUCAGAUUCCACACA	No. 5348	UGUGUGGAAUCUGAAAACCACCU
  BH1100	No. 4647	UGGUUUUCAGAUUCCACACAA	No. 5349	UUGUGUGGAAUCUGAAAACCACC
  BH1101	No. 4648	GGUUUUCAGAUUCCACACAAA	No. 5350	UUUGUGUGGAAUCUGAAAACCAC
  BH1102	No. 4649	GUUUUCAGAUUCCACACAAAA	No. 5351	UUUUGUGUGGAAUCUGAAAACCA
  BH1103	No. 4650	UUUUCAGAUUCCACACAAAAU	No. 5352	AUUUUGUGUGGAAUCUGAAAACC
  BH1104	No. 4651	UUUCAGAUUCCACACAAAAUG	No. 5353	CAUUUUGUGUGGAAUCUGAAAAC
  BH1105	No. 4652	UUCAGAUUCCACACAAAAUGU	No. 5354	ACAUUUUGUGUGGAAUCUGAAAA
  BH1106	No. 4653	UCAGAUUCCACACAAAAUGUC	No. 5355	GACAUUUUGUGUGGAAUCUGAAA
  BH1107	No. 4654	CAGAUUCCACACAAAAUGUCA	No. 5356	UGACAUUUUGUGUGGAAUCUGAA
  BH1109	No. 4655	GAUUCCACACAAAAUGUCACA	No. 5357	UGUGACAUUUUGUGUGGAAUCUG
  BH1111	No. 4656	UUCCACACAAAAUGUCACACU	No. 5358	AGUGUGACAUUUUGUGUGGAAUC
  BH1112	No. 4657	UCCACACAAAAUGUCACACUU	No. 5359	AAGUGUGACAUUUUGUGUGGAAU
  BH1113	No. 4658	CCACACAAAAUGUCACACUUG	No. 5360	CAAGUGUGACAUUUUGUGUGGAA
  BH1114	No. 4659	CACACAAAAUGUCACACUUGU	No. 5361	ACAAGUGUGACAUUUUGUGUGGA
  BH1115	No. 4660	ACACAAAAUGUCACACUUGUU	No. 5362	AACAAGUGUGACAUUUUGUGUGG
  BH1116	No. 4661	CACAAAAUGUCACACUUGUUU	No. 5363	AAAcAAGUGUGACAUUUUGUGUG
  BH1118	No. 4662	CAAAAUGUCACACUUGUUUCU	No. 5364	AGAAACAAGUGUGACAUUUUGUG
  BH1120	No. 4663	AAAUGUCACACUUGUUUCUUG	No. 5365	CAAGAAACAAGUGUGACAUUUUG
  BH1121	No. 4664	AAUGUCACACUUGUUUCUUGU	No. 5366	ACAAGAAACAAGUGUGACAUUUU
  BH1122	No. 4665	AUGUCACACUUGUUUCUUGUU	No. 5367	AACAAGAAACAAGUGUGACAUUU
  BH1124	No. 4666	GUCACACUUGUUUCUUGUUCA	No. 5368	UGAACAAGAAACAAGUGUGACAU
  BH1125	No. 4667	UCAGACUUGUUUCUUGUUCAU	No. 5369	AUGAACAAGAAACAAGUGUGACA
  BH1127	No. 4668	ACACUUGUUUCUUGUUCAUCC	No. 5370	GGAUGAACAAGAAACAAGUGUGA
  BH1128	No. 4669	CACUUGUUUCUUGUUCAUCCA	No. 5371	UGGAUGAACAAGAAACAAGUGUG
  BH1129	No. 4670	ACUUGUUUCUUGUUCAUCCAA	No. 5372	UUGGAUGAACAAGAAACAAGUGU
  BH1130	No. 4671	CUUGUUUCUUGUUCAUCCAAG	No. 5373	CUUGGAUGAACAAGAAACAAGUG
  BH1131	No. 4672	UUGUUUCUUGUUCAUCCAAGG	No. 5374	CCUUGGAUGAACAAGAAACAAGU
  BH1133	No. 4673	GUUUCUUGUUCAUCCAAGGAA	No. 5375	UUCCUUGGAUGAACAAGAAACAA
  BH1134	No. 4674	UUUCUUGUUCAUCCAAGGAAC	No. 5376	GUUCCUUGGAUGAACAAGAAACA
  BH1135	No. 4675	UUCUUGUUCAUCCAAGGAACC	No. 5377	GGUUCCUUGGAUGAACAAGAAAC
  BH1136	No. 4676	UCUUGUUCAUCCAAGGAACCU	No. 5378	AGGUUCCUUGGAUGAACAAGAAA
  BH1137	No. 4677	CUUGUUCAUCCAAGGAACCUA	No. 5379	UAGGUUCCUUGGAUGAACAAGAA
  BH1138	No. 4678	UUGUUCAUCCAAGGAACCUAA	No. 5380	UUAGGUUCCUUGGAUGAACAAGA
  BH1139	No. 4679	UGUUCAUCCAAGGAACCUAAU	No. 5381	AUUAGGUUCCUUGGAUGAACAAG
  BH1140	No. 4680	GUUCAUCCAAGGAACCUAAUU	No. 5382	AAUUAGGUUCCUUGGAUGAACAA

• TABLE 2-18
  Double stranded		Sense strand sequence		Antisense strand sequence
  nucleic acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  BH1141	No. 4681	UUCAUCCAAGGAACCUAAUUG	No. 5383	CAAUUAGGUUCCUUGGAUGAACA
  BH1142	No. 4682	UCAUCCAAGGAACCUAAUUGA	No. 5384	UCAAUUAGGUUCCUUGGAUGAAC
  BH1143	No. 4683	CAUCCAAGGAACCUAAUUGAA	No. 5385	UUCAAUUAGGUUCCUUGGAUGAA
  BH1144	No. 4684	AUCCAAGGAACCUAAUUGAAA	No. 5386	UUUCAAUUAGGUUCCUUGGAUGA
  BH1145	No. 4685	UCCAAGGAACCUAAUUGAAAU	No. 5387	AUUUCAAUUAGGUUCCUUGGAUG
  BH1146	No. 4686	CCAAGGAACCUAAUUGAAAUU	No. 5388	AAUUUCAAUUAGGUUCCUUGGAU
  BH1147	No. 4687	CAAGGAACCUAAUUGAAAUUU	No. 5389	AAAUUUCAAUUAGGUUCCUUGGA
  BH1148	No. 4688	AAGGAACCUAAUUGAAAUUUA	No. 5390	UAAAUUUCAAUUAGGUUCCUUGG
  BH1149	No. 4689	AGGAACCUAAUUGAAAUUUAA	No. 5391	UUAAAUUUCAAUUAGGUUCCUUG
  BH1150	No. 4690	GGAACCUAAUUGAAAUUUAAA	No. 5392	UUUAAAUUUCAAUUAGGUUCCUU
  BH1151	No. 4691	GAACCUAAUUGAAAUUUAAAA	No. 5393	UUUUAAAUUUCAAUUAGGUUCCU
  BH1155	No. 4692	CUAAUUGAAAUUUAAAAAUAA	No. 5394	UUAUUUUUAAAUUUCAAUUAGGU
  BH1167	No. 4693	UAAAAAUAAAGCUACUGAAUU	No. 5395	AAUUCAGUAGCUUUAUUUUUAAA
  BH1168	No. 4694	AAAAAUAAAGCUACUGAAUUU	No. 5396	AAAUUCAGUAGCUUUAUUUUUAA
  BH1169	No. 4695	AAAAUAAAGCUACUGAAUUUA	No. 5397	UAAAUUCAGUAGCUUUAUUUUUA
  BH1171	No. 4696	AAUAAAGCUACUGAAUUUAUU	No. 5398	AAUAAAUUCAGUAGCUUUAUUUU
  BH1175	No. 4697	AAGCUACUGAAUUUAUUGCCG	No. 5399	CGGCAAUAAAUUCAGUAGCUUUA
  BH1176	No. 4698	AGCUACUGAAUUUAUUGCCGC	No. 5400	GCGGCAAUAAAUUCAGUAGCUUU
  BH1177	No. 4699	GCUACUGAAUUUAUUGCCGCA	No. 5401	UGCGGCAAUAAAUUCAGUAGCUU
  BH1178	No. 4700	CUACUGAAUUUAUUGCCGCAC	No. 5402	GUGCGGCAAUAAAUUCAGUAGCU
  BH1179	No. 4701	CUCUGCCAUGUUGCUAUUGCA	No. 5403	UGCAAUAGCAACAUGGCAGAGGA
  BH1180	No. 4702	GCUGGAAUCUUAGAAAAUGGA	No. 5404	UCCAUUUUCUAAGAUUCCAGCGA

  
  
• The double-stranded nucleic acid in the composition of the present invention can be introduced into cells of a mammal by administering the composition of the present invention to the cells.
• The nucleic acid conjugate of the present invention can be introduced into mammalian cells in vivo by known transfection procedures that can be implemented in vivo. By administering the composition of the present invention intravenously to mammals including humans, it is possible to deliver it to the blood vessels, liver, lungs, pancreas and/or kidneys for example, and thereby introduce the double stranded nucleic acid in the composition of the present invention into cells at the organ or the site.
• By introducing the double-stranded nucleic acid in the composition of the present invention into cells at the organ or the site, it is possible to reduce expression of the β2GPI gene in those cells, and thereby treat or prevent β2GPI-associated diseases such as systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome, complications of blood dialysis in end-stage renal failure patients, and arteriosclerosis. The target of administration is a mammal, preferably a human.
• The lipid particle-containing composition of the present invention may also be used as a tool to verify the effectiveness of β2GPI gene suppression in an in vivo efficacy evaluation model of a therapeutic or preventative agent for such diseases. The in vivo efficacy evaluation model may be a lupus anticoagulant (LA) test or the like. Like anti-β2GPI antibodies, LA is a kind of anti-phospholipid antibody, and inhibits phospholipid-dependent clotting reactions in collected blood in vitro. LA appears mainly in diseases such as SLE and APS. It has been reported a lot that like anti-β2GPI antibodies, LA is associated with the occurrence or pathology of thrombosis and infertility (Blood, 2003, Vol. 101, No. 5, pp. 1827-1832). Moreover, anti-β2GPI antibodies have also been reported to cause β2GPI-dependent LA activity because they acquire phospholipid-binding activity via β2GPI (Thrombosis and Haemostasis, 1998, Vol. 79, No. 1, pp. 79-86). Furthermore, it has been reported that this β2GPI-dependent LA is strongly correlated to the incidence of disease pathology (Blood, 2004, Vol. 104, No. 12, pp. 3598-3602), so it is thought that a novel and effective treatment method for β2GPI-associated disease could be provided if LA activity could be decreased by suppressing β2GPI expression in blood. In clinical testing, LA can be detected by measuring activated partial thromboplastin time, kaolin clotting time and/or dilute Russell viper venom time (dRVVT).
• When the nucleic acid conjugate of the present invention is used as a therapeutic or preventive agent against β2GPI-associated disease, an administration route which is the most effective for the treatment is preferably selected. The route is preferably intravenous administration, subcutaneous administration or intramuscular administration, and more preferably subcutaneous administration.
• The dosage differs depending on the condition and age of the subject and the administration route and the like. The dosage may be 0.1 μg to 1,000 mg per day, and preferably 1 to 100 mg per day (based on the amount of the double-stranded nucleic acid).
EXAMPLES
• Next, the present invention is explained in detail using Reference Examples, Examples and Test Examples. However, the present invention is not limited to these Examples and Test Examples. The proton nuclear magnetic resonance spectra (1H NMR) given in Reference Examples were measured at 270 MHz, 300 MHz or 400 MHz. Exchangeable protons may not be observed clearly depending on the compound and the measurement conditions. The multiplicity of the signal is shown in a conventional way. The term “br” represents an apparently broad signal.
Reference Example 1
• 
• (wherein, Fmoc and DMTr are defined as above.)
• Step 1
• (9H-fluoren-9-yl)methyl((2R,3R)-1,3-dihydroxybutan-2-yl)carbamate (Chem-Impex International, Inc., 1.50 g, 4.58 mmol) was dissolved in pyridine (20 mL), 4,4′-dimethoxytrityl chloride (Tokyo Chemical Industry Co., Ltd., 1.71 g, 5.04 mmol) was added under ice cooling, and the mixture was stirred for 2 hours at room temperature. The reaction solution was ice cooled, 10% aqueous citric acid solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10) to obtain Compound 2 (1.07 g, yield 37%),
• ESI-MS m/z: 630 (M+H)+;
• Step 2
• Compound 2 obtained in step 1 (1.07 g, 1.699 mmol) was dissolved in N,N-dimethylformamide (10 mL), and piperidine (0.336 mL, 3.40 mmol) was added at room temperature, and the mixture was stirred for 3 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate, and the organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by amino silica gel column chromatography (chloroform/methanol=90/10) to obtain Compound 3 (0.59 g, yield 85%).
• ESI-MS m/z: 408 (M+H)+;
• Step 3
• Compound 3 obtained in step 2 (0.590 g, 1.45 mmol) was dissolved in N,N-dimethylformamide (8 mL), 12-ethoxy-12-oxododecanoic acid (Tokyo Chemical Industry Co., Ltd., 0.374 g, 1.45 mmol), diisopropylethylamine (0.632 mL, 3.62 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (Wako Pure Chemicals Industries, Ltd., 0.659 g, 1.74 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, which was then extracted twice with ethyl acetate, and the organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=90/10 to 40/60) to obtain Compound 4 (0.430 g, yield 46%).
• ESI-MS m/z: 648 (M+H)+;
• Step 4
• Compound 4 obtained in step 3 (0.430 g, 0.664 mmol) was dissolved in ethanol (5 mL), and an aqueous lithium hydroxide solution (1.0 mL, 1.99 mol/L) was added, and the mixture was stirred overnight at room temperature. The reaction solution was ice cooled, 10% aqueous citric acid solution was added, the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was then distilled off under reduced pressure to obtain Compound 5 as a crude product (0.420 g, crude yield 100%).
• ESI-MS m/z: 618(M−H)−; 1H-NMR (CDCl3) δ: 1.12 (d, J=6.3 Hz, 3H),1.26-1.35 (m, 12H), 1.57-1.67 (m, 4H), 2.23 (t, J=7.7 Hz, 2H), 2.29 (t, J=7.4 Hz, 2H), 3.25 (dd, J=9.6, 3.9 Hz, 1H), 3.37 (dd, J=9.6, 4.7 Hz, 1H), 3.39-3.41 (m, 1H), 3.79 (s, 6H), 3.91-3.94 (m, 1H), 4.04-4.09 (m, 1H), 6.43 (d, J=8.8 Hz, 1H), 6.83 (d, J=8.8 Hz, 4H), 7.21-7.24 (m, 1H), 7.26-7.30 (m, 6H), 7.37-7.39 (m, 2H).
Reference Example 2
• 

  
• (wherein, Ac and DMTr are defined as above, and Po represents the solid-phase carrier LCAA-CPG.)
• Step 5
• Compound 6 (0.119 g, 0.066 mmol) that had been synthesized by a known method (see Journal of the American Chemical Society, Vol. 136, pp. 16958-16961, 2014) was dissolved in THF (2 mL), to which Compound 5 (0.062 g, 0.100 mmol) obtained in step 4 of Example 1, diisopropylethylamine (0.116 mL, 0.663 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.050 g, 0.133 mmol) and N,N-dimethylaminopyridine (Nacalai Tesque, Inc., 8.1 mg, 0.133 mmol) was added. The mixture was stirred overnight at room temperature. The reaction solution was ice cooled, 10% aqueous citric acid solution was added, the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by amino silica gel column chromatography (methanol/chloroform) to obtain Compound 7 (0.035 g, yield 22%).
• ESI-MS m/z: 1048 (M+2H)2+
• Step 6
• Compound 7 obtained in step 5 (0.135 g, 0.056 mmol) was dissolved in dichloromethane (2 mL), succinic acid anhydride (Tokyo Chemical Industry Co., Ltd., 0.011 g, 0.113 mmol) and N,N-dimethylaminopyridine (0.021 g, 0.169 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction solution was ice cooled, 10% aqueous citric acid solution was added, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated saline and dried with anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain Compound 8 as a crude product (0.110 g, crude yield 78%).
• ESI-MS m/z: 1089 (M+2H)2+;
• 1H-NMR (DMSO-d6) δ: 1.02 (d, J=6.3 Hz, 3H), 1.15-1.25 (m, 12H), 1.39-1.55 (m, 22H), 1.77 (s, 9H), 1.88 (d, J=7.9 Hz, 9H), 1.99 (s, 9H), 2.04 (t, J=7.1 Hz, 6H), 2.10 (s, 9H), 2.11-2.15 (m, 2H), 2.28 (t, J=6.5 Hz, 6H), 2.37-2.42 (m, 2H), 2.49-2.53 (m, 2H), 2.83-2.95 (m, 2H), 2.99-3.08 (m, 12H), 3.31-3.45 (m, 6H), 3.48-3.58 (m, 12H), 3.67-3.75 (m, 2H), 3.73 (s, 6H), 3.83-3.92 (m, 3H), 3.97-4.06 (m, 9H), 4.10-4.18 (m, 1H), 4.49 (d, J=8.4 Hz, 3H), 4.97 (dd, J=11.3, 3.4 Hz, 3H), 5.09-5.16 (m, 1H), 5.21 (d, J=3.3 Hz, 3H), 6.84-6.91 (m, 4H), 6.99 (s, 1H), 7.12-7.40 (m, 9H), 7.71-7.89 (m, 10H).
• Step 7
• Compound 8 obtained in step 6 (0.050 g, 0.014 mmol), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.011 g, 0.028 mmol) and diisopropylethylamine (0.098 mL, 0.056 mmol) were dissolved in N,N-dimethylformamide (2 mL), and the solid-phase carrier LCAA-CPG (Sigma-Aldrich Corporation, 0.25 g, 0.014 mmol) was added, and the mixture was stirred overnight at room temperature. The mixture was filtered through frit, washed with dichloromethane, 10% methanol dichloromethane solution and diethyl ether, and reacted with an acetic anhydride/pyridine solution to obtain Compound 9 (17.7 μmol/g, yield 30%). The yield was calculated from an introduction rate onto the solid-phase carrier, which can be determined from the absorption derived from DMTr groups by adding a 1% trifluoroacetic acid/dichloromethane solution to the solid-phase carrier.
Test Example 1Measuring Knockdown Activity of β2GPI mRNA
• HepG2 cells (obtained from ATCC, ATCC No. HB-8065), a cell strain derived from human liver cancer, were seeded on 96-well culture plates so as to be 5,000 cells/80 μL/well. MEM medium (Life Technologies Corporation, Catalog No. 11095-098) containing 10% fetal bovine serum (FBS) was used. The double-stranded nucleic acids described in Tables 4-1 to 4-16 and RNAiMax transfection reagent (Life Technologies Corporation, Catalog No. 1401251) were diluted with Opti-MEM medium (Life Technologies Corporation, Catalog No. 11058-021), and 20 μL of the siRNA/RNAiMax mixture was added to each 96-well culture plate so as to be a final concentration of the double-stranded nucleic acid of 100 pmol/L, and the plate was cultured for 24 hours under conditions of 37° C., 5% CO₂. The cells were then washed with PBS (phosphate-buffered saline), and cDNA was synthesized from each plate using a Cells-to-Ct kit (Applied Biosystems, Inc., Catalog No. AM1728) according to the methods described in the attached instruction. 5 μL of this cDNA was added to a MicroAmpOptical 96-well plate (Applied Biosystems, Inc., Catalog No. 4326659), to which 10 μL of TaqMan Gene Expression Master Mix (Applied Biosystems, Inc., Catalog No. 4369016), 3 μL of UltraPure Distilled Water (Life Technologies Corporation, Catalog No. 10977-015), 1 μL of a human β2GPI probe and 1 μL of a human GAPDH probe were further added. Using an ABI7900 HT real time PCR system, real time PCR was performed on the human β2GPI gene and human GAPDH (D-glyceraldehyde-3-phosphate dehydrogenase). GAPDH is a constitutively expressed gene, which was measured as an internal control and used to correct the expressed amount of β2GPI. The amount of β2GPI mRNA obtained when HepG2 cells were treated with the transfection reagent alone without adding siRNA being set to be 1.0, the relative expressed amount of β2GPI mRNA obtained when each siRNA was introduced was calculated. This test was performed three times, and the average values of the relative expressed amounts of β2GPI mRNA are described in Tables 4-1 to 4-16.

• TABLE 4-1
  Double
  stranded
  nucleic	SEQ ID	Sense strand sequence		Antisense strand
  acid No.	NO.	(5′→3′)	SEQ ID NO.	sequence (5′→3′)	SEQ ID NO.
  AH0033	No. 33	GUAGUGCCAGUGUGACUCAUC	No. 1213	UGAGUCACACUGGCACUACCA	No. 2393
  AH0034	No. 34	UAGUGCCAGUGUGACUCAUCC	No. 1214	AUGAGUCACACUGGCACUACC	No. 2394
  AH0035	No. 35	AGUGCCAGUGUGACUCAUCCA	No. 1215	GAUGAGUCACACUGGCACUAC	No. 2395
  AH0036	No. 36	GUGCCAGUGUGACUCAUCCAC	No. 1216	GGAUGAGUCACACUGGCACUA	No. 2396
  AH0037	No. 37	UGCCAGUGUGAGUCAUCCACA	No. 1217	UGGAUGAGUCACACUGGCACU	No. 2397
  AH0038	No. 38	GCCAGUGUGACUCAUCCACAA	No. 1218	GUGGAUGAGUCACACUGGCAC	No. 2398
  AH0039	No. 39	CCAGUGUGACUCAUCCACAAU	No. 1219	UGUGGAUGAGUCACACUGGCA	No. 2399
  AH0040	No. 40	CAGUGUGACUCAUCCACAAUG	No. 1220	UUGUGGAUGAGUCACACUGGC	No. 2400
  AH0041	No. 41	AGUGUGACUCAUCCACAAUGA	No. 1221	AUUGUGGAUGAGUCACACUGG	No. 2401
  AH0042	No. 42	GUGUGACUCAUCCACAAUGAU	No. 1222	CAUUGUGGAUGAGUCACACUG	No. 2402
  AH0043	No. 43	UGUGACUCAUCCACAAUGAUU	No. 1223	UCAUUGUGGAUGAGUCACACU	No. 2403
  AH0044	No. 44	GUGACUCAUCCACAAUGAUUU	No. 1224	AUCAUUGUGGAUGAGUCACAC	No. 2404
  AH0045	No. 45	UGACUCAUCCACAAUGAUUUC	No. 1225	AAUCAUUGUGGAUGAGUCACA	No. 2405
  AH0046	No. 46	GACUCAUCCACAAUGAUUUCU	No. 1226	AAAUCAUUGTGGAUGAGUCAG	No. 2406
  AH0047	No. 47	ACUCAUCCACAAUGAUUUCUC	No. 1227	GAAAUCAUUGUGGAUGAGUCA	No. 2407
  AH0048	No. 48	CUCAUCCACAAUGAUUUCUCC	No. 1228	AGAAAUCAUUGUGGAUGAGUC	No. 2408
  AH0050	No. 50	CAUCCACAAUGAUUUCUCCAG	No. 1230	GGAGAAAUCAUUGUGGAUGAG	No. 2410
  AH0051	No. 51	AUCCACAAUGAUUUCUCCAGU	No. 1231	UGGAGAAAUCAUUGUGGAUGA	No. 2411
  AH0052	No. 52	UCCACAAUGAUUUCUCCAGUG	No. 1232	CUGGAGAAAUCAUUGUGGAUG	No. 2412
  AH0053	No. 53	CCACAAUGAUUUCUCCAGUGC	No. 1233	ACUGGAGAAAUCAUUGUGGAU	No. 2413
  AH0054	No. 54	CACAAUGAUUUCUCCAGUGCU	No. 1234	CACUGGAGAAAUCAUUGUGGA	No. 2414
  AH0055	No. 55	ACAAUGAUUUCUCCAGUGCUC	No. 1235	GCACUGGAGAAAUCAUUGUGG	No. 2415
  AH0056	No. 56	CAAUGAUUUCUCCAGUGCUCA	No. 1236	AGCACUGGAGAAAUCAUUGUG	No. 2416
  AH0057	No. 57	AAUGAUUUCUCCAGUGCUCAU	No. 1237	GAGCACUGGAGAAAUCAUUGU	No. 2417
  AH0058	No. 58	AUGAUUUCUCCAGUGCUCAUC	No. 1238	UGAGCACUGGAGAAAUCAUUG	No. 2418
  AH0059	No. 59	UGAUUUCUCCAGUGCUCAUCU	No. 1239	AUGAGCACUGGAGAAAUCAUU	No. 2419
  AH0060	No. 60	GAUUUCUCCAGUGCUCAUCUU	No. 1240	GAUGAGGACUGGAGAAAUCAU	No. 2420
  AH0061	No. 61	AUUUCUCCAGUGCUCAUCUUG	No. 1241	AGAUGAGCACUGGAGAAAUCA	No. 2421
  AH0062	No. 62	UUUCUCCAGUGCUCAUCUUGU	No. 1242	AAGAUGAGCACUGGAGAAAUC	No. 2422
  AH0063	No. 63	UUCUCCAGUGCUCAUCUUGUU	No. 1243	CAAGAUGAGCACUGGAGAAAU	No. 2423
  AH0064	No. 64	UCUCCAGUGCUCAUCUUGUUC	No. 1244	ACAAGAUGAGCACUGGAGAAA	No. 2424
  AH0065	No. 65	CUCCAGUGCUCAUCUUGUUCU	No. 1245	AACAAGAUGAGCACUGGAGAA	No. 2425
  AH0066	No. 66	UCCAGUGCUCAUCUUGUUCUC	No. 1246	GAACAAGAUGAGCACUGGAGA	No. 2426
  AH0067	No. 67	CCAGUGCUCAUCUUGUUCUCG	No. 1247	AGAACAAGAUGAGCACUGGAG	No. 2427
  AH0068	No. 68	CAGUGCUCAUCUUGUUCUCGA	No. 1248	GAGAACAAGAUGAGCACUGGA	No. 2428
  AH0069	No. 69	AGUGCUCAUCUUGUUCUCGAG	No. 1249	CGAGAACAAGAUGAGCACUGG	No. 2429
  AH0070	No. 70	GUGGUCAUCUUGUUCUCGAGU	No. 1250	UCGAGAACAAGAUGAGCACUG	No. 2430
  AH0071	No. 71	UGCUCAUCUUGUUCUCGAGUU	No. 1251	CUCGAGAACAAGAUGAGCACU	No. 2431
  AH0072	No. 72	GCUCAUCUUGUUCUCGAGUUU	No. 1252	ACUCGAGAACAAGAUGAGCAC	No. 2432
  AH0073	No. 73	CUCAUCUUGUUCUCGAGUUUU	No. 1253	AACUCGAGAACAAGAUGAGCA	No. 2433
  AH0074	No. 74	UCAUCUUGUUCUCGAGUUUUC	No. 1254	AAACUCGAGAACAAGAUGAGC	No. 2434
  AH0075	No. 75	CAUCUUGUUCUCGAGUUUUCU	No. 1255	AAAACUCGAGAACAAGAUGAG	No. 2435
  AH0076	No. 76	AUCUUGUUCUCGAGUUUUCUC	No. 1256	GAAAACUCGAGAACAAGAUGA	No. 2436
  AH0077	No. 77	UCUUGUUCUCGAGUUUUCUCU	No. 1257	AGAAAACUCGAGAACAAGAUG	No. 2437
  AH0078	No. 78	CUUGUUCUCGAGUUUUCUCUG	No. 1258	GAGAAAACUCGAGAACAAGAU	No. 2438
  			Double
  			stranded
  			nucleic	Target β2GPI	Relative expressed
  			acid No.	mRNA sequence	amount of β2GPI
  			AH0033	GTAGTGCCAGTGTGACTCA	0.172
  			AH0034	TAGTGCCAGTGTGACTCAT	0.185
  			AH0035	AGTGCCAGTGTGACTCATC	0.178
  			AH0036	GTGCCAGTGTGACTCATCC	0.191
  			AH0037	TGCCAGTGTGACTCATCCA	0.148
  			AH0038	GGCAGTGTGACTCATCCAC	0.166
  			AH0039	CCAGTGTGACTCATCCACA	0.179
  			AH0040	CAGTGTGACTCATCCACAA	0.126
  			AH0041	AGTGTGACTCATCCACAAT	0.081
  			AH0042	GTGTGACTCATCGACAATG	0.123
  			AH0043	TGTGACTCATCCACAATGA	0.144
  			AH0044	GTGACTCATCCACAATGAT	0.148
  			AH0045	TGACTCATCCACAATGATT	0.100
  			AH0046	GACTCATCCACAATGATTT	0.114
  			AH0047	ACTCATCCACAATGATTTC	0.211
  			AH0048	CTCATCCACAATGATTTCT	0.136
  			AH0050	CATCCACAATGATTTCTCC	0.157
  			AH0051	ATCCACAATGATTTCTCCA	0.136
  			AH0052	TCCACAATGATTTCTCCAG	0.290
  			AH0053	CCACAATGATTTCTCCAGT	0.128
  			AH0054	CACAATGATTTCTCCAGTG	0.130
  			AH0055	ACAATGATTTCTCCAGTGC	0.291
  			AH0056	CAATGATTTCTCCAGTGCT	0.139
  			AH0057	AATGATTTCTCCAGTGCTC	0.247
  			AH0058	ATGATTTCTCCAGTGCTCA	0.110
  			AH0059	TGATTTCTCCAGTGCTCAT	0.118
  			AH0060	GATTTCTCCAGTGCTCATC	0.111
  			AH0061	ATTTCTCCAGTGCTCATCT	0.146
  			AH0062	TTTCTCCAGTGCTCATCTT	0.202
  			AH0063	TTCTCCAGTGCTCATCTTG	0.187
  			AH0064	TCTCCAGTGCTCATCTTGT	0.103
  			AH0065	CTCCAGTGCTCATCTTGIT	0.094
  			AH0066	TCCAGTGGTCATCTTGTTC	0.128
  			AH0067	CCAGTGCTCATCTTGTTCT	0.106
  			AH0068	CAGTGCTCATCTTGTTCTC	0.103
  			AH0069	AGTGCTCATCTTGTTCTCG	0.152
  			AH0070	GTGCTCATCTTGTTCTCGA	0.078
  			AH0071	TGCTCATCTTGTTCTCGAG	0.091
  			AH0072	GCTCATCTTGTTCTCGAGT	0.111
  			AH0073	CTCATCTTGTTCTCGAGTT	0.086
  			AH0074	TCATCTTGTTCTCGAGTTT	0.073
  			AH0075	CATCTTGTTCTCGAGTTTT	0.078
  			AH0076	ATCTTGTTCTCGAGTTTTC	0.107
  			AH0077	TCTTGTTCTCGAGTTTTCT	0.137
  			AH0078	CTTGTTCTCGAGTTTTCTC	0.123

• TABLE 4-2
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0079	No. 79	UUGUUCUCGAGUUUUCUCUGC	No. 1259	AGAGAAAACUCGAGAACAAGA
  AH0080	No. 80	UGUUCUCGAGUUUUCUCUGCC	No. 1260	CAGAGAAAACUCGAGAACAAG
  AH0081	No. 81	GUUCUCGAGUUUUCUCUGCCA	No. 1261	GCAGAGAAAACUCGAGAACAA
  AH0083	No. 83	UCUCGAGUUUUCUCUGCCAUG	No. 1263	UGGCAGAGAAAACUCGAGAAC
  AH0084	No. 84	CUCGAGUUUUCUCUGCCAUGU	No. 1264	AUGGCAGAGAAAACUCGAGAA
  AH0085	No. 85	UCGAGUUUUCUCUGCCAUGUU	No. 1265	CAUGGCAGAGAAAACUCGAGA
  AH0086	No. 86	CGAGUUUUCUCUGCCAUGUUG	No. 1266	ACAUGGCAGAGAAAACUCGAG
  AH0087	No. 87	GAGUUUUCUCUGCCAUGUUGC	No. 1267	AACAUGGCAGAGAAAACUCGA
  AH0088	No. 88	AGUUUUCUCUGCCAUGUUGCU	No. 1268	CAACAUGGCAGAGAAAACUCG
  AH0089	No. 89	GUUUUCUCUGCCAUGUUGCUA	No. 1269	GCAACAUGGCAGAGAAAACUC
  AH0090	No. 90	UUUUCUCUGCCAUGUUGCUAU	No. 1270	AGCAACAUGGCAGAGAAAACU
  AH0091	No. 91	UUUCUCUGCCAUGUUGCUAUU	No. 1271	UAGCAACAUGGCAGAGAAAAC
  AH0092	No. 92	UUCUCUGCCAUGUUGCUAUUG	No. 1272	AUAGCAACAUGGCAGAGAAAA
  AH0093	No. 93	UCUCUGCCAUGUUGCUAUUGC	No. 1273	AAUAGCAACAUGGCAGAGAAA
  AH0096	No. 96	CUGCCAUGUUGCUAUUGCAGG	No. 1276	UGCAAUAGCAACAUGGCAGAG
  AH0093	No. 97	UGCCAUGUUGCUAUUGCAGGA	No. 1277	CUGCAAUAGCAACAUGGCAGA
  AH0098	No. 98	GCCAUGUUGCUAUUGCAGGAC	No. 1278	CCUGCAAUAGCAACAUGGCAG
  AH0099	No. 99	CCAUGUUGCUAUUGGAGGACG	No. 1279	UCCUGCAAUAGCAACAUGGCA
  AH0103	No. 103	GUUGCUAUUGCAGGACGGACC	No. 1283	UCCGUCCUGCAAUAGCAACAU
  AH0106	No. 106	GCUAUUGCAGGACGGACCUGU	No. 1286	AGGUCCGUCCUGCAAUAGCAA
  AH0107	No. 107	CUAUUGCAGGACGGACCUGUC	No. 1287	CAGGUCCGUCCUGCAAUAGCA
  AH0106	No. 108	UAUUGGAGGACGGACCUGUCC	No. 1288	ACAGGUCCGUCCUGCAAUAGC
  AH9109	No. 109	AUUGGAGGACGGACCUGUCCC	No. 1289	GACAGGUCCGUCCUGCAAUAG
  AH0112	No. 112	GCAGGACGGACCUGUCCCAAG	No. 1292	UGGGACAGGUCCGUCCUGCAA
  AH0114	No. 114	AGGACGGACCUGUCCCAAGCC	No. 1294	CUUGGGACAGGUCCGUCCUGC
  AH0115	No. 115	GGACGGACCUGUCCCAAGCCA	No. 1295	GCUUGGGACAGGUCCGUCCUG
  AH0117	No. 117	ACGGACCUGUCCCAAGCCAGA	No. 1297	UGGCUUGGGACAGGUCCGUCC
  AH0118	No. 118	CGGACCUGUCCCAAGCCAGAU	No. 1298	CUGGCUUGGGACAGGUCCGUC
  AH0119	No. 119	GGACCUGUCCCAAGCCACAUG	No. 1299	UCUGGCUUGGGACAGGUCCGU
  AH0120	No. 120	GACCUGUCCCAAGCCAGAUGA	No. 1300	AUCUGGCUUGGGACAGGUCCG
  AH0121	No. 121	ACCUGUCCCAAGCCAGAUGAU	No. 1301	CAUCUGGCUUGGGACAGGUCC
  AH0122	No. 122	CCUGUCCCAAGCCAGAUGAUU	No. 1302	UCAUCUGGCUUGGGACAGGUC
  AH0123	No. 123	CUGUCCCAAGCCAGAUGAUUU	No. 1303	AUCAUCUGGCUUGGGACAGGU
  AH0124	No. 124	UGUCCCAAGCCAGAUGAUUUA	No. 1304	AAUCAUCUGGCUUGGGACAGG
  AH0125	No. 125	GUCCCAAGCCAGAUGAUUUAC	No. 1305	AAAUCAUCUGGCUUGGGACAG
  AH0126	No. 126	UCCCAAGCCAGAUGAUUUACC	No. 1306	UAAAUCAUCUGGCUUGGGACA
  AH0127	No. 127	CCCAAGCCAGAUGAUUUACCA	No. 1307	GUAAAUCAUCUGGCUUGGGAC
  AH0128	No. 128	CCAAGCCAGAUGAUUUACCAU	No. 1308	GGUAAAUCAUCUGGCUUGGGA
  AH0129	No. 129	CAAGCCAGAUGAUUUACCAUU	No. 1309	UGGUAAAUCAUCUGGCUUGGG
  AH0130	No. 130	AAGCCAGAUGAUUUACCAUUU	No. 1310	AUGGUAAAUCAUCUGGCUUGG
  AH0131	No. 131	AGCCAGAUGAUUUACCAUUUU	No. 1311	AAUGGUAAAUCAUCUGGCUUG
  AH0132	No. 132	GCCAGAUGAUUUACCAUUUUC	No. 1312	AAAUGGUAAAUCAUCUGGCUU
  AH0133	No. 133	CCAGAUGAUUUACCAUUUUCC	No. 1313	AAAAUGGUAAAUCAUCUGGCU
  AH0134	No. 134	CAGAUGAUUUACCAUUUUCCA	No. 1314	GAAAAUGGUAAAUCAUCUGGC
  AH0135	No. 135	AGAUGAUUUACCAUUUUCCAC	No. 1315	GGAAAAUGGUAAAUCAUCUGG
  AH0136	No. 136	GAUGAUUUACCAUUUUCCACA	No. 1316	UGGAAAAUGGUAAAUCAUCUG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0079	No. 2439	TTGTTCTCGAGTTTTCTCT	0.163
  	AH0080	No. 2440	TGTTCTCGAGTTTTCTCTG	0.291
  	AH0081	No. 2441	GTTCTCGAGTTTTCTCTGC	0.298
  	AH0083	No. 2443	TCTCGAGTTTTCTCTGCCA	0.148
  	AH0084	No. 2444	CTCGAGTTTTCTCTGCCAT	0.187
  	AH0085	No. 2445	TCGAGTTTTCTCTGCCATG	0.146
  	AH0086	No. 2446	CGAGTTTTCTCTGCCATGT	0.149
  	AH0087	No. 2447	GAGTTTTCTCTGCCATGTT	0.221
  	AH0088	No. 2448	AGTTTTCTCTGCCATGTTG	0.088
  	AH0089	No. 2449	GTTTTCTCTGCCATGTTGC	0.194
  	AH0090	No. 2450	TTTTCTCTGCCATGTTGCT	0.200
  	AH0091	No. 2451	TTTCTCTGCCATGTTGCTA	0 296
  	AH0092	No. 2452	TTCTCTGCCATGTTGCTAT	0.203
  	AH0093	No. 2453	TCTCTGCCATGTTGCTATT	0.204
  	AH0096	No. 2456	CTGCCATGTTGCTATTGCA	0.051
  	AH0093	No. 2457	TGCCATGTTGCTATTGCAG	0.226
  	AH0098	No. 2458	GCCATGTTGCTATTGCAGG	0.184
  	AH0099	No. 2459	CCATGTTGCTATTGCAGGA	0.066
  	AH0103	No. 2463	GTTGCTATTGCAGGACGGA	0.101
  	AH0106	No. 2466	GCTATTGCAGGACGGACCT	0.118
  	AH0107	No. 2467	CTATTGCAGGACGGACCTG	0.170
  	AH0106	No. 2468	TATTGCAGGACGGACCTGT	0.212
  	AH9109	No. 2469	ATTGCAGGACGGACCTGTC	0.210
  	AH0112	No. 2472	GCAGGACGGACCTGTCCCA	0.225
  	AH0114	No. 2474	AGGACGGACCTGTCCCAAG	0.155
  	AH0115	No. 2475	GGACGGACCTGTCCCAAGC	0.073
  	AH0117	No. 2417	ACGGACCTGTCCCAAGCCA	0.194
  	AH0118	No. 2478	CGGACCTGTCCCAAGCCAG	0.111
  	AH0119	No. 2479	GGACCTGTCCCAAGCCAGA	0.057
  	AH0120	No. 2480	GACCTGTCCCAAGCCAGAT	0.136
  	AH0121	No. 2481	ACCTGTCCCAAGCCAGATG	0.298
  	AH0122	No. 2482	CCTGTCCCAAGCCAGATGA	0.111
  	AH0123	No. 2483	CTGTCCCAAGCCAGATGAT	0 156
  	AH0124	No. 2484	TGTCCCAAGCCAGATGATT	0.098
  	AH0125	No. 2485	GTCCCAAGCCAGATGATTT	0.050
  	AH0126	No. 2486	TCCCAAGCCAGATGATTTA	0.063
  	AH0127	No. 2487	CCCAAGCCAGATGATTTAC	0.260
  	AH0128	No. 2488	CCAAGCCAGATGATTTACC	0.326
  	AH0129	No. 2489	CAAGCCAGATGATTTACCA	0.092
  	AH0130	No. 2490	AAGCCAGATGATTTACCAT	0 098
  	AH0131	No. 2491	AGCCAGATGATTTACCATT	0.147
  	AH0132	No. 2492	GCCAGATGATTTACCATTT	0.116
  	AH0133	No. 2493	CCAGATGATTTACCATTTT	0.062
  	AH0134	No. 2494	CAGATGATTTACCATTTTC	0.074
  	AH0135	No. 2495	AGATGATTTACCATTTTCC	0.122
  	AH0136	No. 2496	GATGATTTACCATTTTCCA	0.114

• TABLE 4-3
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0137	No. 137	AUGAUUUACCAUUUUCCACAG	No. 1317	GUGGAAAAUGGUAAAUCAUCU
  AH0138	No. 138	UGAUUUACCAUUUUCCACAGU	No. 1318	UGUGGAAAAUGGUAAAUCAUC
  AH0139	No. 139	GAUUUACCAUUUUCCACAGUG	No. 1319	CUGUGGAAAAUGGUAAAUCAU
  AH0143	No. 143	UACCAUUUUCCACAGUGGUCC	No. 1323	ACCACUGUGGAAAAUGGUAAA
  AH0144	No. 144	ACCAUUUUCCACAGUGGUCCC	No. 1324	GACCACUGUGGAAAAUGGUAA
  AH0145	No. 145	CCAUUUUCCACAGUGGUCCCG	No. 1325	GGACCACUGUGGAAAAUGGUA
  AH0149	No. 149	UUUCCACAGUGGUCCCGUUAA	No. 1329	AACGGGACCACUGUGGAAAAU
  AH0150	No. 150	UUCCACAGUGGUCCCGUUAAA	No. 1330	UAACGGGACCACUGUGGAAAA
  AH0151	No. 151	UCCACAGUGGUCCCGUUAAAA	No. 1331	UUAACGGGACCACUGUGGAAA
  AH01S2	No. 152	CCACAGUGGUCCCGUUAAAAA	No. 1332	UUUAACGGGACCACUGUGGAA
  AH0153	No. 153	CACAGUGGUCCCGUUAAAAAC	No. 1333	UUUUAACGGGACCACUGUGGA
  AH0154	No. 154	ACAGUGGUCCCGUUAAAAACA	No. 1334	UUUUUAACGGGACCACUGUGG
  AH0155	No. 155	CAGUGGUCCCGUUAAAAACAU	No. 1335	GUUUUUAACGGGACCACUGUG
  AH0156	No. 156	AGUGGUCCCGUUAAAAACAUU	No. 1336	UGUUUUUAACGGGACCACUGU
  AH0157	No. 157	GUGGUCCCGUUAAAAACAUUC	No. 1337	AUGUUUUUAACGGGACCACUG
  AH0158	No. 158	UGGUCCCGUUAAAAACAUUCU	No. 1338	AAUGUUUUUAAGGGGACCACU
  AH0159	No. 159	GGUCCCGUUAAAAACAUUCUA	No. 1339	GAAUGUUUUUAACGGGACCAC
  AH0160	No. 160	GUCCCGUUAAAAACAUUCUAU	No. 1340	AGAAUGUUUUUAACGGGACCA
  AH0161	No. 161	UCCCGUUAAAAACAUUCUAUG	No. 1341	UAGAAUGUUUUUAACGGGACC
  AH0162	No. 162	CCCGUUAAAAACAUUCUAUGA	No. 1342	AUAGAAUGUUUUUAACGGGAC
  AH0163	No. 163	CCGUUAAAAACAUUCUAUGAG	No. 1343	CAUAGAAUGUUUUUAACGGGA
  AH0164	No. 164	CGUUAAAAACAUUCUAUGAGC	No. 1344	UCAUAGAAUGUUUUUAACGGG
  AH0173	No. 173	CAUUCUAUGAGCCAGGAGAAG	No. 1353	UCUCCUGGCUCAUAGAAUGUU
  AH0114	No. 174	AUUCUAUGAGCCAGGAGAAGA	No. 1354	UUCUCCUGGCUCAUAGAAUGU
  AH0177	No. 177	CUAUGAGCCAGGAGAAGAGAU	No. 1357	CUCUUCUCCUGGCUCAUAGAA
  AH0178	No. 178	UAUGAGCCAGGAGAAGAGAUU	No. 1358	UCUCUUCUCCUGGCUCAUAGA
  AH0179	No. 179	AUGAGCCAGGAGAAGAGAUUA	No. 1359	AUCUCUUCUCCUGGCUCAUAG
  AH0180	No. 180	UGAGCCAGGAGAAGAGAUUAC	No. 1360	AAUCUCUUCUCCUGGCUCAUA
  AH0181	No. 181	GAGCCAGGAGAAGAGAUUACG	No. 1361	UAAUCUCUUCUCCUGGCUCAU
  AH0183	No. 183	GCCAGGAGAAGAGAUUACGUA	No. 1363	CGUAAUCUCUUCUCCUGGCUC
  AH0184	No. 184	CCAGGAGAAGAGAUUACGUAU	No. 1364	ACGUAAUCUCUUCUCCUGGCU
  AH0185	No. 185	CAGGAGAAGAGAUUACGUAUU	No. 1365	UACGUAAUCUCUUCUCCUGGC
  AH0186	No. 186	AGGAGAAGAGAUUACGUAUUC	No. 1366	AUACGUAAUCUCUUCUCCUGG
  AH0187	No. 187	GGAGAAGAGAUUACGUAUUCC	No. 1367	AAUACGUAAUCUCUUCUCCUG
  AH0188	No. 188	GAGAAGAGAUUACGUAUUCCU	No. 1368	GAAUACGUAAUCUCUUCUCCU
  AH0189	No. 189	AGAAGAGAUUACGUAUUCCUG	No. 1369	GGAAUACGUAAUCUCUUCUCC
  AH0190	No. 190	GAAGAGAUUACGUAUUCCUGC	No. 1370	AGGAAUACGUAAUCUCUUCUC
  AH0193	No. 193	GAGAUUACGUAUUCCUGCAAG	No. 1373	UGCAGGAAUACGUAAUCUCUU
  AH0194	No. 194	AGAUUACGUAUUCCUGCAAGC	No. 1374	UUGCAGGAAUACGUAAUCUCU
  AH0195	No. 195	GAUUACGUAUUCCUGCAAGCC	No. 1375	CUUGCAGGAAUACGUAAUCUC
  AH0199	No. 199	ACGUAUUCCUGCAAGCCGGGC	No. 1379	CCGGCUUGCAGGAAUACGUAA
  AH0203	No. 203	AUUCCUGCAAGCCGGGCUAUG	No. 1383	UAGCCCGGCUUGCAGGAAUAC
  AH0207	No. 207	CUGCAAGCCGGGCUAUGUGUC	No. 1387	CACAUAGCCCGGCUUGCAGGA
  AH0225	No. 225	GUCCCGAGGAGGGAUGAGAAA	No. 1405	UCUCAUCCCUCCUCGGGACAC
  AH0226	No. 226	UCCCGAGGAGGGAUGAGAAAG	No. 1406	UUCUCAUCCCUCCUCGGGACA
  AH0229	No. 229	CGAGGAGGGAUGAGAAAGUUU	No. 1409	ACUUUCUCAUCCCUCCUCGGG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0137	No. 2497	ATGATTTACCATTTTCCAC	0.333
  	AH0138	No. 2498	TGATTTACCATTTTCCACA	0.210
  	AH0139	No. 2499	GATTTACCATTTTCCACAG	0.303
  	AH0143	No. 2503	TACCATTTTCCACAGTGGT	0.298
  	AH0144	No. 2504	ACCATTTTCCACAGTGGTC	0.155
  	AH0145	No. 2505	CCATTTTCCACAGTGGTCC	0.305
  	AH0149	No. 2509	TTTCCACAGTGGTCCCGTT	0.080
  	AH0150	No. 2510	TTCCACAGTGGTCCCGTTA	0.184
  	AH0151	No. 2511	TCCACAGTGGTCCCGTTAA	0.164
  	AH01S2	No. 2512	CCACAGTGGTCCCGTTAAA	0.060
  	AH0153	No. 2513	CACAGTGGTCCCGTTAAAA	0.198
  	AH0154	No. 2514	ACAGTGGTCCCGTTAAAAA	0.077
  	AH0155	No. 2515	CAGTGGTCCCGTTAAAAAC	0.062
  	AH0156	No. 2516	AGTGGTCCCGTTAAAAACA	0.238
  	AH0157	No. 2517	GTGGTCCCGTTAAAAACAT	0.130
  	AH0158	No. 2518	TGGTCCCGTTAAAAACATT	0.145
  	AH0159	No. 2519	GGTCCCGTTAAAAACATTC	0.266
  	AH0160	No. 2520	GTCCCGTTAAAAACATTCT	0.265
  	AH0161	No. 2521	TCCCGTTAAAAACATTCTA	0.116
  	AH0162	No. 2522	CCCGTTAAAAACATTCTAT	0.096
  	AH0163	No. 2523	CCGTTAAAAACATTCTATG	0.116
  	AH0164	No. 2524	CGTTAAAAACATTCTATGA	0.109
  	AH0173	No. 2533	CATTCTATGAGCCAGGAGA	0.131
  	AH0114	No. 2534	ATTCTATGAGCCAGGAGAA	0.255
  	AH0177	No. 2537	CTATGAGCCAGGAGAAGAG	0.168
  	AH0178	No. 2538	TATGAGCCAGGAGAAGAGA	0.319
  	AH0179	No. 2539	ATGAGCCAGGAGAAGAGAT	0.260
  	AH0180	No. 2540	TGAGCCAGGAGAAGAGATT	0.128
  	AH0181	No. 2541	GAGCCAGGAGAAGAGATTA	0.049
  	AH0183	No. 2543	GCCAGGAGAAGAGATTACG	0.053
  	AH0184	No. 2544	CCAGGAGAAGAGATTACGT	0.066
  	AH0185	No. 2545	CAGGAGAAGAGATTACGTA	0.055
  	AH0186	No. 2546	AGGAGAAGAGATTACGTAT	0.094
  	AH0187	No. 2547	GGAGAAGAGATTACGTATT	0.071
  	AH0188	No. 2548	GAGAAGAGATTACGTATTC	0.069
  	AH0189	No. 2549	AGAAGAGATTACGTATTCC	0.168
  	AH0190	No. 2550	GAAGAGATTACGTATTCCT	0.157
  	AH0193	No. 2553	GAGATTACGTATTCCTGCA	0.070
  	AH0194	No. 2554	AGATTACGTATTCCTGCAA	0.186
  	AH0195	No. 2555	GATTACGTATTCCTGCAAG	0.095
  	AH0199	No. 2559	ACGTATTCCTGCAAGCCGG	0.294
  	AH0203	No. 2563	ATTCCTGCAAGCCGGGCTA	0.232
  	AH0207	No. 2567	CTGCAAGCCGGGCTATGTG	0.341
  	AH0225	No. 2585	GTCCCGAGGAGGGATGAGA	0.212
  	AH0226	No. 2586	TCCCGAGGAGGGATGAGAA	0.133
  	AH0229	No. 2589	CGAGGAGGGATGAGAAAGT	0.182

• TABLE 4-4
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0230	No. 230	GAGGAGGGAUGAGAAAGUUUA	No. 1410	AACUUUCUCAUCCCUCCUCGG
  AH0231	No. 231	AGGAGGGAUGAGAAAGUUUAU	No. 1411	AAACUUUCUCAUCCCUCCUCG
  AH0232	No. 232	GGAGGGAUGAGAAAGUUUAUC	No. 1412	UAAACUUUCUCAUCCCUCCUC
  AH0233	No. 233	GAGGGAUGAGAAAGUUUAUCU	No. 1413	AUAAACUUUCUCAUCCCUCCU
  AH0234	No. 234	AGGGAUGAGAAAGUUUAUCUG	No. 1414	GAUAAACUUUCUGAUCCCUCC
  AH0235	No. 235	GGGAUGAGAAAGUUUAUCUGC	No. 1415	AGAUAAACUUUCUCAUCCCUC
  AH0236	No. 236	GGAUGAGAAAGUUUAUCUGCC	No. 1416	CAGAUAAACUUUCUCAUCCCU
  AH0242	No. 242	GAAAGUUUAUCUGGCCUCUCA	No. 1422	AGAGGGCAGAUAAACUUUCUC
  AH0244	No. 244	AAGUUUAUCUGCCGUCUCACA	No. 1424	UGAGAGGGCAGAUAAACUUUC
  AH0255	No. 255	CCCUCUCACAGGAGUGUGGCC	No. 1435	CCACAGUCCUGUGAGAGGGCA
  AH0260	No. 260	UCACAGGACUGUGGCCCAUCA	No. 1440	AUGGGCCACAGUCCUGUGAGA
  AH0262	No. 262	ACAGGACUGUGGCCCAUCAAC	No. 1442	UGAUGGGCCACAGUCCUGUGA
  AH0265	No. 265	GGACUGUGGCCCAUCAACACU	No. 1445	UGUUGAUGGGCCACAGUCCUG
  AH0266	No. 256	GACUGUGGCCCAUCAACACUC	No. 1446	GUGUUGAUGGGCCACAGUCCU
  AH0272	No. 272	GGCCCAUCAACACUCUGAAAU	No. 1452	UUCAGAGUGUUGAUGGGCCAC
  AH0274	No. 274	CCCAUCAACACUCUGAAAUGU	No. 1454	AUUUCAGAGUGUUGAUGGGCC
  AH0275	No. 275	CCAUCAACACUCUGAAAUGUA	No. 1455	CAUUUCAGAGUGUUGAUGGGC
  AH0276	No. 276	CAUCAACACUCUGAAAUGUAC	No. 1456	ACAUUUCAGAGUGUUGAUGGG
  AH0277	No. 277	AUCAACACUCUGAAAUGUACA	No. 1457	UACAUUUCAGAGUGUUGAUGG
  AH0279	No. 279	CAACACUCUGAAAUGUACACC	No. 1459	UGUACAUUUCAGAGUGUUGAU
  AH0283	No. 283	ACUCUGAAAUGUACACCCAGA	No. 1463	UGGGUGUACAUUUCAGAGUGU
  AH0285	No. 285	UCUGAAAUGUACACCCAGAGU	No. 1465	UCUGGGUGUACAUUUCAGAGU
  AH0288	No. 288	GAAAUGUACACCCAGAGUAUG	No. 1468	UACUCUGGGUGUACAUUUCAG
  AH0289	No. 284	AAAUGUACACCCAGAGUAUGU	No. 1469	AUACUCUGGGUGUACAUUUCA
  AH0291	No. 291	AUGUACACCCAGAGUAUGUCC	No. 1471	ACAUACUCUGGGUGUACAUUU
  AH0294	No. 294	UACACCCAGAGUAUGUCCUUU	No. 1474	AGGACAUACUCUGGGUGUACA
  AH0295	No. 295	ACACCCAGAGUAUGUCCUUUU	No. 1475	AAGGACAUACUCUGGGUGUAC
  AH0296	No. 296	CACCCAGAGUAUGUCCUUUUG	No. 1476	AAAGGACAUACUCUGGGUGUA
  AH0297	No. 297	ACCCAGAGUAUGUCCUUUUGC	No. 1477	AAAAGGACAUACUCUGGGUGU
  AH0298	No. 298	CCCAGAGUAUGUCCUUUUGCU	No. 1478	CAAAAGGACAUACUCUGGGUG
  AH0300	No. 300	CAGAGUAUGUCCUUUUGCUGG	No. 1480	AGCAAAAGGACAUACUCUGGG
  AH0301	No. 301	AGAGUAUGUCCUUUUGCUGGA	No. 1481	CAGCAAAAGGACAUACUCUGG
  AH0302	No. 302	GAGUAUGUCCUUUUGCUGGAA	No. 1482	CCAGCAAAAGGACAUACUCUG
  AH0303	No. 303	AGUAUGUCCUUUUGCUGGAAU	No. 1483	UCCAGCAAAAGGACAUACUCU
  AH0304	No. 304	GUAUGUCCUUUUGCUGGAAUC	No. 1484	UUCCAGCAAAAGGACAUACUC
  AH0306	No. 306	AUGUCCUUUUGCUGGAAUCUU	No. 1486	GAUUCCAGCAAAAGGACAUAC
  AH0307	No. 307	UGUCCUUUUGCUGGAAUCUUA	No. 1487	AGAUUCCAGCAAAAGGACAUA
  AH0308	No. 308	GUCCUUUUGCUGGAAUCUUAG	No. 1488	AAGAUUCCAGCAAAAGGACAU
  AH0309	No. 309	UCCUUUUGCUGGAAUCUUAGA	No. 1489	UAAGAUUCCAGCAAAAGGACA
  AH0310	No. 310	CCUUUUGCUGGAAUCUUAGAA	No. 1490	CUAAGAUUCCAGCAAAAGGAC
  AH0311	No. 311	CUUUUGCUGGAAUCUUAGAAA	No. 1491	UCUAAGAUUCCAGCAAAAGGA
  AH0314	No. 314	UUGCUGGAAUCUUAGAAAAUG	No. 1494	UUUUCUAAGAUUCCAGCAAAA
  AH0315	No. 315	UGCUGGAAUCUUAGAAAAUGG	No. 1495	AUUUUCUAAGAUUCCAGCAAA
  AH0316	No. 316	GCUGGAAUCUUAGAAAAUGGA	No. 1496	CAUUUUCUAAGAUUCCAGCAA
  AH0317	No. 317	CUGGAAUCUUAGAAAAUGGAG	No. 1497	CCAUUUUCUAAGAUUCCAGCA
  AH0318	No. 318	UGGAAUCUUAGAAAAUGGAGC	No. 1498	UCCAUUUUCUAAGAUUCCAGC
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0230	No. 2590	GAGGAGGGATGAGAAAGTT	0.290
  	AH0231	No. 2591	AGGAGGGATGAGAAAGTTT	0.149
  	AH0232	No. 2592	GGAGGGATGAGAAAGTTTA	0.080
  	AH0233	No. 2593	GAGGGATGAGAAAGTTTAT	0.046
  	AH0234	No. 2594	AGGGATGAGAAAGTTTATC	0.252
  	AH0235	No. 2595	GGGATGAGAAAGTTTATCT	0.134
  	AH0236	No. 2596	GGATGAGAAAGTTTATCTG	0.065
  	AH0242	No. 2602	GAAAGTTTATCTGCCCTCT	0.318
  	AH0244	No. 2604	AAGTTTATGTGCCCTCTCA	0.192
  	AH0255	No. 2615	CCCTCTCACAGGACTGTGG	0.340
  	AH0260	No. 2620	TCACAGGACTGTGGCCCAT	0.295
  	AH0262	No. 2622	ACAGGACTGTGGCCCATCA	0.305
  	AH0265	No. 2625	GGACTGTGGCCCATCAACA	0.137
  	AH0266	No. 2626	GACTGTGGCCCATCAACAC	0.169
  	AH0272	No. 2632	GGCCCATCAACAGTCTGAA	0.166
  	AH0274	No. 2634	CCCATCAACACTCTGAAAT	0.253
  	AH0275	No. 2635	CCATCAACACTCTGAAATG	0.068
  	AH0276	No. 2636	CATCAACACTCTGAAATGT	0.165
  	AH0277	No: 2637	ATCAACACTCTGAAATGTA	0.172
  	AH0279	No. 2639	CAACACTCTGAAATGTACA	0.229
  	AH0283	No. 2643	ACTCTGAAATGTACACCCA	0.288
  	AH0285	No. 2645	TCTGAAATGTACACCCAGA	0.305
  	AH0288	No. 2648	GAAATGTACACCCAGAGTA	0.221
  	AH0289	No. 2649	AAATGTACACCCAGAGTAT	0.297
  	AH0291	No. 2651	ATGTACACCCAGAGTATGT	0.209
  	AH0294	No. 2654	TACACCCAGAGTATGTCCT	0.179
  	AH0295	No. 2655	ACACCCAGAGTATGTCCTT	0.125
  	AH0296	No. 2656	CACCCAGAGTATGTCCTTT	0.076
  	AH0297	No. 2657	ACCCAGAGTATGTCCTTTT	0.139
  	AH0298	No. 2658	CCCAGAGTATGTCCTTTTG	0.134
  	AH0300	No. 2660	CAGAGTATGTCCTTTTGCT	0.125
  	AH0301	No. 2661	AGAGTATGTCCTTTTGCTG	0.176
  	AH0302	No. 2662	GAGTATGTCCTTTTGCTGG	0.076
  	AH0303	No. 2663	AGTATGTCCTTTTGCTGGA	0.083
  	AH0304	No. 2664	GTATGTCCTTTTGCTGGAA	0.156
  	AH0306	No. 2666	ATGTCCTTTTGCTGGAATC	0.261
  	AH0307	No. 2667	TGTCCTTTTGCTGGAATCT	0.168
  	AH0308	No. 2668	GTCCTTTTGCTGGAATCTT	0.076
  	AH0309	No. 2669	TCCTTTTGCTGGAATCTTA	0.072
  	AH0310	No. 2670	CCTTTTGCTGGAATCTTAG	0.097
  	AH0311	No. 2671	CTTTTGCTGGAATCTTAGA	0.198
  	AH0314	No. 2674	TTGCTGGAATCTTAGAAAA	0.139
  	AH0315	No. 2675	TGCTGGAATCTTAGAAAAT	0.132
  	AH0316	No. 2676	GCTGGAATCTTAGAAAATG	0.102
  	AH0317	No. 2677	CTGGAATCTTAGAAAATGG	0.304
  	AH0318	No. 2678	TGGAATCTTAGAAAATGGA	0.122

• TABLE 4-5
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0319	No. 319	GGAAUCUUAGAAAAUGGAGCC	No. 1499	CUCCAUUUUCUAAGAUUCCAG
  AH0324	No. 324	CUUAGAAAAUGGAGCCGUACG	No. 1504	UACGGCUCCAUUUUCUAAGAU
  AH0327	No. 327	AGAAAAUGGAGCCGUACGCUA	No. 1507	GCGUACGGCUCCAUUUUCUAA
  AH0328	No. 328	GAAAAUGGAGCCGUACGCUAU	No. 1508	AGCGUACGGCUCCAUUUUCUA
  AH0329	No. 329	AAAAUGGAGCCGUACGCUAUA	No. 1509	UAGCGUACGGCUCCAUUUUCU
  AH0330	No. 330	AAAUGGAGGCCUACGCUAUAC	No. 1510	AUAGCGUACGGCUCCAUUUUC
  AH0331	No. 331	AAUGGAGCCGUACGCUAUACG	No. 1511	UAUAGCGUACGGCUCCAUUUU
  AH0334	No. 334	GGAGCCGUACGCUAUACGACU	No. 1514	UCGUAUAGCGUACGGGUCCAU
  AH0335	No. 335	GAGCCGUACGCUAUACGACUU	No. 1515	GUCGUAUAGCGUACGGCUCCA
  AH0336	NO. 336	AGCCGUACGCUAUACGACUUU	No. 1516	AGUCGUAUAGCGUACGGCUCC
  AH0337	No. 337	GCCGUACGCUAUACGACUUUU	No. 1517	AAGUCGUAUAGCGUACGGCUC
  AH0338	No. 338	CCGUACGCUAUACGACUUUUG	No. 1518	AAAGUCGUAUAGCGUACGGCU
  AH0339	No. 339	CGUACGCUAUACGACUUUUGA	No. 1519	AAAAGUCGUAUAGCGUACGGC
  AH0340	No. 340	GUACGCUAUACGACUUUUGAA	No. 1520	CAAAAGUCGUAUAGCGUACGG
  AH0341	No. 341	UACGCUAUACGACUUUUGAAU	No. 1521	UCAAAAGUCGUAUAGCGUACG
  AH0342	No. 342	ACGCUAUACGACUUUUGAAUA	No. 1522	UUCAAAAGUCGUAUAGCGUAC
  AH0343	No. 343	CGCUAUACGACUUUUGAAUAU	No. 1523	AUUCAAAAGUCGUAUAGCGUA
  AH0345	No. 345	CUAUACGACUUUUGAAUAUCC	No. 1525	AUAUUCAAAAGUCGUAUAGCG
  AH0346	No. 346	UAUACGACUUUUGAAUAUCCC	No. 1526	GAUAUUCAAAAGUCGUAUAGC
  AH0349	No. 349	ACGACUUUUGAAUAUCCCAAC	No. 1529	UGGGAUAUUCAAAAGUCGUAU
  AH0350	No. 350	CGACUUUUGAAUAUCCCAACA	No. 1530	UUGGGAUAUUCAAAAGUCGUA
  AH0351	No. 351	GACUUUUGAAUAUCCCAACAC	No. 1531	GUUGGGAUAUUCAAAAGUCGU
  AH0352	No. 352	ACUUUUGAAUAUCCCAACACG	No. 1532	UGUUGGGAUAUUCAAAAGUCG
  AH0355	No. 355	UUUGAAUAUCCCAACACGAUC	No. 1535	UCGUGUUGGGAUAUUCAAAAG
  AH0356	No. 356	UUGAAUAUCCCAACACGAUCA	No. 1536	AUCGUGUUGGGAUAUUCAAAA
  AH0357	No. 357	UGAAUAUCCCAACACGAUCAG	No. 1537	GAUCGUGUUGGGAUAUUCAAA
  AH0358	No. 358	GAAUAUCCCAACACGAUCAGU	No. 1538	UGAUCGUGUUGGGAUAUUCAA
  AH0361	No. 361	UAUCCCAACACGAUCAGUUUU	No. 1541	AACUGAUCGUGUUGGGAUAUU
  AH0362	No. 362	AUCCCAACACGAUCAGUUUUU	No. 1542	AAACUGAUCGUGUUGGGAUAU
  AH0363	No. 363	UCCCAACACGAUCAGUUUUUC	No. 1543	AAAACUGAUCGUGUUGGGAUA
  AH0364	No. 364	CCCAACACGAUCAGUUUUUCU	No. 1544	AAAAACUGAUCGUGUUGGGAU
  AH0365	No. 365	CCAACACGAUCAGUUUUUCUU	No. 1545	GAAAAACUGAUCGUGUUGGGA
  AH0366	No. 366	CAACACGAUCAGUUUUUCUUG	No. 1546	AGAAAAACUGAUCGUGUUGGG
  AH0367	No. 367	AACACGAUCAGUUUUUCUUGU	No. 1547	AAGAAAAACUGAUCGUGUUGG
  AH0369	No. 369	CACGAUCAGUUUUUCUUGUAA	No. 1549	ACAAGAAAAACUGAUCGUGUU
  AH0370	No. 370	ACGAUCAGUUUUUCUUGUAAC	No. 1550	UACAAGAAAAACUGAUCGUGU
  AH0371	No. 371	CGAUCAGUUUUUCUUGUAACA	No. 1551	UUACAAGAAAAACUGAUCGUG
  AH0372	No. 372	GAUCAGUUUUUCUUGUAACAC	No. 1552	GUUACAAGAAAAACUGAUCGU
  AH0373	No. 373	AUCAGUUUUUCUUGUAACACU	No. 1553	UGUUACAAGAAAAACUGAUCG
  AH0375	No. 375	CAGUUUUUCUUGUAACACUGG	No. 1555	AGUGUUACAAGAAAAACUGAU
  AH0376	No. 376	AGUUUUUCUUGUAACACUGGG	No. 1556	CAGUGUUACAAGAAAAACUGA
  AH0382	No. 382	UCUUGUAACACUGGGUUUUAU	No. 1562	AAAACCCAGUGUUACAAGAAA
  AH0383	No. 363	CUUGUAACACUGGGUUUUAUC	No. 1563	UAAAACCCAGUGUUACAAGAA
  AH0384	No. 364	UUGUAACACUGGGUUUUAUCU	No. 1564	AUAAAACCCAGUGUUACAAGA
  AH0385	No. 385	UGUAACACUGGGUUUUAUCUG	No. 1565	GAUAAAACCCAGUGUUACAAG
  AH0386	No. 386	GUAACACUGGGUUUUAUCUGA	No. 1566	AGAUAAAACCCAGUGUUACAA
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0319	No. 2679	GGAATCTTAGAAAATGGAG	0.232
  	AH0324	No. 2684	CTTAGAAAATGGAGCCGTA	0.125
  	AH0327	No. 2687	AGAAAATGGAGCCGTACGC	0.334
  	AH0328	No. 2688	GAAAATGGAGCCGTACGCT	0.153
  	AH0329	No. 2689	AAAATGGAGCCGTACGCTA	0.063
  	AH0330	No. 2690	AAATGGAGCCGTACGCTAT	0.182
  	AH0331	No. 2691	AATGGAGCCGTACGCTATA	0.149
  	AH0334	No. 2694	GGAGCCGTACGCTATACGA	0.164
  	AH0335	No. 2695	GAGCCGTACGCTATACGAC	0.181
  	AH0336	No. 2696	AGCCGTACGCTATACGACT	0.114
  	AH0337	No. 2697	GCCGTACGCTATACGACTT	0.106
  	AH0338	No. 2698	CCGTACGCTATACGACTTT	0.077
  	AH0339	No. 2699	CGTACGCTATACGACTTTT	0.102
  	AH0340	No. 2700	GTACGCTATACGACTTTTG	0.224
  	AH0341	No. 2701	TACGCTATACGACTTTTGA	0.233
  	AH0342	No. 2702	ACGCTATACGACTTTTGAA	0.120
  	AH0343	No. 2703	CGCTATACGACTTTTGAAT	0.102
  	AH0345	No. 2705	CTATACGACTTTTGAATAT	0.096
  	AH0346	No. 2706	TATACGACTTTTGAATATC	0.220
  	AH0349	No. 2709	ACGACTTTTGAATATCCCA	0.316
  	AH0350	No. 2710	CGACTTTTGAATATCCCAA	0.120
  	AH0351	No. 2711	GACTTTTGAATATCCCAAC	0.230
  	AH0352	No. 2712	ACTTTTGAATATCCCAACA	0.114
  	AH0355	No. 2715	TTTGAATATCCCAACACGA	0.293
  	AH0356	No. 2716	TTGAATATCCCAACACGAT	0.131
  	AH0357	No. 2717	TGAATATCCCAACACGATC	0.280
  	AH0358	No. 2718	GAATATCCCAACACGATCA	0.113
  	AH0361	No. 2721	TATCCCAACACGATCAGTT	0.244
  	AH0362	No. 2722	ATGCCAACACGATGAGTTT	0.194
  	AH0363	No. 2723	TCCCAACACGATCAGTTTT	0.332
  	AH0364	No. 2724	CCCAACACGATCAGTTTTT	0.171
  	AH0365	No. 2725	CCAACACGATCAGTTTTTC	0.165
  	AH0366	No. 2726	CAACACGATCAGTTTTTCT	0.119
  	AH0367	No. 2727	AACACGATCAGTTTTTCTT	0.216
  	AH0369	No. 2729	CACGATCAGTTTTTCTTGT	0.131
  	AH0370	No. 2730	ACGATCAGTTTTTCTTGTA	0.152
  	AH0371	No. 2731	CGATCAGTTTTTCTTGTAA	0.077
  	AH0372	No. 2732	GATCAGTTTTTCTTGTAAC	0.185
  	AH0373	No. 2733	ATCAGTTTTTCTTGTAACA	0.141
  	AH0375	No. 2735	CAGTTTTTCTTGTAACACT	0.139
  	AH0376	No. 2736	AGTTTTTCTTGTAACACTG	0.233
  	AH0382	No. 2742	TCTTGTAACACTGGGTTTT	0.134
  	AH0383	No. 2743	CTTGTAACACTGGGTTTTA	0.134
  	AH0384	No. 2744	TTGTAACACTGGGTTTTAT	0.074
  	AH0385	No. 2745	TGTAACACTGGGTTTTATC	0.246
  	AH0386	No. 2746	GTAACACTGGGTTTTATCT	0.137

• TABLE 4-6
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0388	No. 388	AACACUGGGUUUUAUCUGAAU	No. 1568	UCAGAUAAAACCCAGUGUUAC
  AH0389	No. 389	ACACUGGGUUUUAUCUGAAUG	No. 1569	UUCAGAUAAAACCCAGUGUUA
  AH0390	No. 390	CACUGGGUUUUAUCUGAAUGG	No. 1570	AUUCAGAUAAAACCCAGUGUU
  AH0392	No. 392	CUGGGUUUUAUCUGAAUGGCG	No. 1572	CCAUUCAGAUAAAACCCAGUG
  AH0394	No. 394	GGGUUUUAUCUGAAUGGCGCU	No. 1574	CGCCAUUCAGAUAAAACCCAG
  AH0395	No. 395	GGUUUUAUCUGAAUGGCGCUG	No. 1575	GCGCCAUUCAGAUAAAACCCA
  AH0196	No. 396	GUUUUAUCUGAAUGGCGCUGA	No. 1576	AGCGCCAUUCAGAUAAAACCC
  AH0399	No. 399	UUAUCUGAAUGGCGCUGAUUC	No. 1579	AUCAGCGCCAUUCAGAUAAAA
  AH0402	No. 402	UCUGAAUGGCGCUGAUUCUGC	No. 1582	AGAAUCAGCGCCAUUCAGAUA
  AH0406	No. 406	AAUGGCGCUGAUUCUGCCAAG	No. 1586	UGGCAGAAUCAGCGCCAUUCA
  AH0409	No. 409	GGCGCUGAUUCUGCCAAGUGC	No. 1589	ACUUGGCAGAAUCAGCGCCAU
  AH0410	No. 410	GCGCUGAUUCUGCCAAGUGCA	No. 1590	CACUUGGCAGAAUCAGCGCCA
  AH0411	No. 411	CGCUGAUUCUGCCAAGUGCAC	No. 1591	GCACUUGGCAGAAUCAGCGCC
  AH0412	No. 412	GCUGAUUCUGCCAAGUGCACU	No. 1592	UGCACUUGGCAGAAUCAGCGC
  AH0413	No. 413	CUGAUUCUGCCAAGUGCACUG	No. 1593	GUGCACUUGGCAGAAUCAGCG
  AH0414	No. 414	UGAUUCUGCCAAGUGCACUGA	No. 1594	AGUGCACUUGGCAGAAUCAGC
  AH0415	No. 415	GAUUCUGCCAAGUGCACUGAG	No. 1595	CAGUGCACUUGGCAGAAUCAG
  AH0419	No. 419	CUGCCAAGUGCACUGAGGAAG	No. 1599	UCCUCAGUGCACUUGGCAGAA
  AH0420	No. 420	UGCCAAGUGCACUGAGGAAGG	No. 1600	UUCCUCAGUGCACUUGGCAGA
  AH0422	No. 422	CCAAGUGCACUGAGGAAGGAA	No. 1602	CCUUCCUCAGUGCACUUGGCA
  AH0423	No. 423	CAAGUGCACUGAGGAAGGAAA	No. 1603	UCCUUCCUCAGUGCACUUGGC
  AH0424	No. 424	AAGUGCACUGAGGAAGGAAAA	No. 1604	UUCCUUCCUCAGUGCACUUGG
  AH0425	No. 425	AGUGCACUGAGGAAGGAAAAU	No. 1605	UUUCCUUCCUCAGUGCACUUG
  AH0426	No. 426	GUGCACUGAGGAAGGAAAAUG	No. 1606	UUUUCCUUCCUCAGUGCACUU
  AH0427	No. 427	UGCACUGAGGAAGGAAAAUGG	No. 1607	AUUUUCCUUCCUCAGUGCACU
  AH0436	No. 436	GAAGGAAAAUGGAGCCCGGAG	No. 1616	CCGGGCUCCAUUUUCCUUCCU
  AH0449	No. 449	GCCCGGAGCUUCCUGUCUGUG	No. 1629	CAGACAGGAAGCUCCGGGCUC
  AH0450	No. 450	CCCGGAGCUUCCUGUCUGUGC	No. 1630	ACAGACAGGAAGCUCCGGGCU
  AH0453	No. 453	GGAGCUUCCUGUCUGUGCUCC	No. 1633	AGCACAGACAGGAAGCUCCGG
  AH0454	No. 454	GAGCUUCCUGUCUGUGCUCCC	No. 1634	GAGCACAGACAGGAAGCUCCG
  AH0457	No. 457	CUUCCUGUCUGUGCUCCCAUC	No. 1637	UGGGAGCACAGACAGGAAGCU
  AH0461	No. 461	CUGUCUGUGCUCCCAUCAUCU	No. 1641	AUGAUGGGAGCACAGACAGGA
  AH0463	No. 463	GUCUGUGCUCCCAUCAUCUGC	No. 1643	AGAUGAUGGGAGCACAGACAG
  AH0472	No. 472	CCCAUCAUCUGCCCUCCACCA	No. 1652	GUGGAGGGCAGAUGAUGGGAG
  AH0475	No. 475	AUCAUCUGCCCUCCACCAUCC	No. 1655	AUGGUGGAGGGCAGAUGAUGG
  AH0476	No. 476	UCAUCUGCCCUCCACCAUCCA	No. 1656	GAUGGUGGAGGGCAGAUGAUG
  AH0480	No. 480	CUGCCCUCCACCAUCCAUACC	No. 1660	UAUGGAUGGUGGAGGGCAGAU
  AH0484	No. 484	CCUCCACCAUCCAUACCUACG	No. 1664	UAGGUAUGGAUGGUGGAGGGC
  AH0487	No. 487	CCACCAUCCAUACCAUCGUUU	No. 1667	ACGUAGGUAUGGAUGGUGGAG
  AH0488	No. 488	CACCAUCCAUACCUACGUUUG	No. 1668	AACGUAGGUAUGGAUGGUGGA
  AH0489	No. 489	ACCAUCCAUACCUACGUUUGC	No. 1669	AAACGUAGGUAUGGAUGGUGG
  AH0490	No. 490	CCAUCCAUACCUACGUUUGCA	No. 1670	CAAACGUAGGUAUGGAUGGUG
  AH0491	No. 491	CAUCCAUACCUACGUUUGCAA	No. 1671	GCAAACGUAGGUAUGGAUGGU
  AH0492	No. 492	AUCCAUACCUACGUUUGCAAC	No. 1672	UGCAAACGUAGGUAUGGAUGG
  AH0493	No. 493	UCCAUACCUACGUUUGCAACA	No. 1673	UUGCAAACGUAGGUAUGGAUG
  AH0495	No. 495	CAUACCUACGUUUGCAACACU	No. 1675	UGUUGCAAACGUAGGUAUGGA
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0388	No. 2748	AACACTGGGTTTTATCTGA	0.107
  	AH0389	No. 2749	ACACTGGGTTTTATCTGAA	0.275
  	AH0390	No. 2750	CACTGGGTTTTATCTGAAT	0.294
  	AH0392	No. 2752	CTGGGTTTTATCTGAATGG	0.254
  	AH0394	No. 2754	GGGTTTTATCTGAATGGCG	0.080
  	AH0395	No. 2755	GGTTTTATCTGAATGGCGC	0.139
  	AH0196	No. 2756	GTTTTATCTGAATGGCGCT	0.169
  	AH0399	No. 2759	TTATCTGAATGGCGCTGAT	0.113
  	AH0402	No. 2762	TCTGAATGGCGCTGATTCT	0.335
  	AH0406	No. 2766	AATGGCGCTGATTCTGCCA	0.177
  	AH0409	No. 2769	GGCGCTGATTCTGCCAAGT	0.189
  	AH0410	No. 2770	GCGCTGATTCTGCCAAGTG	0.251
  	AH0411	No. 2771	CGCTGATTCTGCCAAGTGC	0.070
  	AH0412	No. 2772	GCTGATTCTGCCAAGTGCA	0.104
  	AH0413	No. 2773	CTGATTCTGCCAAGTGCAC	0.217
  	AH0414	No. 2774	TGATTCTGCCAAGTGCACT	0.301
  	AH0415	No. 2775	GATTCTGCCAAGTGCACTG	0.151
  	AH0419	No. 2779	CTGCCAAGTGCACTGAGGA	0.097
  	AH0420	No. 2780	TGCCAAGTGCACTGAGGAA	0.184
  	AH0422	No. 2782	CCAAGTGCACTGAGGAAGG	0.243
  	AH0423	No. 2783	CAAGTGCACTGAGGAAGGA	0.095
  	AH0424	No. 2784	AAGTGCACTGAGGAAGGAA	0.166
  	AH0425	No. 2785	AGTGCACTGAGGAAGGAAA	0.084
  	AH0426	No. 2786	GTGCACTGAGGAAGGAAAA	0.299
  	AH0427	No. 2787	TGCACTGAGGAAGGAAAAT	0.236
  	AH0436	No. 2796	GAAGGAAAATGGAGCCCGG	0.337
  	AH0449	No. 2809	GCCCGGAGCTTCCTGTCTG	0.166
  	AH0450	No. 2810	CCCGGAGCTTCCTGTCTGT	0.138
  	AH0453	No. 2813	GGAGCTTCCTGTCTGTGCT	0.128
  	AH0454	No. 2814	GAGCTTCCTGTCTGTGCTC	0.203
  	AH0457	No. 2817	CTTCCTGTCTGTGCTCCCA	0.244
  	AH0461	No. 2821	CTGTCTGTGCTCCCATCAT	0.306
  	AH0463	No. 2823	GTCTGTGCTCCCATCATCT	0.257
  	AH0472	No. 2832	CCCATCATCTGCCCTCCAC	0.196
  	AH0475	No. 2835	ATCATCTGCCCTCCACCAT	0.250
  	AH0476	No. 2836	TCATCTGCCCTCCACCATC	0.249
  	AH0480	No. 2840	CTGCCCTCCACCATCCATA	0.291
  	AH0484	No. 2844	CCTCCACCATCCATACCTA	0.113
  	AH0487	No. 2847	CCACCATCCATACCTACGT	0.213
  	AH0488	No. 2848	CACCATCCATACCTACGTT	0.210
  	AH0489	No. 2849	ACCATCCATACCTACGTTT	0.160
  	AH0490	No. 2850	CCATCCATACCTACGTTTG	0.171
  	AH0491	No. 2851	CATCCATACCTACGTTTGC	0.078
  	AH0492	No. 2852	ATCCATACCTACGTTTGCA	0.153
  	AH0493	No. 2853	TCCATACCTACGTTTGCAA	0.157
  	AH0495	No. 2855	CATACCTACGTTTGCAACA	0.161

• TABLE 4-7
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0498	No. 498	ACCUACGUUUGCAACACUUCG	No. 1678	AAGUGUUGCAAACGUAGGUAU
  AH0499	No. 499	CCUACGUUUGCAACACUUCGU	No. 1679	GAAGUGUUGCAAACGUAGGUA
  AH0500	No. 500	CUACGUUUGCAACACUUCGUG	No. 1680	CGAAGUGUUGCAAACGUAGGU
  AH0501	No. 501	UACGUUUGCAACACUUCGUGU	No. 1681	ACGAAGUGUUGCAAACGUAGG
  AH0502	No. 502	ACGUUUGCAACACUUCGUGUU	No. 1682	CACGAAGUGUUGCAAACGUAG
  AH0503	No. 503	CGUUUGCAACACUUCGUGUUU	No. 1683	ACACGAAGUGUUGCAAACGUA
  AH0504	No. 504	GUUUGCAACACUUCGUGUUUA	No. 1684	AACACGAAGUGUUGCAAACGU
  AH0505	No. 505	UUUGCAACACUUCGUGUUUAU	No. 1685	AAACACGAAGUGUUGCAAACG
  AH0506	No. 506	UUGCAACACUUCGUGUUUAUA	No. 1686	UAAACACGAAGUGUUGCAAAC
  AH0501	No. 507	UGCAACACUUCGUGUUUAUAA	No. 1687	AUAAACACGAAGUGUUGCAAA
  AH0508	No. 508	GCAACACUUCGUGUUUAUAAG	No. 1688	UAUAAACACGAAGUGUUGCAA
  AH0509	No. 509	CAACACUUCGUGUUUAUAAGC	No. 1689	UUAUAAACACGAAGUGUUGCA
  AH0510	No. 510	AACACUUCGUGUUUAUAAGCC	No. 1690	CUUAUAAACACGAAGUGUUGC
  AH0513	No. 513	ACUUCGUGUUUAUAAGCCAUC	No. 1693	UGGCUUAUAAACACGAAGUGU
  AH0514	No. 514	CUUCGUGUUUAUAAGCCAUCA	No. 1694	AUGGCUUAUAAACACGAAGUG
  AH0518	No. 518	GUGUUUAUAAGCCAUCAGCUG	No. 1698	GCUGAUGGCUUAUAAACACGA
  AH0519	No. 519	UGUUUAUAAGCCAUCAGCUGG	No. 1699	AGCUGAUGGCUUAUAAACACG
  AH0520	No. 520	GUUUAUAAGCCAUCAGCUGGA	No. 1700	CAGCUGAUGGCUUAUAAACAC
  AH0526	No. 526	AAGCCAUCAGCUGGAAACAAU	No. 1706	UGUUUCCAGCUGAUGGCUUAU
  AH0527	No. 527	AGCCAUCAGCUGGAAACAAUU	No. 1707	UUGUUUCCAGCUCAUGGCUUA
  AH0528	No. 528	GCCAUCAGCUGGAAACAAUUC	No. 1708	AUUGUUUCCAGCUGAUGGCUU
  AH0529	No. 529	CCAUCAGCUGGAAACAAUUCC	No. 1709	AAUUGUUUCCAGCUGAUGGCU
  AH0530	No. 530	CAUCAGCUGGAAACAAUUCCC	No. 1710	GAAUUGUUUCCAGCUGAUGGC
  AH0534	No. 534	AGCUGGAAACAAUUCCCUCUA	No. 1714	GAGGGAAUUGUUUCCAGCUGA
  AH0535	No. 535	GCUGGAAACAAUUCCCUCUAU	No. 1715	AGAGGGAAUUGUUUCCAGCUG
  AH0538	No. 538	GGAAACAAUUCCCUCUAUCGG	No. 1718	GAUAGAGGGAAUUGUUUCCAG
  AH0542	No. 542	ACAAUUCCCUCUAUCGGGACA	No. 1722	UCCCGAUAGAGGGAAUUGUUU
  AH0549	No. 549	CCUCUAUCGGGACACAGCAGU	No. 1729	UGCUGUGUCCCGAUAGAGGGA
  AH0552	No. 552	CUAUCGGGACACAGCAGUUUU	No. 1732	AACUGCUGUGUCCCGAUAGAG
  AH0553	No. 553	UAUCGGGACACAGCAGUUUUU	No. 1733	AAACUGCUGUGUCCCGAUAGA
  AH0554	No. 554	AUCGGGACACAGCAGUUUUUG	No. 1734	AAAACUGCUGUGUCCCGAUAG
  AH0555	No. 555	UCGGGACACAGCAGUUUUUGA	No. 1735	AAAAACUGCUGUGUCCCGAUA
  AH0551	No. 557	GGGACACAGCAGUUUUUGAAU	No. 1737	UGAAAAACUGCUGUGUCCCGA
  AH0558	No. 558	GGACACAGCAGUUUUUGAAUG	No. 1738	UUCAAAAACUGCUGUGUCCCG
  AH0559	No. 559	GACACAGCAGUUUUUGAAUGU	No. 1739	AUUCAAAAACUGCUGUGUCCC
  AH0561	No. 561	CACAGCAGUUUUUGAAUGUUU	No. 1741	ACAUUCAAAAACUGCUGUGUC
  AH0562	No. 562	ACAGCAGUUUUUGAAUGUUUG	No. 1742	AACAUUCAAAAACUGCUGUGU
  AH0563	No. 563	CAGCAGUUUUUGAAUGUUUGC	No. 1743	AAACAUUCAAAAACUGCUGUG
  AH0564	No. 564	AGCAGUUUUUGAAUGUUUGCC	No. 1744	CAAACAUUCAAAAACUGCUGU
  AH0565	No. 565	GCAGUUUUUGAAUGUUUGCCA	No. 1745	GCAAACAUUCAAAAACUGCUG
  AH0567	No. 567	AGUUUUUGAAUGUUUGCCACA	No. 1747	UGGCAAACAUUCAAAAACUGC
  AH0568	No. 568	GUUUUUGAAUGUUUGCCACAA	No. 1748	GUGGCAAACAUUCAAAAACUG
  AH0570	No. 570	UUUUGAAUGUUUGCCACAACA	No. 1750	UUGUGGCAAACAUUCAAAAAC
  AH0572	No. 572	UUGAAUGUUUGCCACAACAUG	No. 1752	UGUUGUGGCAAACAUUCAAAA
  AH0573	No. 573	UGAAUGUUUGCCACAACAUGC	No. 1753	AUGUUGUGGCAAACAUUCAAA
  AH0574	No. 574	GAAUGUUUGCCACAACAUGCG	No. 1754	CAUGUUGUGGCAAACAUUCAA
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0498	No. 2858	ACCTACGTTTGCAACACTT	0.214
  	AH0499	No. 2859	CCTACGTTTGCAACACTTC	0.213
  	AH0500	No. 2860	CTACGTTTGCAACACTTCG	0.150
  	AH0501	No. 2861	TACGTTTGCAACACTTCGT	0.201
  	AH0502	No. 2862	ACGTTTGCAACACTTCGTG	0.159
  	AH0503	No. 2863	CGTTTGCAACACTTCGTGT	0.126
  	AH0504	No. 2864	GTTTGCAACACTTCGTGTT	0.055
  	AH0505	No. 2865	TTTGCAACACTTCGTGTTT	0.170
  	AH0506	No. 2866	TTGCAACACTTCGTGTTTA	0.076
  	AH0501	No. 2867	TGCAACACTTCGTGTTTAT	0.091
  	AH0508	No. 2868	GCAACACTTCGTGTTTATA	0.146
  	AH0509	No. 2869	CAACACTTCGTGTTTATAA	0.125
  	AH0510	No. 2870	AACACTTCGTGTTTATAAG	0.330
  	AH0513	No. 2873	ACTTCGTGTTTATAAGCCA	0.119
  	AH0514	No. 2874	CTTCGTGTTTATAAGCCAT	0.118
  	AH0518	No. 2878	GTGTTTATAAGCCATCAGC	0.233
  	AH0519	No. 2879	TGTTTATAAGCCATCAGCT	0.297
  	AH0520	No. 2880	GTTTATAAGCCATCAGCTG	0.216
  	AH0526	No. 2886	AAGCCATCAGCTGGAAACA	0.299
  	AH0527	No. 2887	AGCCATCAGCTGGAAACAA	0.258
  	AH0528	No. 2888	GCCATCAGCTGGAAACAAT	0.091
  	AH0529	No. 2889	CCATCAGCTGGAAACAATT	0.067
  	AH0530	No. 2890	CATCAGCTGGAAACAATTC	0.229
  	AH0534	No. 2894	AGCTGGAAACAATTCCCTC	0.183
  	AH0535	No. 2895	AGCTGGAAACAATTCCCTC	0.202
  	AH0538	No. 2898	GGAAACAATTCCCTCTATC	0.245
  	AH0542	No. 2902	ACAATTCCCTCTATCGGGA	0.102
  	AH0549	No. 2909	CCTCTATCGGGACACAGCA	0.275
  	AH0552	No. 2912	CTATCGGGACACAGCAGTT	0.230
  	AH0553	No. 2913	TATCGGGACACAGCAGTTT	0.789
  	AH0554	No. 2914	ATCGGGACACAGCAGTTTT	0.324
  	AH0555	No. 2915	TCGGGACACAGCAGTTTTT	0.203
  	AH0551	No. 2917	GGGACACAGCAGTTTTTGA	0.208
  	AH0558	No. 2918	GGACACAGCAGTTTTTGAA	0.237
  	AH0559	No. 2919	GACACAGCAGTTTTTGAAT	0.226
  	AH0561	No. 2921	CACAGCAGTTTTTGAATGT	0.151
  	AH0562	No. 2922	ACAGCAGTTTTTGAATGTT	0.096
  	AH0563	No. 2923	CAGCAGTTTTTGAATGTTT	0.077
  	AH0564	No. 2924	AGCAGTTTTTGAATGTTTG	0.206
  	AH0565	No. 2925	GCAGTTTTTGAATGTTTGC	0.080
  	AH0567	No. 2927	AGTTTTTGAATGTTTGCCA	0.078
  	AH0568	No. 2928	GTTTTTGAATGTTTGCCAC	0.250
  	AH0570	No. 2930	TTTTGAATGTTTGCCACAA	0.286
  	AH0572	No. 2932	TTGAATGTTTGCCACAACA	0.152
  	AH0573	No. 2933	TGAATGTTTGCCACAACAT	0.266
  	AH0574	No. 2934	GAATGTTTGCCACAACATG	0.142

• TABLE 4-8
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0578	No. 578	GUUUGCCACAACAUGCGAUGU	No. 1758	AUCGCAUGUUGUGGCAAACAU
  AH0582	No. 582	GCCACAACAUGCGAUGUUUGG	No. 1762	AAACAUCGCAUGUUGUGGCAA
  AH0583	No. 583	CCACAACAUGCGAUGUUUGGA	No. 1763	CAAACAUCGCAUGUUGUGGCA
  AH0585	No. 585	ACAACAUGCGAUGUUUGGAAA	No. 1765	UCCAAACAUCGCAUGUUGUGG
  AH0586	No. 586	CAACAUGCGAUGUGUGGAAAU	No. 1766	UUCCAAACAUCGCAUGUUGUG
  AH0588	No. 588	ACAUGCGAUGUUUGGAAAUGA	No. 1768	AUUUCCAAACAUCGCAUGUUG
  AH0590	No. 590	AUGCGAUGUUUGGAAAUGAUA	No. 1770	UCAUUUCCAAACAUCGCAUGU
  AH0591	No. 591	UGCGAUGUUUGGAAAUGAUAC	No. 1771	AUCAUUUCCAAACAUCGCAUG
  AH0592	No. 592	GCGAUGUUUGGAAAUGAUACA	No. 1772	UAUCAUUUCCAAACAUCGCAU
  AH0593	No. 593	CGAUGUUUGGAAAUGAUACAA	No. 1773	GUAUCAUUUCCAAACAUCGCA
  AH0594	No. 594	GAUGUUUGGAAAUGAUACAAU	No. 1774	UGUAUCAUUUCCAAACAUCGC
  AH0595	No. 595	AUGUUUGGAAAUGAUACAAUU	No. 1775	UUGUAUCAUUUCCAAACAUCG
  AH0597	No. 597	GUUUGGAAAUGAUACAAUUAC	No. 1777	AAUUGUAUCAUUUCCAAACAU
  AH0598	No. 598	UUUGGAAAUGAUACAAUUACC	No. 1778	UAAUUGUAUCAUUUCCAAACA
  AH0601	No. 601	GGAAAUGAUACAAUUACCUGC	No. 1781	AGGUAAUUGUAUCAUUUCCAA
  AH0607	No. 607	GAUACAAUUACCUGCACGACA	No. 1787	UCGUGCAGGUAAUUGUAUCAU
  AH0609	No. 609	UACAAUUACCUGCACGACACA	No. 1789	UGUCGUGCAGGUAAUUGUAUC
  AH0610	No. 610	ACAAUUACCUGCACGACACAU	No. 1790	GUGUCGUGCAGGUAAUUGUAU
  AH0611	No. 611	CAAUUACCUGCACGACACAUG	No. 1791	UGUGUCGUGCAGGUAAUUGUA
  AH0612	No. 612	AAUUACCUGCACGACACAUGG	No. 1792	AUGUGUCGUGCAGGUAAUUGU
  AH0616	No. 616	ACCUGCACGACACAUGGAAAU	No. 1796	UUCCAUGUGUCGUGCAGGUAA
  AH0617	No. 617	CCUGCACGACACAUGGAAAUU	No. 1797	UUUCCAUGUGUCGUGCAGGUA
  AH0618	No. 618	CUGCACGACACAUGGAAAUUG	No. 1798	AUUUCCAUGUGUCGUGCAGGU
  AH0622	No. 622	ACGACACAUGGAAAUUGGACU	No. 1802	UCCAAUUUCCAUGUGUCGUGC
  AH0624	No. 624	GACACAUGGAAAUUGGACUAA	No. 1804	AGUCCAAUUUCCAUGUGUCGU
  AH0625	No. 625	ACACAUGGAAAUUGGACUAAA	No. 1805	UAGUCCAAUUUCCAUGUGUCG
  AH0627	No. 627	ACAUGGAAAUUGGACUAAAUU	No. 1807	UUUAGUCCAAUUUCCAUGUGU
  AH0628	No. 628	CAUGGAAAUUGGACUAAAUUA	No. 1808	AUUUAGUCCAAUUUCCAUGUG
  AH0629	No. 629	AUGGAAAUUGGACUAAAUUAC	No. 1809	AAUUUAGUCCAAUUUCCAUGU
  AH0630	No. 630	UGGAAAUUGGACUAAAUUACC	No. 1810	UAAUUUAGUCCAAUUUCCAUG
  AH0631	No. 631	GGAAAUUGGACUAAAUUACCA	No. 1811	GUAAUUUAGUCCAAUUUCCAU
  AH0633	No. 633	AAAUUGGACUAAAUUACCAGA	No. 1813	UGGUAAUUUAGUCCAAUUUCC
  AH0638	No. 638	GGACUAAAUUACCAGAAUGCA	No. 1818	CAUUCUGGUAAUUUAGUCCAA
  AH0649	No. 649	CCAGAAUGCAGGGAAGUAAAA	No. 1829	UUACUUCCCUGCAUUCUGGUA
  AH0650	No. 650	CAGAAUGCAGGGAAGUAAAAU	No. 1830	UUUACUUCCCUGCAUUCUGGU
  AH0651	No. 651	AGAAUGCAGGGAAGUAAAAUG	No. 1831	UUUUACUUCCCUGCAUUCUGG
  AH0652	No. 652	GAAUGCAGGGAAGUAAAAUGC	No. 1832	AUUUUACUUCCCUGCAUUCUG
  AH0653	No. 653	AAUGCAGGGAAGUAAAAUGCC	No. 1833	CAUUUUACUUCCCUGCAUUCU
  AH0657	No. 657	CAGGGAAGUAAAAUGCCCAUU	No. 1837	UGGGCAUUUUACUUCCCUGCA
  AH0661	No. 661	GAAGUAAAAUGCCCAUUCCCA	No. 1841	GGAAUGGGCAUUUUACUUCCC
  AH0664	No. 664	GUAAAAUGCCCAUUCCCAUCA	No. 1844	AUGGGAAUGGGCAUUUUACUU
  AH0669	No. 669	AUGCCCAUCCCCAUCAAGACC	No. 1849	UCUUGAUGGGAAUGGGCAUUU
  AH0610	No. 670	UGCCCAUUCCCAUCAAGACCA	No. 1850	GUCUUGAUGGGAAUGGGCAUU
  AH0672	No. 672	CCCAUUCCCAUCAAGACCAGA	No. 1852	UGGUCUUGAUGGGAAUGGGCA
  AH0673	No. 673	CCAUUCCCAUCAAGACCAGAC	No. 1853	CUGGUCUUGAUGGGAAUGGGC
  AH0674	No. 674	CAUUCCCAUCAAGACCAGACA	No. 1854	UCUGGUCUUGAUGGGAAUGGG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0578	No. 2938	GTTTGCCACAACATGCGAT	0.120
  	AH0582	No. 2942	GCCACAACATGCGATGTTT	0.208
  	AH0583	No. 2943	CCACAACATGCGATGTTTG	0.222
  	AH0585	No. 2945	ACAAGATGCGATGTTTGGA	0.188
  	AH0586	No. 2946	CAACATGCGATGTTTGGAA	0.151
  	AH0588	No. 2948	ACATGCGATGTTTGGAAAT	0.261
  	AH0590	No. 2950	ATGCGATGTTTGGAAATGA	0.248
  	AH0591	No. 2951	TGCGATGTTTGGAAATGAT	0.183
  	AH0592	No. 2952	GCGATGTTTGGAAATGATA	0.098
  	AH0593	No. 2953	CGATGTTTGGAAATGATAC	0.135
  	AH0594	No. 2954	GATGTTTGGAAATGATACA	0.114
  	AH0595	No. 2955	ATGTTTGGAAATGATACAA	0.333
  	AH0597	No. 2957	GTTTGGAAATGATACAATT	0.343
  	AH0598	No. 2958	TTTGGAAATGATACAATTA	0.166
  	AH0601	No. 2961	GGAAATGATACAATTACCT	0.177
  	AH0607	No. 2967	GATACAATTACCTGCACGA	0.093
  	AH0609	No. 2969	TACAATTACCTGCACGACA	0.159
  	AH0610	No. 2970	ACAATTACCTGCACGACAC	0.159
  	AH0611	No. 2971	CAATTACCTGCACGACACA	0.156
  	AH0612	No. 2972	AATTACCTGCACGACACAT	0.257
  	AH0616	No. 2976	ACCTGCACGACACATGGAA	0.292
  	AH0617	No. 2977	CCTGCACGACACATGGAAA	0.143
  	AH0618	No. 2978	CTGCACGACACATGGAAAT	0.118
  	AH0622	No. 2982	ACGACACATGGAAATTGGA	0.310
  	AH0624	No. 2984	GACACATGGAAATTGGACT	0.240
  	AH0625	No. 2985	ACACATGGAAATTGGACTA	0.184
  	AH0627	No. 2987	ACATGGAAATTGGACTAAA	0.104
  	AH0628	No. 2988	CATGGAAATTGGACTAAAT	0.163
  	AH0629	No. 2989	ATGGAAATTGGACTAAATT	0.298
  	AH0630	No. 2990	TGGAAATTGGACTAAATTA	0.215
  	AH0631	No. 2991	GGAAATTGGACTAAATTAC	0.307
  	AH0633	No. 2993	AAATTGGACTAAATTACCA	0.306
  	AH0638	No. 2998	GGACTAAATTACCAGAATG	0.128
  	AH0649	No. 3009	CCAGAATGCAGGGAAGTAA	0.139
  	AH0650	No. 3010	CAGAATGCAGGGAAGTAAA	0.126
  	AH0651	No. 3011	AGAATGCAGGGAAGTAAAA	0.117
  	AH0652	No. 3012	GAATGCAGGGAAGTAAAAT	0.331
  	AH0653	No. 3013	AATGCAGGGAAGTAAAATG	0.198
  	AH0657	No. 3017	CAGGGAAGTAAAATGCCCA	0.139
  	AH0661	No. 3021	GAAGTAAAATGCCCATTCC	0.321
  	AH0664	No. 3024	GTAAAATGCCCATTCCCAT	0.091
  	AH0669	No. 3029	ATGCCCATTCCCATCAAGA	0.249
  	AH0610	No. 3030	TGCCCATTCCCATCAAGAC	0.160
  	AH0672	No. 3032	CCCATTCCCATCAAGACCA	0.097
  	AH0673	No. 3033	CCATTCCCATCAAGACCAG	0.137
  	AH0674	No. 3034	CATTCCCATCAAGACCAGA	0.335

• TABLE 4-9
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0678	No. 678	CCCAUCAAGACCAGACAAUGG	No. 1858	AUUGUCUGGUCUUGAUGGGAA
  AH8679	No. 679	CCAUCAAGACCAGACAAUGGA	No. 1859	CAUUGUCUGGUCUUGAUGGGA
  AH0680	No. 680	CAUCAAGACCAGACAAUGGAU	No. 1860	CCAUUGUCUGGUCUUGAUGGG
  AH0681	No. 681	AUCAAGACCAGACAAUGGAUU	No. 1861	UCCAUUGUCUGGUCUUGAUGG
  AH0662	No. 682	UCAAGACCAGACAAUGGAUUU	No. 1862	AUCCAUUGUCUGGUCUUGAUG
  AH0683	No. 683	CAAGACCAGACAAUGGAUUUG	No. 1863	AAUCCAUUGUCUGGUCUUGAU
  AH0684	No. 684	AAGACCAGACAAUGGAUUUGU	No. 1864	AAAUCCAUUGUCUGGUCUUGA
  AH0685	No. 685	AGACCAGACAAUGGAUUUGUG	No. 1865	CAAAUCCAUUGUCUGGUCUUG
  AH0687	No. 687	ACCAGACAAUGGAUUUGUGAA	No. 1867	CACAAAUCCAUUGUCUGGUCU
  AH0688	No. 688	CCAGACAAUGGAUUUGUGAAC	No. 1868	UCACAAAUCCAUUGUCUGGUC
  AH0689	No. 689	CAGACAAUGGAUUUGUGAACU	No. 1869	UUCACAAAUCCAUUGUCUGGU
  AH0690	No. 690	AGACAAUGGAUUUGUGAACUA	No. 1870	GUUCACAAAUCCAUUGUCUGG
  AH0692	No. 692	ACAAUGGAUUUGUGAACUAUC	No. 1872	UAGUUCACAAAUCCAUUGUCU
  AH0693	No. 693	CAAUGGAUUUGUGAACUAUCC	No. 1873	AUAGUUCACAAAUCCAUUGUC
  AH0694	No. 694	AAUGGAUCUGUGAACUAUCCU	No. 1874	GAUAGUUCACAAAUCCAUUGU
  AH0691	No. 697	GGAUUUGUGAACUAUCCUGCA	No. 1877	CAGGAUAGUUCACAAAUCCAU
  AH0699	No. 699	AUUUGUGAACUAUCCUGCAAA	No. 1879	UGCAGGAUAGUUCACAAAUCC
  AH0700	No. 700	UUUGUGAACUAUCCUGCAAAA	No. 1880	UUGCAGGAUAGUUCACAAAUC
  AH0701	No. 701	UUGUGAACUAUCCUGCAAAAC	No. 1881	UUUGCAGGAUAGUUCACAAAU
  AH0702	No. 702	UGUGAACUAUCCUGCAAAACC	No. 1882	UUUUGCAGGAUAGUUCACAAA
  AH0705	No. 705	GAACUAUCCUGCAAAACCAAC	No. 1885	UGGUUUUGCAGGAUAGUUCAC
  AH0706	No. 706	AACUAUCCUGCAAAACCAACA	No. 1886	UUGGUUUUGCAGGAUAGUUCA
  AH0708	No. 708	CUAUCCUGCAAAACCAACACU	No. 1888	UGUUGGUUUUGCAGGAUAGUU
  AH0709	No. 709	UAUCCUGCAAAACCAACACUU	No. 1889	GUGUUGGUUUUGCAGGAUAGU
  AH0711	No. 711	UCCUGCAAAACCAACACUUUA	No. 1891	AAGUGUUGGUUUUGCAGGAUA
  AH0712	No. 712	CCUGCAAAACCAACACUUUAU	No. 1892	AAAGUGUUGGUUUUGCAGGAU
  AH0713	No. 713	CUGCAAAACCAACACUUUAUU	No. 1893	UAAAGUGUUGGUUUUGCAGGA
  AH0714	No. 714	UGCAAAACCAACACUUUAUUA	No. 1894	AUAAAGUGUUGGUUUUGCAGG
  AH0715	No. 715	GCAAAACCAACACUUUAUUAC	No. 1895	AAUAAAGUGUUGGUUUUGCAG
  AH0716	No. 716	CAAAACCAACACUUUAUUACA	No. 1896	UAAUAAAGUGUUGGUUUUGCA
  AH0718	No. 718	AAACCAACACUUUAUUACAAG	No. 1898	UGUAAUAAAGUGUUGGUUUUG
  AH0119	No. 719	AACCAACACUUUAUUACAAGG	No. 1899	UUGUAAUAAAGUGUUGGUUUU
  AH0721	No. 721	CCAACACUUUAUUACAAGGAU	No. 1901	CCUUGUAAUAAAGUGUUGGUU
  AH0723	No. 723	AACACUUUAUUACAAGGAUAA	No. 1903	AUCCUUGUAAUAAAGUGUUGG
  AH0724	No. 724	ACACUUUAUUACAAGGAUAAA	No. 1904	UAUCCUUGUAAUAAAGUGUUG
  AH0725	No. 725	CACUUUAUUACAAGGAUAAAG	No. 1905	UUAUCCUUGUAAUAAAGUGUU
  AH0735	No. 735	CAAGGAUAAAGCCACAUUUGG	No. 1915	AAAUGUGGCUUUAUCCUUGUA
  AH0737	No. 737	AGGAUAAAGCCACAUUUGGCU	No. 1917	CCAAAUGUGGCUUUAUCCUUG
  AH0739	No. 739	GAUAAAGCCACAUUUGGCUGC	No. 1919	AGCCAAAUGUGGCUUUAUCCU
  AH0743	No. 743	AAGCCACAUUUGGCUGCCAUG	No. 1923	UGGCAGCCAAAUGUGGCUUUA
  AH0744	No. 744	AGCCACAUUUGGCUGCCAUGA	No. 1924	AUGGCAGCCAAAUGUGGCUUU
  AH0745	No. 745	GCCACAUUUGGCUGCCAUGAU	No. 1925	CAUGGGAGCCAAAUGUGGCUU
  AH0746	No. 746	CCACAUUUGGCUGCCAUGAUG	No. 1926	UCAUGGCAGCCAAAUGUGGCU
  AH0747	No. 747	CACAUUUGGCUGCCAUGAUGG	No. 1927	AUCAUGGCAGCCAAAUGUGGC
  AH0748	No. 748	ACAUUUGGCUGCCAUGAUGGA	No. 1928	CAUCAUGGCAGCCAAAUGUGG
  AH0749	No. 749	CAUUUGGCUGCCAUGAUGGAU	No. 1929	CCAUCAUGGCAGCCAAAUGUG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0678	No. 3038	CCCATCAAGACCAGACAAT	0.139
  	AH8679	No. 3039	CCATCAAGACCAGACAATG	0.148
  	AH0680	No. 3040	CATCAAGACCAGACAATGG	0.286
  	AH0681	No. 3041	ATCAAGACCAGACAATGGA	0.159
  	AH0662	No. 3042	TCAAGACCAGACAATGGAT	0.218
  	AH0683	No. 3043	CAAGACCAGACAATGGATT	0.096
  	AH0684	No. 3044	AAGACCAGACAATGGATTT	0.220
  	AH0685	No. 3045	AGACCAGACAATGGATTTG	0.135
  	AH0687	No. 3041	ACCAGACAATGGATTTGTG	0.146
  	AH0688	No. 3048	CCAGACAATGGATTTGTGA	0.114
  	AH0689	No. 3049	CAGACAATGGATTTGTGAA	0.067
  	AH0690	No. 3050	AGACAATGGATTTGTGAAC	0.280
  	AH0692	No. 3052	ACAATGGATTTGTGAACTA	0.296
  	AH0693	No. 3053	CAATGGATTTGTGAACTAT	0.086
  	AH0694	No. 3054	AATGGATTTGTGAACTATC	0.267
  	AH0691	No. 3057	GGATTTGTGAACTATCCTG	0.196
  	AH0699	No. 3059	ATTTGTGAACTATCCTGCA	0.268
  	AH0700	No. 3060	TTTGTGAACTATCCTGCAA	0.319
  	AH0701	No. 3061	TTGTGAACTATCCTGCAAA	0.112
  	AH0702	No. 3062	TGTGAACTATCCTGCAAAA	0.231
  	AH0705	No. 3065	GAACTATCCTGCAAAACCA	0.057
  	AH0706	No. 3066	AACTATCCTGCAAAACCAA	0.092
  	AH0708	No. 3068	CTATCCTGCAAAACCAACA	0.088
  	AH0709	No. 3069	TATCCTGCAAAACCAACAC	0.340
  	AH0711	No. 3071	TCCTGCAAAACCAACACTT	0.146
  	AH0712	No. 3072	CCTGCAAAACCAACACTTT	0.060
  	AH0713	No. 3073	CTGCAAAACCAACACTTTA	0.059
  	AH0714	No. 3074	TGCAAAACCAACACTTTAT	0.092
  	AH0715	No. 3075	GCAAAACCAACACTTTATT	0.183
  	AH0716	No. 3076	CAAAACCAACACTTTATTA	0.189
  	AH0718	No. 3078	AAACCAACACTTTATTACA	0.133
  	AH0119	No. 3079	AACCAACACTTTATTACAA	0.202
  	AH0721	No. 3081	CCAACACTTTATTACAAGG	0.247
  	AH0723	No. 3083	AACACTTTATTACAAGGAT	0.174
  	AH0724	No. 3084	ACACTTTATTACAAGGATA	0.090
  	AH0725	No. 3085	CACTTTATTACAAGGATAA	0.146
  	AH0735	No. 3095	CAAGGATAAAGCCACATTT	0.134
  	AH0737	No. 3097	AGGATAAAGCCACATTTGG	0.321
  	AH0739	No. 3099	GATAAAGCCACATTTGGCT	0.304
  	AH0743	No. 3103	AAGCCACATTTGGCTGCCA	0.216
  	AH0744	No. 3104	AGCCACATTTGGCTGCCAT	0.306
  	AH0745	No. 3105	GCCACATTTGGCTGCCATG	0.112
  	AH0746	No. 3106	CCACATTTGGCTGCCATGA	0.342
  	AH0747	No. 3107	CACATTTGGCTGGCATGAT	0.185
  	AH0748	No. 3108	ACATTTGGCTGCCATGATG	0.107
  	AH0749	No. 3109	CATTTGGCTGCCATGATGG	0.214

• TABLE 4-10
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0750	No. 750	AUUUGGCUGCCAUGAUGGAUA	No. 1930	UCCAUCAUGGCAGCCAAAUGU
  AH0753	No. 753	UGGCUGCCAUGAUGGAUAUUC	No. 1933	AUAUCCAUCAUGGCAGCCAAA
  AH0754	No. 758	GGCUGCCAUGAUGGAUAUUCU	No. 1934	AAUAUCCAUCAUGGCAGCCAA
  AH0756	No. 756	CUGCCAUGAUGGAUAUUCUCU	No. 1936	AGAAUAUCCAUCAUGGCAGCC
  AH0757	No. 757	UGCCAUGAUGGAUAUUCUCUG	No. 1937	GAGAAUAUCCAUCAUGGCAGC
  AH0759	No. 759	CCAUGAUGGAUAUUCUCUGGA	No. 1939	CAGAGAAUAUCCAUCAUGGCA
  AH0760	No. 760	CAUGAUGGAUAUUCUCUGGAU	No. 1940	CCAGAGAAUAUCCAUCAUGGC
  AH0762	No. 762	UGAUGGAUAUUCUCUGGAUGG	No. 1942	AUCCAGAGAAUAUCCAUCAUG
  AH0763	No. 763	GAUGGAUAUUCUCUGGAUGGC	No. 1943	CAUCCAGAGAAUAUCCAUCAU
  AH0766	No. 766	GGAUAUUCUCUGGAUGGCCCG	No. 1946	GGCCAUCCAGAGAAUAUCCAU
  AH0771	No. 771	UUCUCUGGAUGGCCCGGAAGA	No. 1951	UUCCGGGCCAUCCAGAGAAUA
  AH0773	No. 773	CUCUGGAUGGCCCGGAAGAAA	No. 1953	UCUUCCGGGCCAUCCAGAGAA
  AH0774	No. 774	UCUGGAUGGCCCGGAAGAAAU	No. 1954	UUCUUCCGGGCCAUCCAGAGA
  AH0775	No. 775	CUGGAUGGCCCGGAAGAAAUA	No. 1955	UUUCUUCCGGGCCAUCCAGAG
  AH0776	No. 776	UGGAUGGCCCGGAAGAAAUAG	No. 1956	AUUUCUUCCGGGCCAUCCAGA
  AH0777	No. 777	GGAUGGCCCGGAAGAAAUAGA	No. 1957	UAUUUCUUCCGGGCCAUCCAG
  AH0779	No. 779	AUGGCCCGGAAGAAAUAGAAU	No. 1959	UCUAUUUCUUCCGGGCCAUCC
  AH0788	No. 780	UGGCCCGGAAGAAAUAGAAUG	No. 1960	UUCUAUUUCUUCCGGGCCAUC
  AH0781	No. 781	GGCCCGGAAGAAAUAGAAUGU	No. 1961	AUUCUAUUUCUUCCGGGCCAU
  AH0782	No. 782	GCCCGGAAGAAAUAGAAUGUA	No. 1962	CAUUCUAUUUCUUCCGGGCCA
  AH0783	No. 783	CCCGGAAGAAAUAGAAUGUAC	No. 1963	ACAUUCUAUUUCUUCCGGGCC
  AH0785	No. 785	GGGAAGAAAUAGAAUGUACCA	No. 1965	GUACAUUCUAUUUCUUCCGGG
  AH0786	No. 786	GGAAGAAAUAGAAUGUACCAA	No. 1966	GGUACAUUCUAUUUCUUCCGG
  AH0787	No. 787	GAAGAAAUAGAAUGUACCAAA	No. 1967	UGGUACAUUCUAUUUCUUCCG
  AH0790	No. 790	GAAAUAGAAUGUACCAAACUG	No. 1970	GUUUGGUACAUUCUAUUUCUU
  AH0795	No. 795	AGAAUGUACCAAACUGGGAAA	No. 1975	UCCCAGUUUGGUACAUUCUAU
  AH0796	No. 796	GAAUGUACCAAACUGGGAAAC	No. 1976	UUCCCAGUUUGGUACAUUCUA
  AH0797	No. 797	AAUGUACCAAACUGGGAAACU	No. 1977	UUUCCCAGUUUGGUACAUUCU
  AH0800	No. 800	GUACCAAACUGGGAAACUGGU	No. 1980	CAGUUUCCCAGUUUGGUACAU
  AH0804	No. 804	CAAACUGGGAAACUGGUCUGC	No. 1984	AGACCAGUUUCCCAGUUUGGU
  AH0805	No. 805	AAACUGGGAAACUGGUCUGCC	No. 1985	CAGACCAGUUUCCCAGUUUGG
  AH0808	No. 808	CUGGGAAACUGGUCUGCCAUG	No. 1988	UGGCAGACCAGUUUCCCAGUU
  AH0809	No. 809	UGGGAAACUGGUCUGCCAUGC	No. 1989	AUGGCAGACCAGUUUCCCAGU
  AH0810	No. 810	GGGAAACUGGUCUGCCAUGCC	No. 1990	CAUGGCAGACCAGUUUCCCAG
  AH0811	No. 811	GGAAACUGGUCUGCCAUGCCA	No. 1991	GCAUGGCAGACCAGUUUCCCA
  AH0813	No. 813	AAACUGGUCUGCCAUGCCAAG	No. 1993	UGGCAUGGCAGACCAGUUUCC
  AH0814	No. 814	AACUGGUCUGCCAUGCCAAGU	No. 1994	UUGGCAUGGCAGACCAGUUUC
  AH0815	No. 815	ACUGGUCUGCCAUGCCAAGUU	No. 1995	CUUGGCAUGGCAGACCAGUUU
  AH0816	No. 816	CUGGUCUGCCAUGCCAAGUUG	No. 1996	ACUUGGCAUGGCAGACCAGUU
  AH0817	No. 817	UGGUCUGCCAUGCCAAGUUGU	No. 1997	AACUUGGCAUGGCAGACCAGU
  AH0818	No. 818	GGUCUGCCAUGCCAAGUUGUA	No. 1998	CAACUUGGCAUGGCAGACCAG
  AH0819	No. 819	GUGUGCCAUGCCAAGUUGUAA	No. 1999	ACAACUUGGCAUGGCAGACCA
  AH0820	No. 820	UCUGCCAUGCCAAGUUGUAAA	No. 2000	UACAACUUGGCAUGGCAGACC
  AH0821	No. 821	CUGCCAUGCCAAGUUGUAAAG	No. 2001	UUACAACUUGGCAUGGCAGAC
  AH0822	No. 822	UGCCAUGCCAAGUUGUAAAGC	No. 2002	UUUACAACUUGGCAUGGCAGA
  AH0823	No. 823	GCCAUGCCAAGUUGUAAAGCA	No. 2003	CUUUACAACUUGGCAUGGCAG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0750	No. 3110	ATTTGGCTGCCATGATGGA	0.128
  	AH0753	No. 3113	TGGCTGCCATGATGGATAT	0.117
  	AH0754	No. 3114	GGCTGCCATGATGGATATT	0.162
  	AH0756	No. 3116	CTGCCATGATGGATATTCT	0.095
  	AH0757	No. 3117	TGCCATGATGGATATTCTC	0.226
  	AH0759	No. 3119	CCATGATGGATATTCTCTG	0.283
  	AH0760	No. 3120	CATGATGGATATTCTCTGG	0.337
  	AH0762	No. 3122	TGATGGATATTCTCTGGAT	0.195
  	AH0763	No. 3123	GATGGATATTCTCTGGATG	0.141
  	AH0766	No. 3126	GGATATTCTCTGGATGGCC	0.199
  	AH0771	No. 3131	TTCTCTGGATGGCCCGGAA	0.267
  	AH0773	No. 3133	CTCTGGATGGCCCGGAAGA	0.167
  	AH0774	No. 3134	TCTGGATGGCCCGGAAGAA	O.207
  	AH0775	No. 3135	CTGGATGGCCCGGAAGAAA	0.310
  	AH0776	No. 3136	TGGATGGCCCGGAAGAAAT	0.134
  	AH0777	No. 3137	GGATGGCCCGGAAGAAATA	0.010
  	AH0779	No. 3139	ATGGCCCGGAAGAAATAGA	0.201
  	AH0788	No. 3140	TGGCCCGGAAGAAATAGAA	0.160
  	AH0781	No. 3141	GGCCCGGAAGAAATAGAAT	0.205
  	AH0782	No. 3142	GCCCGGAAGAAATAGAATG	0.066
  	AH0783	No. 3143	CCCGGAAGAAATAGAATCT	0.153
  	AH0785	No. 3145	CGGAAGAAATAGAATGTAC	0.126
  	AH0786	No. 3146	GGAAGAAATAGAATGTACC	0.295
  	AH0787	No. 3147	GAAGAAATAGAATGTACCA	0.244
  	AH0790	No. 3150	GAAATAGAATGTACCAAAC	0.196
  	AH0795	No. 3155	AGAATGTACCAAACTGGGA	0.172
  	AH0796	No. 3156	GAATGTACCAAACTGGGAA	0.082
  	AH0797	No. 3157	AATGTACCAAACTGGGAAA	0.310
  	AH0800	No. 3160	GTACCAAACTGGGAAACTG	0.113
  	AH0804	No. 3164	CAAACTGGGAAACTGGTCT	0.115
  	AH0805	No. 3165	AAACTGGGAAACTGGTCTG	0.174
  	AH0808	No. 3168	CTGGGAAACTGGTCTGCCA	0.025
  	AH0809	No. 3169	TGGGAAACTGGTCTGCCAT	0.143
  	AH0810	No. 3170	GGGAAACTGGTCTGCCATG	0.331
  	AH0811	No. 3171	GGAAACTGGTCTGCCATGC	0.326
  	AH0813	No. 3173	AAACTGCTCTGCCATGCCA	0.125
  	AH0814	No. 3174	AACTGGTCTGCCATGCCAA	0.127
  	AH0815	No. 3175	ACTGGTCTGCCATGCCAAG	0.280
  	AH0816	No. 3176	CTGGTCTGCCATGCCAAGT	0.323
  	AH0817	No. 3177	TGGTCTGCCATGCCAAGTT	0.167
  	AH0818	No. 3178	GGTCTGCCATGCCAAGTTG	0.156
  	AH0819	No. 3179	GTCTGCCATGCCAAGTTGT	0.118
  	AH0820	No. 3180	TCTGCCATGCCAAGTTGTA	0.072
  	AH0821	No. 3181	CTGCCATGCCAAGTTGTAA	0.066
  	AH0822	No. 3182	TGCCATGCCAAGTTGTAAA	0.090
  	AH0823	No. 3183	GCCATGCCAAGTTGTAAAG	0.128

• TABLE 4-11
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0825	No. 825	CAUGCCAAGUUGUAAAGCAUC	No. 2005	UGCUUUACAACUUGGCAUGGC
  AH0826	No. 826	AUGCCAAGUUGUAAAGCAUCU	No. 2006	AUGCUUUACAACUUGGCAUGG
  AH0827	No. 827	UGCCAAGUUGUAAAGCAUCUU	No. 2007	GAUGCUUUACAACUUGGCAUG
  AH0828	No. 828	GCCAAGUUGUAAAGCAUCUUG	No. 2008	AGAUGCUUUACAACUUGGCAU
  AH0829	No. 829	CCAAGUUGUAAAGCAUCUUGU	No. 2009	AAGAUGCUUUACAACUUGGCA
  AH0830	No. 830	CAAGUUGUAAAGCAUCUUGUA	No. 2010	CAAGAUGCUUUACAACUUGGC
  AH0831	No. 831	AAGUUGUAAAGCAUCUUGUAA	No. 2011	ACAAGAUGCUUUACAACUUGG
  AH0832	No. 832	AGUUGUAAAGCAUCUUGUAAA	No. 2012	UACAAGAUGCUUUACAACUUG
  AH0833	No. 833	GUUGUAAAGCAUCUUGUAAAG	No. 2013	UUACAAGAUGCUUUACAACUU
  AH0834	No. 834	UUGUAAAGCAUCUUGUAAAGU	No. 2014	UUUACAAGAUGCUUUACAACU
  AH0835	No. 835	UGUAAAGCAUCUUGUAAAGUA	No. 2015	CUUUACAAGAUGCUUUACAAC
  AH0837	No. 337	UAAAGCAUCUUGUAAAGUACC	No. 2017	UACUUUACAAGAUGCUUUACA
  AH0838	No. 838	AAAGCAUCUUGUAAAGUACCU	No. 2018	GUACUUUACAAGAUGCUUUAC
  AH0840	No. 840	AGCAUCUUGUAAAGUACCUGU	No. 2020	AGGUACUUUACAAGAUGCUUU
  AH0842	No. 842	CAUCUUGUAAAGUACCUGUGA	No. 2022	ACAGGUACUUUACAAGAUGCU
  AH0845	No. 845	CUUGUAAAGUACCUGUGAAAA	No. 2025	UUCACAGGUACUUUACAAGAU
  AH0846	No. 846	UUGUAAAGUACCUGUGAAAAA	No. 2026	UUUCACAGGUACUUUACAAGA
  AH0841	No. 847	UGUAAAGUACCUGUGAAAAAA	No. 2027	UUUUCACAGGUACUUUACAAG
  AH0852	No. 852	AGUACCUGUGAAAAAAGCCAC	No. 2032	GGCUUUUUUCACAGGUACUUU
  AH0853	No. 853	GUACCUGUGAAAAAAGCCACU	No. 2033	UGGCUUUUUUCACAGGUACUU
  AH0854	No. 854	UACCUGUGAAAAAAGCCACUG	No. 2034	GUGGCUUUUUUCACAGGUACU
  AH0855	No. 855	ACCUGUGAAAAAAGCCACUGU	No. 2035	AGUGGCUUUUUUCACAGGUAC
  AH0857	No. 857	CUGUGAAAAAAGCCACUGUGG	No. 2037	ACAGUGGCUUUUUUCACAGGU
  AH0858	No. 858	UGUGAAAAAAGCCACUGUGGU	No. 2038	CACAGUGGCUUUUUUCACAGG
  AH0859	No. 859	GUGAAAAAAGCCACUGUGGUG	No. 2039	CCACAGUGGCUUUUUUCACAG
  AH0860	No. 860	UGAAAAAAGCCACUGUGGUGU	No. 2040	ACCACAGUGGCUUUUUUCACA
  AH0861	No. 861	GAAAAAAGCCACUGUGGUGUA	No. 2041	CACCACAGUGGCUUUUUUCAC
  AH0863	No. 863	AAAAAGCCACUGUGGUGUACC	No. 2043	UACACCACAGUGGCUUUUUUC
  AH0864	No. 854	AAAAGCCACUGUGGUGUACCA	No. 2044	GUACACCACAGUGGCUUUUUU
  AH0866	No. 866	AAGGCACUGUGGUGUACCAAG	No. 2046	UGGUACACCACAGUGGCUUUU
  AH0861	No. 867	AGCCACUGUGGUGUACCAAGG	No. 2047	UUGGUACACCACAGUGGCUUU
  AH0868	No. 868	GCCACUGUGGUGUACCAAGGA	No. 2048	CUUGGUACACCACAGUGGCUU
  AH0870	No. 870	CACUGUGGUGUACCAAGGAGA	No. 2050	UCCUUGGUACACCACAGUGGC
  AH0872	No. 872	CUGUGGUGUACCAAGGAGAGA	No. 2052	UCUCCUUGGUACACCACAGUG
  AH0873	No. 873	UGUGGUGUACCAAGGAGAGAG	No. 2053	CUCUCCUUGGUACACCACAGU
  AH0874	No. 874	GUGGUGUACCAAGGAGAGAGA	No. 2054	UCUCUCCUUGGUACACCACAG
  AH8875	No. 875	UGGUGUACCAAGGAGAGAGAG	No. 2055	CUCUCUCCUUGGUACACCACA
  AH0876	No. 876	GGUGUACCAAGGAGAGAGAGU	No. 2056	UCUCUCUCCUUGGUACACCAC
  AH0877	No. 877	GUGUACCAAGGAGAGAGAGUA	No. 2057	CUCUCUCUCCUUGGUACACCA
  AH0879	No. 879	GUACCAAGGAGAGAGAGUAAA	No. 2059	UACUCUCUCUCCUUGGUACAC
  AH0880	No. 880	UACCAAGGAGAGAGAGUAAAG	No. 2060	UUACUCUCUCUCCUUGGUACA
  AH0881	No. 881	ACCAAGGAGAGAGAGUAAAGA	No. 2061	UUUACUCUCUCUCCUUGGUAC
  AH0882	No. 882	CCAAGGAGAGAGAGUAAAGAU	No. 2062	CUUUACUCUCUCUCCUUGGUA
  AH0883	No. 883	CAAGGAGAGAGAGUAAAGAUU	No. 2063	UCUUUACUCUCUCUCCUUGGU
  AH0884	No. 884	AAGGAGAGAGAGUAAAGAUUC	No. 2064	AUCUUUACUCUCUCUCCUUGG
  AH0885	No. 885	AGGAGAGAGAGUAAAGAUUCA	No. 2065	AAUCUUUACUCUCUCUCCUUG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0825	No. 3185	CATGCCAAGTTGTAAAGCA	0.086
  	AH0826	No. 3186	ATGCCAAGTTGTAAAGGCT	0.082
  	AH0827	No. 3187	TGCCAAGTTGTAAAGCATC	0.342
  	AH0828	No. 3188	GCCAAGTTGTAAAGCATCT	0_160
  	AH0829	No. 3189	CCAAGTTGTAAAGCATCTT	0.159
  	AH0830	No. 3190	CAAGTTGTAAAGCATCTTG	0.134
  	AH0831	No. 3191	AAGTTGTAAAGCATCTTGT	0.110
  	AH0832	No. 3192	AGTTGTAAAGCATCTTGTA	0.064
  	AH0833	No. 3193	GTTGTAAAGCATCTTGTAA	0.175
  	AH0834	No. 3194	TTGTAAAGCATCTTGTAAA	0.092
  	AH0835	No. 3195	TGTAAAGCATCTTGTAAAG	0.129
  	AH0837	No. 3197	TAAAGCATCTTGTAAAGTA	0.087
  	AH0838	No. 3198	AAAGCATCTTGTAAAGTAC	0.174
  	AH0840	No. 3200	AGCATCTTGTAAAGTACCT	0.326
  	AH0842	No. 3202	CATCTTGTAAAGTACCTGT	0.260
  	AH0845	No. 3205	CTTGTAAAGTACCTGTGAA	0.181
  	AH0846	No. 3206	TTGTAAAGTACCTGTGAAA	0.166
  	AH0841	No. 3207	TGTAAAGTACCTGTGAAAA	0.210
  	AH0852	No. 3212	AGTACCTGTGAAAAAAGCC	0.247
  	AH0853	No. 3213	GTACCTGTGAAAAAAGCCA	0.334
  	AH0854	No. 3214	TACCTGTGAAAAAAGCCAC	0.302
  	AH0855	No. 3215	ACCTGTGAAAAAAGCCACT	0.312
  	AH0857	No. 3217	CTGTGAAAAAAGCCACTGT	0.196
  	AH0858	No. 3218	TGTGAAAAAAGCCACTGTG	0.091
  	AH0859	No. 3219	GTGAAAAAAGCCACTGTGG	0.287
  	AH0860	No. 3220	TGAAAAAAGCCACTGTGGT	0.278
  	AH0861	No. 3221	GAAAAAAGCCACTGTGGTG	0.170
  	AH0863	No. 3223	AAAAAGCCACTGTGGTGTA	0.269
  	AH0864	No. 3224	AAAAGCCACTGTGGTGTAC	0.185
  	AH0866	No. 3226	AAGCCACTGTGGTGTACCA	0.209
  	AH0861	No. 3227	AGCCACTGTGGTGTACCAA	0.235
  	AH0868	No. 3228	GCCACTGTGGTGTACCAAG	0.106
  	AH0870	No. 3230	CACTGTGGTGTACCAAGGA	0.154
  	AH0872	No. 3232	CTGTGGTGTACCAAGGAGA	0.230
  	AH0873	No. 3233	TGTGGTGTACCAAGGAGAG	0.289
  	AH0874	No. 3234	GTGGTGTACCAAGGAGAGA	0.174
  	AH8875	No. 3235	TGGTGTACCAAGGAGAGAG	0.281
  	AH0876	No. 3236	GGTGTACCAAGGAGAGAGA	0.117
  	AH0877	No. 3237	GTGTACCAAGGAGAGAGAG	0.149
  	AH0879	No. 3239	GTACCAAGGAGAGAGAGTA	0.325
  	AH0880	No. 3240	TACCAAGGAGAGAGAGTAA	0.198
  	AH0881	No. 3241	ACCAAGGAGAGAGAGTAAA	0.159
  	AH0882	No. 3242	CCAAGGAGAGAGAGTAAAG	0.244
  	AH0883	No. 3243	CAAGGAGAGAGAGTAAAGA	0.046
  	AH0884	No. 3244	AAGGAGAGAGAGTAAAGAT	0.118
  	AH0885	No. 3245	AGGAGAGAGAGTAAAGATT	0.150

• TABLE 4-12
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0886	No. 886	GGAGAGAGAGUAAAGAUUCAG	No. 2066	GAAUCUUUACUCUCUCUCCUU
  AH0887	No. 887	GAGAGAGAGUAAAGAUUCAGG	No. 2067	UGAAUCUUUACUCUCUCUCCU
  AH0888	No. 888	AGAGAGAGUAAAGAUUCAGGA	No. 2068	CUGAAUCUUUACUCUCUCUCC
  AH0890	No. 890	AGAGAGUAAAGAUUCAGGAAA	No. 2070	UCCUGAAUCUUUACUCUCUCU
  AH0891	No. 891	GAGAGUAAAGAUUCAGGAAAA	No. 2071	UUCCUGAAUCUUUACUCUCUC
  AH0892	No. 892	AGAGUAAAGAUUCAGGAAAAA	No. 2072	UUUCCUGAAUCUUUACUCUCU
  AH0893	No. 893	GAGUAAAGAUUCAGGAAAAAU	No. 2073	UUUUCCUGAAUCUUUACUCUC
  A80894	No. 894	AGUAAAGAUUCAGGAAAAAUU	No. 2074	UUUUUCCUGAAUCUUUACUCU
  AH0895	No. 895	GUAAAGAUUCAGGAAAAAUUU	No. 2075	AUUUUUCCUGAAUCUUUACUC
  AH0896	No. 896	UAAAGAUUCAGGAAAAAUUUA	No. 2076	AAUUUUUCCUGAAUCUUUACU
  AH9892	No. 897	AAAGAUUCAGGAAAAAUUUAA	No. 2077	AAAUUUUUCCUGAAUCUUUAC
  AH0898	No. 898	AAGAUUCAGGAAAAAUUUAAG	No. 2078	UAAAUUUUUCCUGAAUCUUUA
  AH0899	No. 899	AGAUUCAGGAAAAAUUUAAGA	No. 2079	UUAAAUUUUUCCUGAAUCUUU
  AH0905	No. 905	AGGAAAAAUUUAAGAAUGGAA	No. 2085	CCAUUCUUAAAUUUUUCCUGA
  AH0906	No. 906	GGAAAAAUUUAAGAAUGGAAU	No. 2086	UCCAUUCUUAAAUUUUUCCUG
  AH0907	No. 907	GAAAAAUUUAAGAAUGGAAUG	No. 2087	UUCCAUUCUUAAAUUUUUCCU
  AH0912	No. 912	AUUUAAGAAUGGAAUGCUACA	No. 2092	UAGCAUUCCAUUCUUAAAUUU
  AH0914	No. 914	UUAAGAAUGGAAUGCUACAUG	No. 2094	UGUAGCAUUCCAUUCUUAAAU
  AH0917	No. 917	AGAAUGGAAUGCUACAUGGUG	No. 2097	CCAUGUAGCAUUCCAUUCUUA
  AH0918	No. 918	GAAUGGAAUGCUACAUGGUGA	No. 2098	ACCAUGUAGCAUUCCAUUCUU
  AH0919	No. 919	AAUGGAAUGCUACAUGGUGAU	No. 2099	CACCAUGUAGCAUUCCAUUCU
  AH0920	No. 920	AUGGAAUGCUACAUGGUGAUA	No. 2100	UCACCAUGUAGCAUUCCAUUC
  AH0921	No. 921	UGGAAUGCUACAUGGUGAUAA	No. 2101	AUCACCAUGUAGCAUUCCAUU
  AH0922	No. 922	GGAAUGCUACAUGGUGAUAAA	No. 2102	UAUCACCAUGUAGCAUUCCAU
  AH0923	No. 923	GAAUGCUACAUGGUGAUAAAG	No. 2103	UUAUCACCAUGUAGCAUUCCA
  AH0924	No. 924	AAUGCUACAUGGUGAUAAAGU	No. 2104	UUUAUCACCAUGUAGCAUUCC
  AH0926	No. 926	UGCUACAUGGUGAUAAAGUUU	No. 2106	ACUUUAUCACCAUGUAGCAUU
  AH0927	No. 927	GCUACAUGGUGAUAAAGUUUC	No. 2107	AACUUUAUCACCAUGUAGCAU
  AH0928	No. 928	CUACAUGGUGAUAAAGUUUCU	No. 2108	AAACUUUAUCACCAUGUAGCA
  AH0930	No. 930	ACAUGGUGAUAAAGUUUCUUU	No. 2110	AGAAACUUUAUCACCAUGUAG
  AH0932	No. 932	AUGGUGAUAAAGUUUCUUUCU	No. 2112	AAAGAAACUUUAUCACCAUGU
  AH0934	No. 934	GGUGAUAAAGUUUCUUUCUUC	No. 2114	AGAAAGAAACUUUAUCACCAU
  AH0935	No. 935	GUGAUAAAGUUUCUUUCUUCU	No. 2115	AAGAAAGAAACUUUAUCACCA
  AH0936	No. 936	UGAUAAAGUUUCUUUCUUCUG	No. 2116	GAAGAAAGAAACUUUAUCACC
  AH0937	No. 937	GAUAAAGUUUCUUUCUUCUGC	No. 2117	AGAAGAAAGAAACUUUAUCAC
  AH0940	No. 940	AAAGUUUCUUUCUUCUGCAAA	No. 2120	UGCAGAAGAAAGAAACUUUAU
  AH0941	No. 941	AAGUUUCUUUCUUCUGCAAAA	No. 2121	UUGCAGAAGAAAGAAACUUUA
  AH0942	No. 942	AGUUUCUUUCUUCUGCAAAAA	No. 2122	UUUGCAGAAGAAAGAAACUUU
  AH0943	No. 943	GUUUCUUUCUUCUGCAAAAAU	No. 2123	UUUUGCAGAAGAAAGAAACUU
  AH0944	No. 944	UUUCUUUCUUCUGCAAAAAUA	No. 2124	UUUUUGCAGAAGAAAGAAACU
  AH0945	No. 945	UUCUUUCUUCUGCAAAAAUAA	No. 2125	AUUUUUGCAGAAGAAAGAAAC
  AH0946	No. 946	UCUUUCUUCUGCAAAAAUAAG	No. 2126	UAUUUUUGCAGAAGAAAGAAA
  AH0947	No. 947	CUUUCUUCUGCAAAAAUAAGG	No. 2127	UUAUUUUUGCAGAAGAAAGAA
  AH0948	No. 948	UUUCUUCUGCAAAAAUAAGGA	No. 2128	CUUAUUUUUGCAGAAGAAAGA
  AH0953	No. 953	UCUGCAAAAAUAAGGAAAAGA	No. 2133	UUUUCCUUAUUUUUGCAGAAG
  AH0955	No. 955	UGCAAAAAUAAGGAAAAGAAG	No. 2135	UCUUUUCCUUAUUUUUGCAGA
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0886	No. 3246	GGAGAGAGAGTAAAGATTC	0.187
  	AH0887	No. 3247	GAGAGAGAGTAAAGATTCA	0.061
  	AH0888	No. 3248	AGAGAGAGTAAAGATTCAG	0.230
  	AH0890	No. 3250	AGAGAGTAAAGATTCAGGA	0.270
  	AH0891	No. 3251	GAGAGTAAAGATTCAGGAA	0.100
  	AH0892	No. 3252	AGAGTAAAGATTCAGGAAA	0.212
  	AH0893	No. 3253	GAGTAAAGATTCAGGAAAA	0.114
  	A80894	No. 3254	AGTAAAGATTCAGGAAAAA	0.185
  	AH0895	No. 3255	GTAAAGATTCAGGAAAAAT	0.203
  	AH0896	No. 3256	TAAAGATTCAGGA&AAATT	0.149
  	AH9892	No. 3257	AAAGATTCAGGAAAAATTT	0.218
  	AH0898	No. 3258	AAGATTCAGGAAAAATTTA	0.262
  	AH0899	No. 3259	AGATTCAGGAAAAATTTAA	0.334
  	AH0905	No. 3265	AGGAAAAATTTAAGAATGG	0.172
  	AH0906	No. 3266	GGAAAAATTTAAGAATGGA	0.171
  	AH0907	No. 3267	GAAAAATTTAAGAATGGAA	0.260
  	AH0912	No. 3272	ATTTAAGAATGGAATGCTA	0.323
  	AH0914	No. 3274	TTAAGAATGGAATGCTACA	0.342
  	AH0917	No. 3277	AGAATGGAATGCTACATGG	0.221
  	AH0918	No. 3278	GAATGGAATGCTACATGGT	0.162
  	AH0919	No. 3279	AATGGAATGCTACATGGTG	0.287
  	AH0920	No. 3280	ATGGAATGGTACATGGTGA	0.212
  	AH0921	No. 3281	TGGAATGCTACATGGTGAT	0.127
  	AH0922	No. 3282	GGAATGCTACATGGTGATA	0.241
  	AH0923	No. 3283	GAATGCTACATGGTGATAA	0.343
  	AH0924	No. 3284	AATGCTACATGGTGATAAA	0.269
  	AH0926	No. 3286	TGCTACATGGTGATAAAGT	0.259
  	AH0927	No. 3287	GCTACATGGTGATAAAGTT	0.240
  	AH0928	No. 3288	CTACATGGTGATAAAGTTT	0.080
  	AH0930	No. 3290	ACATGGTGATAAAGTTTCT	0.119
  	AH0932	No. 3292	ATGGTGATAAAGTTTCTTT	0.342
  	AH0934	No. 3294	GGTGATAAAGTTTCTTTCT	0.145
  	AH0935	No. 3295	GTGATAAAGTTTCTTTCTT	0.185
  	AH0936	No. 3296	TGATAAAGTTTCTTTCTTC	0.132
  	AH0937	No. 3297	GATAAAGTTTCTTTCTTCT	0.145
  	AH0940	No. 3300	AAAGTTTCTTTCTTCTGCA	0.213
  	AH0941	No. 3301	AAGTTTCTTTCTTCTGCAA	0.162
  	AH0942	No. 3302	AGTTTCTTTCTTCTGCAAA	0.229
  	AH0943	No. 3303	GTTTCTTTCTTCTGCAAAA	0.081
  	AH0944	No. 3304	TTTCTTTCTTCTGCAAAAA	0.119
  	AH0945	No. 3305	TTCTTTCTTCTGCAAAAAT	0.168
  	AH0946	No. 3306	TCTTTCTTCTGCAAAAATA	0.106
  	AH0947	No. 3307	CTTTCTTCTGCAAAAATAA	0.115
  	AH0948	No. 3308	TTTCTTCTGCAAAAATAAG	0.299
  	AH0953	No. 3313	TCTGCAAAAATAAGGAAAA	0.188
  	AH0955	No. 3315	TGCAAAAATAAGGAAAAGA	0.305

• TABLE 4-13
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH0956	No. 956	GCAAAAAUAAGGAAAAGAAGU	No. 2136	UUCUUUUCCUUAUUUUUGCAG
  AH0957	No. 957	CAAAAAUAAGGAAAAGAAGUG	No. 2137	CUUCUUUUCCUUAUUUUUGCA
  AH0964	No. 964	AAGGAAAAGAAGUGUAGCUAU	No. 2144	AGCUACACUUCUUUUCCUUAU
  AH0965	No. 965	AGGAAAAGAAGUGUAGCUAUA	No. 2145	UAGCUACACUUCUUUUCCUUA
  AH0966	No. 966	GGAAAAGAAGUGUAGCUAUAC	No. 2146	AUAGCUACACUUCUUUUCCUU
  AH0967	No. 967	GAAAAGAAGUGUAGCUAUACA	No. 2147	UAUAGCUACACUUCUUUUCCU
  AH0969	No. 969	AAAGAAGUGUAGCUAUACAGA	No. 2149	UGUAUAGCUACACUUCUUUUC
  AH0972	No. 972	GAAGUGUAGCUAUACAGAGGA	No. 2152	CUCUGUAUAGCUACACUUCUU
  AH0974	No. 974	AGUGUAGCUAUACAGAGGAUG	No. 2154	UCCUCUGUAUAGCUACACUUC
  AH0975	No. 975	GUGUAGCUAUACAGAGGAUGC	No. 2155	AUCCUCUGUAUAGCUACACUU
  AH0977	No. 977	GUAGCUAUACAGAGGAUGCUC	No. 2157	GCAUCCUCUGUAUAGCUACAC
  AH0978	No. 978	UAGCUAUACAGAGGAUGCUCA	No. 2158	AGCAUCCUCUGUAUAGCUACA
  AH0980	No. 980	GCUAUACAGAGGAUGCUCAGU	No. 2160	UGAGCAUCCUCUGUAUAGCUA
  AH0981	No. 981	CUAUACAGAGGAUGCUCAGUG	No. 2161	CUGAGCAUCCUCUGUAUAGCU
  AH0985	No. 985	ACAGAGGAUGCUCAGUGUAUA	No. 2165	UACACUGAGCAUCCUCUGUAU
  AH0987	No. 987	AGAGGAUGCUCAGUGUAUAGA	No. 2167	UAUACACUGAGCAUCCUCUGU
  AH0988	No. 988	GAGGAUGCUCAGUGUAUAGAU	No. 2168	CUAUACACUGAGCAUCCUCUG
  AH0989	No. 989	AGGAUGCUCAGUGUAUAGAUG	No. 2169	UCUAUACACUGAGCAUCCUCU
  AH0990	No. 990	GGAUGCUCAGUGUAUAGAUGG	No. 2170	AUCUAUACACUGAGCAUCCUC
  AH0991	No. 991	GAUGCUCAGUGUAUAGAUGGC	No. 2171	CAUCUAUACACUGAGCAUCCU
  AH0996	No. 996	UCAGUGUAUAGAUGGCACUAU	No. 2176	AGUGCCAUCUAUACACUGAGC
  AH0997	No. 997	CAGUGUAUAGAUGGCACUAUC	No. 2177	UAGUGCCAUCUAUACACUGAG
  AH0996	No. 998	AGUGUAUAGAUGGCACUAUCG	No. 2178	AUAGUGCCAUCUAUACACUGA
  AH0999	No. 999	GUGUAUAGAUGGCACUAUCGA	No. 2179	GAUAGUGCCAUCUAUACACUG
  AH1000	No. 1000	UGUAUAGAUGGCACUAUCGAA	No. 2180	CGAUAGUGCCAUCUAUACACU
  AH1001	No. 1001	GUAUAGAUGGCACUAUCGAAG	No. 2181	UCGAUAGUGCCAUCUAUACAC
  AH1002	No. 1002	UAUAGAUGGCACUAUCGAAGU	No. 2182	UUCGAUAGUGCCAUCUAUACA
  AH1003	No. 1003	AUAGAUGGCACUAUCGAAGUC	No. 2183	GUUCGAUAGUGCCAUCUAUAC
  AH1005	No. 1005	AGAUGGCACUAUCGAAGUCCC	No. 2185	GACUUCGAUAGUGCCAUCUAU
  AH1007	No. 1007	AUGGCACUAUCGAAGUCCCCA	No. 2187	GGGACUUCGAUAGUGCCAUCU
  AH1009	No. 1009	GGCACUAUCGAAGUCCCCAAA	No. 2189	UGGGGACUUCGAUAGUGGCAU
  AH1010	No. 1010	GCACUAUCGAAGUCCCCAAAU	No. 2190	UUGGGGACUUCGAUAGUGCCA
  AH1011	No. 1011	CACUAUCGAAGUCCCCAAAUG	No. 2191	UUUGGGGACUUCGAUAGUGGC
  AH1013	No. 1013	CUAUCGAAGUCCCCAAAUGCU	No. 2193	CAUUUGGGGACUUCGAUAGUG
  AH1015	No. 1015	AUCGAAGUCCCCAAAUGCUUC	No. 2195	AGCAUUUGGGGACUUCGAUAG
  AH1016	No. 1016	UCGAAGUCCCCAAAUGCUUCA	No. 2196	AAGCAUUUGGGGACUUCGAUA
  AH1017	No. 1017	CGAAGUCCCCAAAUGCUUCAA	No. 2197	GAAGCAUUUGGGGACUUCGAU
  AH1018	No. 1018	GAAGUCCCCAAAUGCUUCAAG	No. 2198	UGAAGCAUUUGGGGACUUGGA
  AH1021	No. 1021	GUCCCCAAAUGCUUCAAGGAA	No. 2201	CCUUGAAGCAUUUGGGGACUU
  AH1022	No. 1022	UCCCCAAAUGCUUCAAGGAAC	No. 2202	UCCUUGAAGCAUUUGGGGACU
  AH1023	No. 1023	CCCCAAAUGCUUCAAGGAACA	No. 2203	UUCCUUGAAGCAUUUGGGGAC
  AH1024	No. 1024	CCCAAAUGCUUCAAGGAACAC	No. 2204	GUUCCUUGAAGCAUUUGGGGA
  AH1025	No. 1025	CCAAAUGCUUCAAGGAACACA	No. 2205	UGUUCCUUGAAGCAUUUGGGG
  AH1026	No. 1026	CAAAUGCUUCAAGGAACACAG	No. 2206	GUGUUCCUUGAAGCAUUUGGG
  AH1027	No. 1027	AAAUGCUUCAAGGAACACAGU	No. 2207	UGUGUUCCUUGAAGCAUUUGG
  AH1028	No. 1028	AAUGCUUCAAGGAACACAGUU	No. 2208	CUGUGUUCCUUGAAGCAUUUG
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH0956	No. 3316	GCAAAAATAAGGAAAAGAA	0.185
  	AH0957	No. 3317	CAAAAATAAGGAAAATAAG	0.335
  	AH0964	No. 3324	AAGGAAAAGAAGTGTAGCT	0.329
  	AH0965	No. 3325	AGGAAAAGAAGTGTAGCTA	0.153
  	AH0966	No. 3326	GGAAAAGAAGTGTAGCTAT	0.106
  	AH0967	No. 3327	GAAAAGAAGTGTAGCTATA	0.097
  	AH0969	No. 3329	AAAGAAGTGTAGCTATACA	0.228
  	AH0972	No. 3332	GAAGTGTAGCTATACAGAG	0.293
  	AH0974	No. 3334	AGTGTAGCTATACAGAGGA	0.160
  	AH0975	No. 3335	GTGTAGCTATACAGAGGAT	0.227
  	AH0977	No. 3337	GTAGCTATACAGAGGATGC	0.285
  	AH0978	No. 3338	TAGCTATACAGAGGATGCT	0.245
  	AH0980	No. 3340	GCTATACAGAGGATGCTCA	0.090
  	AH0981	No. 3341	CTATACAGAGGATGCTCAG	0.137
  	AH0985	No. 3345	ACAGAGGATGCTCAGTGTA	0.308
  	AH0987	No. 3347	AGAGGATGCTCAGTGTATA	0.082
  	AH0988	No. 3348	GAGGATGCTCAGTGTATAG	0.292
  	AH0989	No. 3349	AGGATGCTCAGTGTATAGA	0.338
  	AH0990	No. 3350	GGATGCTCAGTGTATAGAT	0.252
  	AH0991	No. 3351	GATGCTCAGTGTATAGATG	0.111
  	AH0996	No. 3356	TGAGTGTATAGATGGCACT	0.233
  	AH0997	No. 3357	CAGTGTATAGATGGCACTA	0.290
  	AH0996	No. 3358	AGTGTATAGATGGCACTAT	0.199
  	AH0999	No. 3359	GTGTATAGATGGCACTATC	0.101
  	AH1000	No. 3360	TGTATAGATGGCACTATCG	0.310
  	AH1001	No. 3361	GTATAGATGGCACTATCGA	0.082
  	AH1002	No. 3362	TATAGATGGCACTATCGAA	0.084
  	AH1003	No. 3363	ATAGATGGCACTATCGAAG	0.265
  	AH1005	No. 3365	AGATGGCACTATCGAAGTC	0.100
  	AH1007	No. 3367	ATGGCACTATCGAAGTCCC	0.232
  	AH1009	No. 3369	GGCACTATCGAAGTCCCCA	0.122
  	AH1010	No. 3370	GCACTATCGAAGTCCCCAA	0.089
  	AH1011	No. 3371	CACTATCGAAGTCCCCAAA	0.154
  	AH1013	No. 3373	CTATCGAAGTCCCCAAATG	0.139
  	AH1015	No. 3375	ATCGAAGTCCCCAAATGCT	0.125
  	AH1016	No. 3376	TCGAAGTCCCCAAATGCTT	0.112
  	AH1017	No. 3377	CGAAGTCCCCAAATGCTTC	0.109
  	AH1018	No. 3378	GAAGTCCCCAAATGCTTCA	0.170
  	AH1021	No. 3381	GTCCCCAAATGCTTCAAGG	0.261
  	AH1022	No. 3382	TCCCCAAATGCTTCAAGGA	0.074
  	AH1023	No. 3383	CCCCAAATGCTTGAAGGAA	0.154
  	AH1024	No. 3384	CCCAAATGCTTCAAGGAAC	0.108
  	AH1025	No. 3385	CCAAATGCTTCAAGGAACA	0.056
  	AH1026	No. 3386	CAAATGCTTCAAGGAACAC	0.325
  	AH1027	No. 3387	AAATGCTTCAAGGAACACA	0.158
  	AH1028	No. 3385	AATGCTTCAAGGAACACAG	0.257

• TABLE 4-14
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH1029	No. 1029	AUGCUUCAAGGAACACAGUUC	No. 2209	ACUGUGUUCCUUGAAGCAUUU
  AH1030	No. 1030	UGCUUCAAGGAACACAGUUCU	No. 2210	AACUGUGUUCCUUGAAGCAUU
  AH1031	No. 1031	GCUUCAAGGAACACAGUUCUC	No. 2211	GAACUGUGUUCCOUGAAGCAU
  AH1032	No. 1032	CUUCAAGGAACACAGUUCUCU	No. 2212	AGAACUGUGUUCCUUGAAGCA
  AH1034	No. 1034	UCAAGGAACACAGUUCUCUGG	No. 2214	AGAGAACUGUGUUCCUUGAAG
  AH1035	No. 1035	CAAGGAACACAGUUCUCUGGC	No. 2215	CAGAGAACUGUGUUCCUUGAA
  AH1038	No. 1038	GGAACACAGUUCUCUGGCUUU	No. 2218	AGCCAGAGAACUGUGUUCCUU
  AH1039	No. 1039	GAACACAGUUCUCUGGCUUUU	No. 2219	AAGCCAGAGAACUGUGUUCCU
  AH1040	No. 1040	AACACAGUUCUCUGGCUUUUU	No. 2220	AAAGCCAGAGAACUGUGUUCC
  AH1041	No. 1041	ACACAGUUCUCUGGCUUCUUG	No. 2221	AAAAGCCAGAGAACUGUGUUC
  AH1042	No. 1042	CACAGUUCUCUGGCUUUUUGG	No. 2222	AAAAAGCCAGAGAACUGUGUU
  AH1043	No. 1043	ACAGUUCUCUGGCUUUUUGGA	No. 2223	CAAAAAGCCAGAGAACUGUGU
  AH1044	No. 1044	CAGUUCUCUGGCUUUUUGGAA	No. 2224	CCAAAAAGCCAGAGAACUGUG
  AH1045	No. 1045	AGUUCUCUGGCUUUUUGGAAA	No. 2225	UCCAAAAAGCCAGAGAACUGU
  AH1046	No. 1046	GUUCUCUGGCUUUUUGGAAAA	No. 2226	UUCCAAAAAGCCAGAGAACUG
  AH1047	No. 1047	UUCUCUGGCUUUUUGGAAAAC	No. 2227	UUUCCAAAAAGCCAGAGAACU
  AH1048	No. 1048	UCUCUGGCUUUUUGGAAAACU	No. 2228	UUUUCCAAAAAGCCAGAGAAC
  AH1051	No. 1051	CUGGCUUUUUGGAAAACUGAU	No. 2231	CAGUUUUCCAAAAAGCCAGAG
  AH1052	No. 1052	UGGCUUUUUGGAAAACUGAUG	No. 2232	UCAGUUUUCCAAAAAGCCAGA
  AH1053	No. 1053	GGCUUUUUGGAAAACUGAUGC	No. 2233	AUCAGUUUUCCAAAAAGCCAG
  AH1054	No. 1054	GCUUUUUGGAAAACUGAUGCA	No. 2234	CAUCAGUUUUCCAAAAAGCCA
  AH1056	No. 1056	UUUUUGGAAAACUGAUGCAUC	No. 2236	UGCAUGAGUUUUCCAAAAAGC
  AH1057	No. 1057	UUUUGGAAAACUGAUGCAUCC	No. 2237	AUGCAUCAGUUUUCCAAAAAG
  AH1061	No. 1061	GGAAAACUGAUGCAUCCGAUG	No. 2241	UCGGAUGCAUCAGUUUUCCAA
  AH1062	No. 1062	GAAAACUGAUGCAUCCGAUGU	No. 2242	AUCGGAUGCAUCAGUUUUCCA
  AH1063	No. 1063	AAAACUGAUGCAUCCGAUGUA	No. 2243	CAUCGGAUGCAUCAGUUUUCC
  AH1064	No. 1064	AAACUGAUGCAUCCGAUGUAA	No. 2244	ACAUCGGAUGCAUCAGUUUUC
  AH1065	No. 1065	AACUGAUGCAUCCGAUGUAAA	No. 2245	UACAUCGGAUGCAUCAGUUUU
  AH1067	No. 1067	CUGAUGCAUCCGAUGUAAAGC	No. 2247	UUUACAUCGGAUGCAUCAGUU
  AH1068	No. 1068	UGAUGCAUCCGAUGUAAAGCC	No. 2248	CUUUACAUCGGAUGCAUCAGU
  AH1072	No. 1072	GCAUCCGAUGUAAAGCCAUGC	No. 2252	AUGGCUUUACAUCGGAUGCAU
  AH1073	No. 1073	CAUCCGAUGUAAAGCCAUGCU	No. 2253	CAUGGCUUUACAUCGGAUGCA
  AH1076	No. 1076	CCGAUGUAAAGCCAUGCUAAG	No. 2256	UAGCAUGGCUUUACAUCGGAU
  AH1077	No. 1077	CGAUGUAAAGCCAUGCUAAGG	No. 2257	UUAGCAUGGCUUUACAUCGGA
  AH1078	No. 1078	GAUGUAAAGCCAUGCUAAGGU	No. 2258	CUUAGCAUGGCUUUACAUCGG
  AH1083	No. 1083	AAAGCCAUGCUAAGGUGGUUU	No. 2263	ACCACCUUAGCAUGGCUUUAC
  AH1084	No. 1084	AAGCCAUGCUAAGGUGGUUUU	No. 2264	AACCACCUUAGCAUGGCUUUA
  AH1085	No. 1085	AGCCAUGCUAAGGUGGUUUUC	No. 2265	AAACCACCUUAGCAUGGCUUU
  AH1086	No. 1086	GCCAUGCUAAGGUGGUUUUCA	No. 2266	AAAACCACCUUAGCAUGGCUU
  AH1087	No. 1087	CCAUGCUAAGGUGGUUUUCAG	No. 2267	GAAAACCACCUUAGCAUGGCU
  AH1088	No. 1088	CAUGCUAAGGUGGUUUUCAGA	No. 2268	UGAAAACCACCUUAGCAUGGC
  AH1089	No. 1089	AUGCUAAGGUGGUUUUCAGAU	No. 2269	CUGAAAACCACCUUAGCAUGG
  AH1090	No. 1090	UGCUAAGGUGGUUUUCAGAUU	No. 2270	UCUGAAAACCACCUUAGCAUG
  AH1092	No. 1092	CUAAGGUGGUUUUCAGAUUCC	No. 2272	AAUCUGAAAACCACCUUAGCA
  AH1093	No. 1093	UAAGGUGGUUUUCAGAUUCCA	No. 2273	GAAUCUGAAAACCACCUUAGC
  AH1095	No. 1095	AGGUGGUUUUCAGAUUCCACA	No. 2275	UGGAAUCUGAAAACCACCUUA
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH1029	No. 3389	ATGCTTCAAGGAACACAGT	0.175
  	AH1030	No. 3390	TGCTTCAAGGAACACAGTT	0.200
  	AH1031	No. 3391	GCTTCAAGGAACACAGTTC	0.074
  	AH1032	No. 3392	CTTCAAGGAACACAGTTCT	0.083
  	AH1034	No. 3394	TCAAGGAACACAGTTCTCT	0.279
  	AH1035	No. 3395	CAAGGAACACAGTTCTCTG	0.238
  	AH1038	No. 3398	GGAACACAGTTCTCTGGCT	0.067
  	AH1039	No. 3399	GAACACAGTTCTCTGGCTT	0.072
  	AH1040	No. 3400	AACACAGTTCTCTGGCTTT	0.094
  	AH1041	No. 3401	ACACAGTTCTCTGGCTTTT	0.071
  	AH1042	No. 3402	CACAGTTCTCTGGCTTTTT	0.143
  	AH1043	No. 3403	ACAGTTCTCTGGCTTTTTG	0.082
  	AH1044	No. 3404	CAGTTCTCTGGCTTTTTGG	0.199
  	AH1045	No. 3405	AGTTCTCTGGCTTTTTGGA	0.108
  	AH1046	No. 3406	GTTCTCTGGCTTTTTGGAA	0.156
  	AH1047	No. 3407	TTCTCTGGCTTTTTGGAAA	0.111
  	AH1048	No. 3408	TCTCTGGCTTTTTGGAAAA	0.313
  	AH1051	No. 3411	CTGGCTTTTTGGAAAACTG	0.152
  	AH1052	No. 3412	TGGCTTTTTGGAAAACTGA	0.097
  	AH1053	No. 3413	GGCTTTTTGGAAAACTGAT	0.162
  	AH1054	No. 3414	GCTTTTTGGAAAACTGATG	0.200
  	AH1056	No. 3416	TTTTTGGAAAACTGATGCA	0.342
  	AH1057	No. 3417	TTTTGGAAAACTGATGCAT	0.230
  	AH1061	No. 3421	GGAAAACTGATGCATCCGA	0.128
  	AH1062	No. 3422	GAAAACTGATGCATCCGAT	0.182
  	AH1063	No. 3423	AAAACTGATGCATCCGATG	0.229
  	AH1064	No. 3424	AAACTGATGCATCCGATGT	0.336
  	AH1065	No. 3425	AACTGATGCATCCGATGTA	0.216
  	AH1067	No. 3427	CTGATGCATCCGATGTAAA	0.241
  	AH1068	No. 3428	TGATGCATCCGATGTAAAG	0.329
  	AH1072	No. 3432	GCATCCGATGTAAAGCCAT	0.197
  	AH1073	No. 3433	CATCCGATGTAAAGCCATG	0.120
  	AH1076	No. 3436	CCGATGTAAAGCCATGCTA	0.219
  	AH1077	No. 3437	CGATGTAAAGCCATGCTAA	0.061
  	AH1078	No. 3438	GATGTAAAGCCATGCTAAG	0.131
  	AH1083	No. 3443	AAAGCCATGCTAAGGTGGT	0.239
  	AH1084	No. 3444	AAGCCATGCTAAGGTGGTT	0.139
  	AH1085	No. 3445	AGCCATGCTAAGGTGGTTT	0.166
  	AH1086	No. 3446	GCCATGCTAAGGTGGTTTT	0.100
  	AH1087	No. 3447	CCATGCTAAGGTGGTTTTC	0.233
  	AH1088	No. 3448	CATGCTAAGGTGGTTTTCA	0.072
  	AH1089	No. 3449	ATGCTAAGGTGGTTTTCAG	0.175
  	AH1090	No. 3450	TGCTAAGGTGGTTTTCAGA	0.130
  	AH1092	No. 3452	CTAAGGTGGTTTTCAGATT	0.065
  	AH1093	No. 3453	TAAGGTGGTTTTCAGATTC	0.141
  	AH1095	No. 3455	AGGTGGTTTTCAGATTCCA	0.044

• TABLE 4-15
  Double
  stranded
  nucleic		Sense strand sequence		Antisense strand sequence
  acid No.	SEQ ID NO.	(5′→3′)	SEQ ID NO.	(5′→3′)
  AH1096	No. 1096	GGUGGUUUUCAGAUUCCACAC	No. 2276	GUGGAAUCUGAAAACCACCUU
  AH1097	No. 1097	GUGGUUUUCAGAUUCCACACA	No. 2277	UGUGGAAUCUGAAAACCACCU
  AH1099	No. 1099	GGUUUUCAGAUUCCACACAAA	No. 2279	UGUGUGGAAUCUGAAAACCAC
  AH1100	No. 1100	GUUUUCAGAUUCCACACAAAA	No. 2280	UUGUGUGGAAUCUGAAAACCA
  AH1101	No. 1101	UUUUCAGAUUCCACACAAAAU	No. 2281	UUUGUGUGGAAUCUGAAAACC
  AH1102	No. 1102	UUUCAGAUUCCACACAAAAUG	No. 2282	UUUUGUGUGGAAUCUGAAAAC
  AH1103	No. 1103	UUCAGAUUCCACACAAAAUGU	No. 2283	AUUUUGUGUGGAAUCUGAAAA
  AH1104	No. 1104	UCAGAUUCCACACAAAAUGUC	No. 2284	CAUUUUGUGUGGAAUCUGAAA
  AH1105	No. 1105	CAGAUUCCACACAAAAUGUCA	No. 2285	ACAUUUUGUGUGGAAUCUGAA
  AHI106	No. 1106	AGAUUCCACACAAAAUGUCAC	No. 2286	GACAUUUUGUGUGGAAUCUGA
  AH1107	No. 1107	GAUUCCACACAAAAUGUCACA	No. 2287	UGACAUUUUGUGUGGAAUCUG
  AH1109	No. 1109	UUCCACACAAAAUGUCACACU	No. 2289	UGUGACAUUUUGUGUGGAAUC
  AH1111	No. 1111	CCACACAAAAUGUCACACUUG	No. 2291	AGUGUGACAUUUUGUGUGGAA
  AH1112	No. 1112	CACACAAAAUGUCACACUUGU	No. 2292	AAGUGUGACAUUUUGUGUGGA
  AH1113	No. 1113	ACACAAAAUGUCACACUUGUU	No. 2293	CAAGUGUGACAUUUUGUGUGG
  AH1114	No. 1114	CACAAAAUGUCACACUUGUUU	No. 2294	ACAAGUGUGACAUUUUGUGUG
  AH1115	No. 1115	ACAAAAUGUCACACUUGUUUC	No. 2295	AACAAGUGUGACAUUUUGUGU
  AH1116	No. 1116	CAAAAUGUCACACUUGUUUCU	No. 2296	AAACAAGUGUGACAUUUUGUG
  AH1118	No. 1118	AAAUGUCACACUUGUUUCUUG	No. 2298	AGAAACAAGUGUGACAUUUUG
  AH1120	No. 1120	AUGUCACACUUGUUUCUUGUU	No. 2300	CAAGAAACAAGUGUGACAUUU
  AH1121	No. 1121	UGUCACACUUGUUUCUUGUUC	No. 2301	ACAAGAAACAAGUGUGACAUU
  AH1122	No. 1122	GUCACACUUGUUUCUUGUUCA	No. 2302	AACAAGAAACAAGUGUGACAU
  AH1124	No. 1124	CACACUUGUUUCUUGUUCAUC	No. 2304	UGAACAAGAAACAAGUGUGAC
  AH1125	No. 1125	ACACUUGUUUCUUGUUCAUCC	No. 2305	AUGAACAAGAAACAAGUGUGA
  AH1127	No. 1127	ACUUGUUUCUUGUUCAUCCAA	No. 2307	GGAUGAACAAGAAACAAGUGU
  AH1126	No. 1128	CUUGUUUCUUGUUCAUCCAAG	No. 2308	UGGAUGAACAAGAAACAAGUG
  AH1129	No. 1129	UUGUUUCUUGUUCAUCCAAGG	No. 2309	UUGGAUGAACAAGAAACAAGU
  AH1130	No. 1130	UGUUUCUUGUUCAUCCAAGGA	No. 2310	CUUGGAUGAACAAGAAACAAG
  AH1131	No. 1131	GUUUCUUGUUCAUCCAAGGAA	No. 2311	CCUUGGAUGAACAAGAAACAA
  AH1133	No. 1133	UUCUUGUUCAUCCAAGGAACC	No. 2313	UUCCUUGGAUGAACAAGAAAC
  AH1134	No. 1134	UCUUGUUCAUCCAAGGAACCU	No. 2314	GUUCCUUGGAUGAACAAGAAA
  AH1135	No. 1135	CUUGUUCAUCCAAGGAACCUA	No. 2315	GGUUCCUUGGAUGAACAAGAA
  AH1136	No. 1136	UUGUUCAUCCAAGGAACCUAA	No. 2316	AGGUUCCUUGGAUGAACAAGA
  AH1137	No. 1137	UGUUCAUCCAAGGAACCUAAU	No. 2317	UAGGUUCCUUGGAUGAACAAG
  AH1138	No. 1138	GUUCAUCCAAGGAACCUAAUU	No. 2318	UUAGGUUCCUUGGAUGAACAA
  AH1139	No. 1139	UUCAUCCAAGGAACCUAAUUG	No. 2319	AUUAGGUUCCUUGGAUGAACA
  AH1140	No. 1140	UCAUCCAAGGAACCUAAUUGA	No. 2320	AAUUAGGUUCCUUGGAUGAAC
  AH1141	No. 1141	CAUCCAAGGAACCUAAUUGAA	No. 2321	CAAUUAGGUUCCUUGGAUGAA
  AH1142	No. 1142	AUCCAAGGAACCUAAUUGAAA	No. 2322	UCAAUUAGGUUCCUUGGAUGA
  AH1343	No. 1143	UCCAAGGAACCUAAUUGAAAU	No. 2323	UUCAAUUAGGUUCCUUGGAUG
  AH1144	No. 1144	CCAAGGAACCUAAUUGAAAUU	No. 2324	UUUCAAUUAGGUUCCUUGGAU
  AH1145	No. 1145	CAAGGAACCUAAUUGAAAUUU	No. 2325	AUUUCAAUUAGGUUCCUUGGA
  AH1146	No. 1146	AAGGAACCUAAUUGAAAUUUA	No. 2326	AAUUUCAAUUAGGUUCCUUGG
  AH1147	No. 1147	AGGAACCUAAUUGAAAUUUAA	No. 2327	AAAUUUCAAUUAGGUUCCUUG
  AH1148	No. 1148	GGAACCUAAUUGAAAUUUAAA	No. 2328	UAAAUUUCAAUUAGGUUCCUU
  AH1149	No. 1149	GAACCUAAUUGAAAUUUAAAA	No. 2329	UUAAAUUUCAAUUAGGUUCCU
  	Double			Relative
  	stranded			expressed
  	nucleic		Target β2GPI	amount
  	acid No.	SEQ ID NO.	mRNA sequence	of β2GPI
  	AH1096	No. 3456	GGTGGTTTTCAGATTCCAC	0.076
  	AH1097	No. 3457	GTGGTTTTCAGATTCCACA	0.045
  	AH1099	No. 3459	GGTTTTCAGATTCCACACA	0.140
  	AH1100	No. 3460	GTTTTCAGATTCCACACAA	0.120
  	AH1101	No. 3461	TTTTCAGATTCCACACAAA	0.121
  	AH1102	No. 3462	TTTCAGATTCCACACAAAA	0.281
  	AH1103	No. 3463	TTCAGATTCCACACAAAAT	0.197
  	AH1104	No. 3464	TCAGATTCCACACAAAATG	0.274
  	AH1105	No. 3465	CAGATTCCACACAAAATGT	0.193
  	AHI106	No. 3466	AGATTCCACACAAAATGTC	0.175
  	AH1107	No. 3467	GATTCCACACAAAATGTCA	0.095
  	AH1109	No. 3469	TTCCACACAAAATGTCACA	0.193
  	AH1111	No. 3471	CCACACAAAATGTCACACT	0.147
  	AH1112	No. 3472	CACACAAAATGTCACACTT	0.067
  	AH1113	No. 3473	ACACAAAATGTCACACTTG	0.186
  	AH1114	No. 3474	CACAAAATGTCACACTTGT	0.082
  	AH1115	No. 3475	ACAAAATGTCACACTTGTT	0.229
  	AH1116	No. 3476	CAAAATGTCACACTTGTTT	0.074
  	AH1118	No. 3478	AAATGTCACACTTGTTTCT	0 073
  	AH1120	No. 3480	ATGTCACACTTGTTTCTTG	0.140
  	AH1121	No. 3481	TGTCACACTTGTTTCTTGT	0.090
  	AH1122	No. 3482	GTCACACTTGTTTCTTGTT	0.085
  	AH1124	No. 3484	CACACTTGTTTCTTGTTCA	0.050
  	AH1125	No. 3455	ACACTTGTTTCTTGTTCAT	0.065
  	AH1127	No. 3487	ACTTGTTTCTTGTTCATCC	0.169
  	AH1126	No. 3488	CTTGTTTCTTGTTCATCCA	0.029
  	AH1129	No. 3489	TTGTTTCTTGTTCATCCAA	0.065
  	AH1130	No. 3490	TGTTTCTTGTTCATCCAAG	0.307
  	AH1131	No. 3491	GTTTCTTGTTCATCCAAGG	0.163
  	AH1133	No. 3493	TTCTTGTTCATCCAAGGAA	0.196
  	AH1134	No. 3494	TCTTGTTCATCCAAGGAAC	0.251
  	AH1135	No. 3495	CTTGTTCATCCAAGGAACC	0.145
  	AH1136	No. 3495	TTGTTCATCCAAGGAACCT	0.219
  	AH1137	No. 3497	TGTTCATCCAAGGAACCTA	0.044
  	AH1138	No. 3495	GTTCATCCAAGGAACCTAA	0 036
  	AH1139	No. 3499	TTCATCCAAGGAACCTAAT	0 061
  	AH1140	No. 3500	TCATCCAAGGAACCTAATT	0.110
  	AH1141	No. 3501	CATCCAAGGAACCTAATTG	0.063
  	AH1142	No. 3502	ATCCAAGGAACCTAATTGA	0.045
  	AH1343	No. 3503	TCCAAGGAACCTAATTGAA	0.042
  	AH1144	No. 3504	CCAAGGAACCTAATTGAAA	0.036
  	AH1145	No. 3505	CAAGGAACCTAATTGAAAT	0 042
  	AH1146	No. 3506	AAGGAACCTAATTGAAATT	0.056
  	AH1147	No. 3507	AGGAACCTAATTGAAATTT	0.244
  	AH1148	No. 3508	GGAACCTAATTGAAATTTA	0 037
  	AH1149	No. 3509	GAACCTAATTGAAATTTAA	0.034

• TABLE 4-16
  Double
  stranded
  nucleic	SEQ ID	Sense strand sequence		Antisense strand sequence
  acid No.	NO.	(5′→3′)	SEQ ID NO.	(5′→3′)	SEQ ID NO.
  AH1150	No. 1150	AACCUAAUUGAAAUUUAAAAA	No. 2330	UUUAAAUUUCAAUUAGGUUCC	No. 3510
  AH1151	No. 1151	ACCUAAUUGAAAUUUAAAAAU	No. 2331	UUUUAAAUUUCAAUUAGGUUC	No. 3511
  AH1155	No. 1155	AAUUGAAAUUUAAAAAUAAAG	No. 2335	UUAUUUUUAAAUUUCAAUUAG	No. 3515
  AH1167	No. 1167	AAAAUAAAGCUACUGAAUUUA	No. 2347	AAUUCAGUAGCUUUAUUUUUA	No. 3527
  AH1168	No. 1168	AAAUAAAGCUACUGAAUUUAU	No. 2348	AAAUUCAGUAGCUUUAUUUUU	No. 3528
  AH1169	No. 1169	AAUAAAGCUACUGAAUUUAUU	No. 2349	UAAAUUCAGUAGCUUUAUUUU	No. 3529
  AH1171	No. 1171	UAAAGCUACUGAAUUUAUUGC	No. 2351	AAUAAAUUCAGUAGCUUUAUU	No. 3531
  AH1175	No. 1175	GCUACUGAAUUUAUUGCCGCA	No. 2355	CGGCAAUAAAUUCAGUAGCUU	No. 3535
  AH1176	No. 1176	CUACUGAAUUUAUUGCCGCAC	No. 2356	GCGGCAAUAAAUUCAGUAGCU	No. 3536
  AH1177	No. 1177	UACUGAAUUUAUUGCCGCACC	No. 2357	UGCGGCAAUAAAUUCAGUAGC	No. 3537
  AH1178	No. 1178	ACUGAAUUUAUUGCCGCACCC	No. 2358	GUGCGGCAAUAAAUUCAGUAG	No. 3538
  			Double
  			stranded
  			nucleic	Target β2GPI	Relative expressed
  			acid No.	mRNA sequence	amount of β2GPI
  			AH1150	AACCTAATTGAAATTTAAA	0.097
  			AH1151	ACCTAATTGAAATTTAAAA	0.330
  			AH1155	AATTGAAATTTAAAAATAA	0.318
  			AH1167	AAAATAAAGCTACTGAATT	0.313
  			AH1168	AAATAAAGCTACTGAATTT	0.082
  			AH1169	AATAAAGCTACTGAATTTA	0.174
  			AH1171	TAAAGCTACTGAATTTATT	0.191
  			AH1175	GCTACTGAATTTATTGCCG	0.156
  			AH1176	CTACTGAATTTATTGCCGC	0.230
  			AH1177	TACTGAATTTATTGCCGCA	0.155
  			AH1178	ACTGAATTTATTGCCGCAC	0.309

• In order to select double-stranded nucleic acids having high knockdown activity, the relative expressed amount of the β2GPI gene was calculated in the same experimental system with the final concentration of the double-stranded nucleic acid decreased to 10 pmol/L. The results are described in Table 5.

• TABLE 5
  Double stranded	Relative expressed	Double stranded	Relative expressed
  nucleic acid No.	amount of β2GPI	nucleic acid No.	amount of β2GPI
  AH0075	0.206	AH0808	0.283
  AH0096	0.204	AH0821	0.257
  AH0099	0.159	AH0825	0.230
  AH0119	0.170	AH0832	0.277
  AH0125	0.108	AH0876	0.246
  AH0126	0.143	AH0879	0.168
  AH0133	0.202	AH0883	0.173
  AH0134	0.256	AH0887	0.243
  AH0149	0.172	AH0943	0.110
  AH0152	0.114	AH1022	0.288
  AH0154	0.219	AH1025	0.218
  AH0155	0.206	AH1031	0.264
  AH0181	0.240	AH1038	0.277
  AH0184	0.170	AH1039	0.212
  AH0185	0.104	AH1077	0.292
  AH0187	0.117	AH1092	0.240
  AH0188	0.180	AH1095	0.282
  AH0193	0.254	AH1097	0.201
  AH0236	0.127	AH1112	0.156
  AH0275	0.192	AH1116	0.291
  AH0296	0.214	AH1118	0.268
  AH0324	0.255	AH1124	0.160
  AH0330	0.265	AH1125	0.215
  AH0345	0.242	AH1128	0.164
  AH0371	0.167	AH1129	0.276
  AH0394	0.285	AH1137	0.288
  AH0504	0.282	AH1139	0.165
  AH0528	0.197	AH1141	0.130
  AH0529	0.107	AH1142	0.078
  AH0592	0.279	AH1143	0.110
  AH0689	0.178	AH1144	0.073
  AH0693	0.206	AH1145	0.091
  AH0705	0.281	AH1146	0.178
  AH0712	0.149	AH1148	0.106
  AH0713	0.199	AH1149	0.110

Example 1Preparation of Nucleic Acid Conjugate Containing β2GPI Gene-Suppressing Double-Stranded Nucleic Acid (siRNA) and a Ligand Part
• Step 1
• β2GPI-targeting siRNAs (G-CH1179-s, G-CH0099-s and G-CH1180-s) having a ligand part at the 3′ end of the antisense strand of CH1179, CH0099 or CH1180 were synthesized on a scale of 0.2 μmol with a nucleic acid synthesizer (Ultra Fast Parallel Synthesizer, Sigma, hereinafter UFPS). Compound 9 obtained in step 7 of Reference Example 2 was used as the solid-phase carrier. DMT-2′-O-methyl-rA((tert-butyl)phenoxyacetyl)amidite (SAFC-Proligo), DMT-2′-fluoro-dA(benzoyl)amidite (SAFC-Proligo), DMT-2′-O-methyl-rG ((tert-butyl)phenoxyacetyl)amidite (SAFC-Proligo), DMT-2′-fluoro-dG(isobutyryl)amidite (SAFC-Proligo), DMT-2′-O-methyl-rC((tert-butyl)phenoxyacetyl)amidite (SAFC-Proligo), DMT-2′-fluoro-dC(acetyl)amidite (SAFC-Proligo), DMT-2′-O-methyl-rU amidite (SAFC-Proligo) and DMT-2′-fluoro-dU amidite (SAFC-Proligo) were prepared as 0.1 mol/L acetonitrile solutions, chemical phosphorylation reagent II (Glen Research Corporation) was prepared as a 0.06 mol/L acetonitrile solution, and sulfurization reagent II (Glen Research Corporation) was prepared as a 0.05 mol/L acetonitrile solution, and they were used for a condensation reaction. Deblocking solution I (3% trichloracetic acid dichloromethane solution, Wako Pure Chemical Industries, Ltd.) was used as a deprotection reagent. 5-benzylthio-1H-tetrazole (SAFC-Proligo) was used as a phosphoramidite activator, and the condensation time was 10 minutes each. After synthesis with trityl-off, the product was immersed in 28% ammonia solution, and left standing for 4 hours at 55° C. This was concentrated under reduced pressure, and 1-butanol was added to stop the reaction. This was then purified by reverse-phase liquid chromatography (Shiseido Capsell Pak C18, SG300, 6.0 mm×75 mm, 5% acetonitrile/0.1% triethyl ammonium acetate buffer, B solution: 50% acetonitrile/water gradient) to obtain the target oligonucleotide. The results are described in Table 6.

• TABLE 6
  		Molecular	Molecular
  		weight	weight
  		(theoretical	(Measured
  Compound	Sequence (5′→3′)	value)	value)

  G-CH1179-s	C (F) U (M) C (F) U (M) G (F) C (M) C (F) A (M) U (F) G (M) U (F)	8558.3	8556.4
  	U (F) G (M) C (F) U (M) A (F) U (M) U (F) G (M) C (F) A (M) X
  G-CH0099-s	U (F) G (M) C (F) C (M) A (F) U (M) G (F) U (M) U (F) G (M) C (F)	8661.3	8659.4
  	U (F) A (M) U (F) U (M) G (F) C (M) A (F) G (F) G (F) A (M) X
  G-CH1180-s	G (F) C (M) U (F) G (M) G (F) A (M) A (F) U (M) C (F) U (M) U (F)	8755.5	8758.0
  	A (F) G (M) A (F) A (M) A (F) A (M) U (F) G (M) G (F) A (M) X
  indicates data missing or illegible when filed

  
  (wherein, N(M) represents 2′-O-methyl modified RNA, N(F) represents 2′-fluorine modified RNA, A represents phosphorothioate modification, and X represents the ligand part in the nucleic acid conjugate I in Table 1. The phrase “ligand part in the nucleic acid conjugate in Table 1” means a structure of the nucleic acid conjugate I excluding the oligonucleotide part.)
• Step 2
• The resulting single-stranded oligonucleotide was dissolved in a mixed buffer [100 mmol/L potassium acetate, 30 mmol/L 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, HEPES)-KOH (pH 7.4), 2 mmol/L magnesium acetate] so as to be a concentration of 50 μmol/L. The sense strand and the antisense strand were mixed in equal quantities, and left standing for 10 minutes at 80° C. The sense strand sequences were as shown by CH1179, CH0099 and CH1180 in Tables 3-2 and 3-18. The temperature was lowered gradually, and it was left standing for 1 hour at 37° C. to obtain a double-stranded oligonucleotide. The resulting nucleic acid conjugates in which a ligand part was attached to the double-stranded nucleic acid (siRNA) of CH1179, CH0099 or CH1180 were called G-CH1179, G-CH0099 and G-CH1180.
Test Example 2In Vitro Activity of Nucleic Acid Conjugate in Mouse Primary Hepatocytes
• Each of the nucleic acid conjugates obtained in Example 1 was introduced into mouse primary hepatocytes from CD-1 (Life Technologies Corporation, Catalog No. MSCP10) by the method described below.
• Each nucleic acid conjugate was diluted with Opti-MEM (Gibco, 31985) so as to be a final concentration of 10 or 3 nmol/L, and 20 μL of the dilution was dispensed into each well of a 96-well culture plate, to which mouse primary hepatocytes suspended in William's E Medium (Life Technologies Corporation, Catalog No. A12176-01) containing Primary Hepatocyte Thawing and Plating Supplements (Life Technologies Corporation, Catalog No. CM3000) were seeded so as to be 12,500 cells/80 μL/well. The plate was cultured for 6 hours under conditions of 37° C., 5% CO₂The culture supernatant was carefully removed and William's E Medium containing Primary Hepatocyte Maintenance Supplements (Life Technologies Corporation, Catalog No. CM4000) was added. Untreated cells were also seeded as a negative control group.
• The cells to which each preparation was introduced were cultured for 18 hours in an incubator under conditions of 37° C., 5% CO₂and washed with ice-cooled phosphate-buffered saline. Total RNA was collected using a Cells-to-Ct kit (Applied Bioscience (ABI), Catalog No. AM1728) according to the method described in the attached instruction, and cDNA was prepared by a reverse transcription reaction using the resulting total RNA as a template.
• Using the resulting cDNA as a template and a Universal Probe Library (Roche Applied Science, 04683633001) as a probe, a PCR reaction was performed with AB17900HT Fast (ABI) according to the method described in the attached instruction to amplify the mRNAs of the β2GPI gene and D-glyceraldehyde-3-phosphate dehydrogenase (hereinafter referred to as gapdh) gene (which is a constitutively expressed gene). The amplified amounts of the mRNAs were measured, and the semi-quantitative value of the β2GPI mRNA was calculated using the amplified amount of the gapdh mRNA as an internal control. The semi-quantitative value of the β2GPI mRNA of the negative control measured in the same way being set to be 1.0, the expression rate of the β2GPI mRNA was determined from the semi-quantitative value of the β2GPI mRNA. The results for expression rate of the β2GPI mRNA are described in Table 7 as IC50 values.

• TABLE 7
  	Nucleic acid conjugate name

  	G-CH1179	G-CH0099	G-CH1180

  Dosage (nmol/L)	10	3	10	3	10	3
  Amount of β2GPI mRNA	98.7	96.4	80.4	67.6	95.6	86.1
  (suppression rate %)

• It is clear from Table 7 that each nucleic acid conjugate obtained in Example 1 and introduced into mouse primary hepatocytes suppressed expression of β2GPI gene mRNA.
Test Example 3In Vivo Activity of Nucleic Acid Conjugate in Mice
• Each nucleic acid conjugate obtained in Example 1 was evaluated in vivo by the following method. Each nucleic acid conjugate was diluted with phosphate-buffered saline (DPBS, Nacalai Tesque, Inc.) for testing purposes. Mice (Balb/c, obtained from CLEA Japan, Inc.) were tamed, and each nucleic acid conjugate was administered to the mice subcutaneously at dosages of 3 mg/kg or 20 mg/kg. 3 days after administration, the livers were harvested and stored frozen with liquid nitrogen. Total RNA was then collected from the frozen liver samples with Trizol® RNA Isolation Reagents (Life Technologies Corporation, Catalog No. 15596026) and an RNeasy Mini Kit ((Qiagen N.V.), Catalog No. 74106) according to the method described in the attached instruction. Using the resulting RNA as a template, cDNA was then prepared by a reverse transcription reaction with a Transcriptor First Strand cDNA Synthesis Kit (Roche, Catalog No. 04897030001) according to the method described in the attached instruction. Using the resulting cDNA as a template and a TaqMan® Gene Expression Assays Probe (Applied Biosystems, Inc.) as a probe, a PCR reaction was performed with AB17900 HT Fast (ABI) according to the method described in the attached instruction to amplify the mRNAs of the β2GPI gene and D-glyceraldehyde-3-phosphate dehydrogenase (hereinafter referred to as gapdh) gene (which is a constitutively expressed gene). The amplified amounts of the mRNAs were measured, and the semi-quantitative value of the β2GPI mRNA was calculated using the amplified amount of the gapdh mRNA as an internal control. The semi-quantitative value of the β2GPI mRNA of the group receiving phosphate-buffered saline measured in the same way being set to be 1, the expression rate of the β2GPI mRNA was determined from the semi-quantitative value of the β2GPI mRNA. The results for expression rate of the β2GPI mRNA are described in Table 8.

• TABLE 8
  	Nucleic acid conjugate name

  	G-CH1179	G-CH0099	G-CH1180

  Dosage (mg/kg)	3	20	3	20	3	20
  Amount of β2GPI mRNA in	88.2	98.6	80.2	98.6	57.1	95.8
  liver (suppression rate %)

• It is clear from Table 8 that a β2GPI-associated disease can be treated by administering the nucleic acid conjugate of the present invention to a mammal and reducing expression of the β2GPI gene in vivo.
INDUSTRIAL APPLICABILITY
• An administration of the nucleic acid conjugate of the present invention to a mammal can suppress β2GPI gene expression in vivo and thereby treat a β2GPI-associated disease.
SEQUENCE LISTING FREE TEXT
• SEQ ID NOS: 1 to 1180 represent sense strand RNA base sequences of siRNA for a β2GPI gene.
• SEQ ID NOS: 1181 to 2360 represent antisense strand RNA base sequences of siRNA for a β2GPI gene.
• SEQ ID NOS: 2361 to 3540 represent DNA base sequences for a target β2GPI gene.
• SEQ ID NO: 3541 represents the cDNA base sequence of a β2GPI gene.
• SEQ ID NOS: 4001 to 4702 represent the sense strand RNA base sequences of double-stranded nucleic acids (BH033 to BH1180).
• SEQ ID NOS: 4703 to 5404 represent the antisense strand RNA base sequences of double-stranded nucleic acids (BH033 to BH1180).
• SEQ ID NOS: 5405 to 6106 represent the sense strand RNA base sequences of double-stranded nucleic acids (CH033 to CH1180).
• SEQ ID NOS: 6107 to 6808 represent the antisense strand RNA base sequences of double-stranded nucleic acids (CH033 to CH1180).

Claims (21)

1-30. (canceled)

31. A nucleic acid conjugate comprising: a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs; and

a ligand part, wherein an oligonucleotide strand with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to a target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16, and

the 3′ end or 5′ end of the sense strand has the ligand part represented by formula (I), formula (II), formula (III), formula (IV) or formula (V):

(wherein,

X is oligonucleotide-P(Z1)(Z2)-, where the oligonucleotide is the sense strand,

Q is absent or -T4-[Q4-P4]q4-,

R is the following structure

[Chemical Formula 2]

Z1 and Z2 are, independently of each other, O or S;

q1, q2, q3 and q4 are, independently of each other, an integer from 0 to 20;

P1, P2, P3 and P4 and T1, T2, T3 and T4 are, independently of each other, absent or —CO—, —NH—, —O—, —S—, —O—CO—, —NH—CO—, —CO—O— or CO—NH—, respectively, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of P1, P2, P3 and P4 may be the same or different,

Q1, Q2, Q3 and Q4 are, independently of each other, absent or a substituted or unsubstituted C_1-14alkylene, provided that when each of q1, q2, q3 and q4 is an integer from 2 to 20, each of Q1, Q2, Q3 and Q4 may be the same or different,

L1, L2 and L3 are, independently of each other, a sugar ligand.)

32. The nucleic acid conjugate according toclaim 31, wherein one or more of L1, L2 and L3 are a sugar ligand represented by the following structure

(wherein, Ac represents acetyl group).

33. The nucleic acid conjugate according toclaim 31, wherein L1, L2 and L3 are identical.

34. The nucleic acid conjugate according toclaim 31, wherein

T1, T2 and T3 are identical,

q1, q2 and q3 are identical,

Q1, Q2 and Q3 are identical, and

P1, P2 and P3 are identical.

35. The nucleic acid conjugate according toclaim 31, wherein R is

(wherein, Ac represents acetyl group).

36. The nucleic acid conjugate according toclaim 31, comprising a ligand part represented by any of formulae (I) to (V) at the 3′ end of the sense strand of the double-stranded nucleic acid.

37. The nucleic acid conjugate according toclaim 31, comprising a ligand part represented by any of formulae (I) to (V) at the 5′ end of the sense strand of the double-stranded nucleic acid.

38. The nucleic acid conjugate according toclaim 31, wherein

the duplex region comprises 11 to 27 base pairs, and

the second nucleotide from the 5′ end of the antisense strand, which is complementary to the target β2GPI mRNA sequence selected from the group described in Tables 4-1 to 4-16, is complementary to the second ribonucleotide from the 3′ end of the target β2GPI mRNA sequence.

39. The nucleic acid conjugate according toclaim 31, wherein the sense strand has a strand length of 21 to 25 nucleotides, and the antisense strand has a strand length of 21 to 25 nucleotides.

40. The nucleic acid conjugate according toclaim 31, wherein the 3′ end of the sense strand and the 5′ end of the antisense strand form a blunt end.

41. The nucleic acid conjugate according toclaim 31, wherein the double-stranded nucleic acid comprises a 2′-modified nucleotide.

42. The nucleic acid conjugate according toclaim 31, wherein the antisense strand comprises a sequence selected from the group of antisense strands described in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16.

43. The nucleic acid conjugate according toclaim 31, wherein the sense strand comprises a sequence selected from the group of sense strands described in Tables 2-1 to 2-18, Tables 3-1 to 3-18 or Tables 4-1 to 4-16.

44. A nucleic acid conjugate-comprising composition, comprising the nucleic acid conjugate according toclaim 31.

45. A method for suppressing expression of a β2GPI gene, comprising introducing a double-stranded nucleic acid into cells by using the composition according toclaim 44.

46. The method according toclaim 45, wherein the cells are cells in the liver of a mammal.

47. The method according toclaim 45, wherein the method of introduction into cells is a method of introduction into cells by intravenous administration or subcutaneous administration.

48. A method for treating a β2GPI-associated disease, comprising administrating the composition according toclaim 44 to a mammal.

49. The method according toclaim 48, wherein the β2GPI-associated disease is an autoimmune disease or thrombosis.

50. The method according toclaim 48, wherein the method of administration is intravenous administration or subcutaneous administration.